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Enhanced Raman spectroscopy as a tool for the improvement of cervical cancer
screening: a comparison of global and targeted approaches
by Lana WOOLFORD
Half a million women worldwide are diagnosed with cervical cancer annually, with 87%
of mortalities occurring in developing economies. HPV vaccination has reduced disease inci-
dence significantly but must be supplemented with regular cervical screening. In established
practice, cells from the cervix are fixed, stained and observed manually using an optical mi-
croscope. Inter-observer subjectivity and false diagnoses are a relatively frequent occurrence.
The use of molecular pathology allows objective diagnoses to be made based on changes
to the molecular content of cells and tissue with disease. This quantitative, objective and auto-
mated pathological analysis could be integrated with existing services, as well as creating po-
tential for economically deprived regions. Molecular pathology through spectroscopic meth-
ods has shown great promise. For Raman spectroscopy, this is broadly categorised into global
comparison or targeted biomarker approaches.
In the global paradigm, a direct comparison of wavelength modulated with standard Ra-
man spectroscopy showed marked improvement of sensitivity and specificity in fixed cell clas-
sification. Intracellular sampling location studies indicated that the technique is more robust
for fixed than live cells. A functional nanoparticle bioconjugate for the established marker p16
was developed for targeted studies following optimisation of covalent, passive and bioconju-
gation methods. This was applied to fixed smear analogues, both lysed and intact, in lateral
flow assay and SERS mapping contexts respectively. Considerations of hybrid SERS-SRS and
global-targeted imaging were also explored, combining key vibrational modes and labelling
moieties from both arms of the study.
After consideration of the clinical context, the SERS-active paper-based dipstick assay was
selected for further development. Novel binding peptides for p16 capture were discovered
and validated, alternative consensus motifs found through next-generation sequencing and
SERS-based quantification demonstrated to be sufficiently sensitive to detect relevant cellular
analogues. The investigations described provide both a roadmap for further development of
multiple Raman diagnostic tools in a clinical context and the foundational components of a
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Today, medical imaging plays a hugely significant role in the diagnosis and treatment
of diseases such as cancer, from initial radiography and brightfield analysis of tu-
mour margins to fluorescence-guided surgery and follow-up MRI scans. Relatively
novel technologies have revolutionised disease management pathways and become a
common sight in hospitals. Cervical cancer was one of the first cancers to receive the
benefit of a diagnostic test, through the pioneering work of cytopathologist George Pa-
panicolaou in the 1920s [1]. Its widespread clinical acceptance in the US and western
Europe by the 1960s has significantly reduced mortality rates [2]. But despite gen-
eral improvements to the technique, fundamentals remain unchanged, thereby failing
to take advantage of the staggering advances in medicine, biochemistry and imaging
since its inception.
One of those advances is the emergence of Raman spectroscopy, the measurement
of inelastically scattered light from molecules, as a technique for sensitive diagnosis.
Although the optical phenomenon was discovered by Chandrashekhara Venkata Ra-
man in 1928, it did not reach its potential as an analytical technique until the advent of
reliable laser light production in the 1960s. Raman spectroscopy, which is described in
detail below, has since become an established technique in analytical chemistry appli-
cations and has evolved into multiple subspecies with often complementary strengths
and weaknesses.
This thesis aims to consider which manifestation of Raman spectroscopy is best
suited, in its current state, for improvements to the sensitivity and specificity of cer-
vical screening. Once selected, that method will be developed and characterised in
the light of relevant clinical factors to provide the framework for a new approach to
screening. Owing to the variety of approaches and techniques used throughout the
studies presented and for the reader’s convenience, each Chapter (with the exception
of General Materials and Methods) represents a contained body of work with its own
introduction, methods, results, analysis and conclusion. This Chapter outlines the
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overall research landscape, including the initial position of Raman spectroscopy as a
tool for screening and the clinical problem which the proposed Raman spectroscopic
studies seek to address.
1.1 Cervical cancer
An understanding of the epidemiology, mechanisms and current clinical pathways
associated with cervical cancer and its precursor lesions is critical to the development
of a relevant tool. Although the burden of disease is considered from global as well
as local perspectives, reviews of current clinical practice are limited to those provided
by the UK National Health Service. A recent review by Vale et al. considers screening
practice in low and middle income countries [3].
1.1.1 Burden of disease
Cervical cancer is a treatable and preventable disease which remains, for women,
the most common cancer in 38 countries and the leading cause of death in 45. It
is the fourth most common cancer globally, accounting for 7.5% of all female can-
cer deaths [4]. Cancer and precancers of the cervix are particularly associated with
younger women and particularly those living in economically underdeveloped areas.
The disease disproportionately affects women of working age and so was ranked in
2013 amongst the top three causes of lost years of healthy life (Disability-Adjusted Life
Years, DALYS) [5].
Another significant characteristic of cervical cancer epidemiology is the striking
discrepancy in morbidity and mortality between low- and high-income regions on
both a local and national scale. An 18-fold variation in morbidity has been docu-
mented between low and high risk regions in 2017, with 85% of new cases and 87%
of deaths occurring in less developed regions, particularly in Africa [6]. And yet, only
5% of global cancer spending occurs in these areas. Figure 1.1 demonstrates cervical
carcinoma incidence in the context of screening programmes.
Low and middle Human Development Index (HDI) countries are witnessing a
shift in disease burden as non-communicable diseases overtake infectious disease and
maternal complications as the primary causes of mortality. As a cancer overwhelm-
ingly caused by prolonged infection with human papillomavirus (HPV), cervical can-
cer straddles these epidemiological categories, making effective population screening
and affordable treatment critical in the absence of vaccination programmes [9]. In
countries such as Turkey where screening has only recently been introduced, uptake is
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FIGURE 1.1: Left: Global incidence of cervical cancer in 2012 [7]. Right: Proportion
of women, by country, attending regular screening (green), occasional screening (blue)
and no screening (red) [8]. Countries with greater than 50% unscreened population are
marked in red on the incidence map.
too low (1-2%) to be effective [10]. Other risk factors for cervical cancer and pre-cancer
include smoking, prolonged use of oral contraceptives, and a weakened immune sys-
tem (especially due to HIV infection) [11].
In Scotland, the overall incidence rate of cervical cancer has decreased by 6.3 di-
agnoses per 100,000 from 1981 to 2016, but incidence increased marginally from 2013-
2016 [12]. This trend is reflected in other high-income countries and may be caused
by decreased screening uptake, sexual behavioural changes and higher rates of HPV
infection. Both screening and vaccination uptake are influenced by age and Scottish
Index of Multiple Deprivation (SIMD) score, with younger women from poorer back-
grounds demonstrating both lowest preventative uptake and highest HPV risk.
Proven approaches to reducing these inequalities include vaccination against HPV,
population screening, surgery and medicines, with screening identified by the World
Health Organisation as a ‘Best Buy’ for this disease. As a result of the effective im-
plementation of these approaches in high HDI regions, the incidence rate of cervical
cancer 1990-2013 decreased by 59%, leading to an increase in overall incidence of just
8.5% following population adjustment. Cervical cancer comprises up to a third of all
cancers diagnosed (in both sexes) in many low HDI settings, compared with less than
10% in most very high HDI countries [9] and rates are three times lower in countries
with screening programmes than without [5].
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1.1.2 Mechanisms of disease
The pathway of HPV infection and subsequent cancer progression is reasonably well
understood and is intrinsically linked to the process of differentiation in squamous ep-
ithelium [13]. HPV DNA is circular, double-stranded [14] and contains approximately
7900 base pairs [15]. It is coated with L1 and L2 capsid proteins and codes for proteins
E1, E2, E4, E5, the oncogenes E6 and E7, and L1 and L2 themselves. The full sequence
can be seen in Figure 1.2.
In normal epithelium, the basal layer produces cells which exit the cell cycle (1.2
and begin the process of terminal differentiation. The normal biochemical and mor-
phological changes which occur as cells approach the surface of the epithelium are
disrupted following HPV infection.
FIGURE 1.2: A) The genome of HPV16, with the long control region (LCR) expanded to
show the E1 and E2 binding sites and TATA box. L1 and L2 are capsid proteins. E1,2,4 and
5 control viral expression and replication. E6 and E7 are viral oncogenic proteins which
disrupt the cell cycle [16]. B)Stages of the cell cycle. G1 = Gap 1 (readying for synthesis), S
= synthesis of DNA, G2 = Gap 2 (readying for mitosis), M = mitosis. G0 (Gap 0) represents
exit from the cell cycle.
The majority of HPV infections occur at the ‘transformation zone’ [17], where the
columnar epithelium of the endocervix meets the squamous epithelium of the ecto-
cervix [15]. The virus cannot infect terminally differentiated cells directly, but attaches
via the L1 capsid protein to cells in the basal layer of the epithelium which are ex-
posed following epithelial trauma [13]. L2 allows transfer of viral DNA into the basal
cell nuclei, where it initially exists as an extrachromosomal element [16]. E1 and E2
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proteins are then encoded, which are responsible for maintenance and replication of
the virus in infected cells. E2 also controls expression from the viral early promoter
(p97 in HPV-16), as well as of E6 and E7.
Active transcription of oncoproteins E6 and E7 then occurs. E6 binds to and de-
grades p53; a tumour suppressor protein that governs cell cycle arrest, apoptosis and
DNA repair. E7 binds to retinoblastoma protein pRB, preventing it from forming a
complex with E2F-1. Freed E2F-1 allows entrance of the cell into the S-phase of its
cycle. Overall, this has the effect of forcing normally out-of-cycle cells to proliferate
without usual checks for DNA integrity [15]: the full pathway and subsequent protein
expression can be seen in Figure 1.3. E5 then increases cell proliferation and delays dif-
ferentiation through increased protein kinase activity. Increased expression of E1,E2
and E4 drive genome amplification. Finally, the capsid proteins L1 and L2 are pro-
duced to package the new viral particles in cells. The completed virions are released
as the outer layers of the epithelium shed. E4 is also expressed at this stage: its exact
role is unclear, but it interacts with cytoskeletal proteins and is known to be involved
in the production and release of virions [16]. The viral replication process is described
graphically in Figure 1.4.
Critically, in normal productive HPV infection, only a small number of cells close
to the basal layer re-enter the cell cycle and proliferate in order to increase the num-
ber of infected cells. Progression to cancer occurs when strict regulation of E6 and
E7 are lost and ‘runaway’ proliferation occurs. This results in increasing numbers of
replicating cells appearing towards the surface of the epithelium, replacing the normal
differentiated structure (Figure 1.5). The productive replication cycle of HPV is then
aborted. These abnormal HPV-driven cells expand to fill the epithelium, producing
a high-grade squamous intraepithelial lesion (HSIL, equivalent to CIN 2/3), which
may progress to invasive carcinoma if the basement membrane is breached. The most
common metastatic sites are the lungs, liver, kidneys and lower intestinal tract.
It also appears that as cervical precancers progress, an increasing number of cells
demonstrate integration of HPV DNA into the host cell genome [16]. The process
through which this occurs is not fully understood as the integration sites vary in both
number and location from cell to cell[18]. Integration is typically accompanied by loss
or disruption of the coding sequences for E1, E2 and E4 and subsequent overexpres-
sion of E6 and E7 [16].
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FIGURE 1.3: The cell-cycle deregulation pathway for high-risk HPV types. E6 and E7
bind to p53 and pRB respectively, disrupting their role in arrest and regulation of cell
proliferation. In infected epithelium (right), this results in the up-regulation of proteins
such as p16. HPV infection also appears to be dependent on p21 levels relative to E7 [16].
1.1.3 Clinical presentation of cervical cancer
Despite the well-defined progression from pre-invasive lesions to cervical carcinoma,
patients are often asymptomatic until late stage disease. Abnormal vaginal bleeding is
the most common symptom but is a non-specific indicator, occurring in several other
gynaecological pathologies. Thus, screening is critical to identify disease as early as
possible, with minimum disruption to the patient’s quality of life.
If the patient is referred to colposcopy, the cervix is stained with acetic acid to
highlight dysplastic areas. Biopsies are taken if deemed necessary. Tissue sections are
H&E stained for analysis - typical examples of low- (LSIL) and high-grade squamous
intraepithelial lesions (HSIL) and associated cytologies can be seen in Figure 1.6.
1.1.4 Current clinical practice
Current clinical practice varies geographically, reflecting differences in risk, popula-
tion size, cost effectiveness and prevention strategies. The majority of high-income
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FIGURE 1.4: The HPV replication process with associated gene expression levels shown
on the right. Greater intensity of colour corresponds to higher expression. Light blue and
light grey cells are normal undifferentiated and differentiating cells respectively. Modified
from J.Doorbar 2006 [16].
countries have established programmes of vaccination, screening and disease treat-
ment [8].
The bivalent vaccine, providing specific protection against HPV16 and 18 and
cross-protection against HPV31, 33, and 45, was introduced as part of a routine school-
based immunisation programme in Scotland from 2008 to 2012, when it was replaced
with the quadrivalent vaccine (HPV16, 18, 6 and 11). Data from the 1995-6 and later
birth cohorts in the UK showed virtual eradication of HPV16 and 18 infection, with
no significant evidence of replacement with other strains [20, 21].
The vaccine programme has achieved considerable success in Scotland and else-
where, with the first vaccination cohort (1995-1996) demonstrating 89% reduction in
prevalence of CIN3+ compared to the unvaccinated 1988 cohort. Herd protection was
also demonstrated for non-vaccinated girls in the first cohort [22]. However vaccine
uptake in this original cohort was high at 90%. A combination programme of vaccina-
tion and screening is still required. Cervical screening uptake amongst young women,
and particularly unvaccinated young women, was low at 51 and 23% respectively [23].
Self-sampling HPV kits have been posited to increase likelihood of screening uptake
[24].
The national screening programme is estimated to prevent 4,500 deaths in the UK
every year [25]. However, such programmes require large, sustained financial input
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and human resources, and are not completely accurate. Cytological sensitivity can
be as low as 57% in some cases [26, 27], though specificity is typically considerably
higher.
In a cytology screen, cells are brushed from the cervix and stored in fixing solution
as a liquid-based cytology (LBC) sample, prepared according to the ThinPrep method
[22]. This ‘smear’ is transferred to a microscope slide, stained and viewed by a cy-
topathologist, who classifies it as normal, borderline, low or high grade dyskaryosis,
glandular neoplasia or unsatisfactory [22] (Figure 1.7). The interpretation of cell mor-
phology is hugely complex and therefore open to subjectivity and false classification.
In a 2008 clinical trial comparing reviewed with initial pre-treatment histologic diag-
nosis, the probability of unnecessary treatment between 8-27% was found (dependent
on initial cytologic findings) [28], indicating that many women may be being referred
to colposcopy unnecessarily. There is also evidence to suggest that there is a failure
to detect cervical adenocarcinoma [29, 30], which makes up more than 10% of cervical
carcinoma samples.
In the UK until recently, standard practice was to triage borderline cytology sam-
ples according to high-risk HPV status, although this is changing as HPV replaces
cytology as the primary screen. In Scotland until recently, women were referred for
colposcopy after one incidence of either high grade dyskaryosis or atypical squamous
cells, two findings of low grade dyskaryosis, three findings of borderline changes after
follow-up or three abnormal results in 10 years. Any low grade or borderline changes
are followed with cytology after six months [22].
Current clinical practice will change in early 2020 in response to multiple studies
which indicate that use of HPV genotyping instead of cytology as the primary cervical
screen increases diagnostic sensitivity, thereby reducing the number of positive cases
missed during screening [31, 32, 33, 34, 35]. Following a negative result for CIN2+,
HPV-based screening also reduces the likelihood of incidence in the next five years,
providing a case for increasing the screening interval and reducing costs [36, 37].
In the case of a high risk HPV-positive test, reflex liquid-based cytology (LBC) will
be used to confirm the need for further tests. The new testing framework requires
additional patient management streams - negative cytology results following HPV
positivity will lead to increased monitoring and screening frequency. Solutions to
this still vary globally [38]. In Australia, co-testing of HPV and LBC will be used for
patients following treatment of high-grade abnormalities or who are deemed to be
high-risk [39], whereas in the UK, colposcopy referral will be used [31].
Studies have shown that the move to HPV testing results in an increase in col-
poscopy referral of up to 80% [31], owing to the reduced specificity of HPV testing
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compared with cytology. The requirement for retaining cytology to account for this
reduction in specificity of the primary test indicates that a simultaneous test, or one
that increases the overall accuracy of secondary cytology, would be beneficial to re-
ducing the burden on colposcopy.
1.1.5 p16 as a marker of cervical cancer and pre-cancer
The use of biomarker screening has been posited as a potential method for improv-
ing classification accuracy in cytology, but identifying targets relevant to genetically
heterogeneous populations exposed to a variety of environmental factors while main-
taining high positive predictive value is often unfeasible [40]. However, the HPV-
based origins of the vast majority of cervical cancers provide an opportunity for robust
biomarker development which may not be available elsewhere.
Significant work is being undertaken to further understand cervical cancer and
precancer pathology, and the biomarkers that arise during disease progression. A
broadly applicable, robust test should be relevant to all HPV types and resistant to the
changing pattern of disease. In the context of HPV-based primary screening, Bhatia et
al. identify five requirements for an effective triage for hrHPV positive women: "high
specificity for CIN2+; objectivity; high-throughput suitable for automation; amenable
to a wide range of biospecimen types and produced independently of the infecting
virus type." [41]
In a review by Herrington in 2001, two aspects of biomarker discovery were high-
lighted as areas for improvement [42]. The first was that diagnostic and prognostic
markers often fail to distinguish between pathologies requiring different patient man-
agement strategies and are therefore not especially clinically useful. The second is
that many of the studies performed have insufficient power to assess the value of the
marker. Although HPV typing is highly sensitive for predicting lesions of grade CIN2
and higher, it is not capable of distinguishing between CIN grades overall and has low
positive predictive value.
More recently, research has focused on the investigation of universal cellular pro-
teins which are affected by HPV infection and disease progression, which constitute
‘surrogate’ markers. These include MCM5 [43] and CDC6 [44]. One of the most widely
investigated markers is p16 protein expression, also known as p16INK4A or cyclin-
dependent kinase inhibitor 2A (CDKN2A). In normal epithelium, p16 regulates ex-
pression of S-phase entry proteins (PCNA, MCM) by inhibiting CDK activation [45].
Following HPV infection, S-phase entry is determined by the E7 oncogene, which trig-
gers overexpression of p16 in line with E7 levels as an overcompensation mechanism.
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Critically, abnormally high cellular p16 expression is independent of the hrHPV type
and so potentially obviates the need for type-specific testing.
Diffuse staining with p16 has been demonstrated for virtually all cervical carcino-
mas and high-grade lesions, as well as in CIN1 lesions which were shown to be at
higher risk of progression [44]. Thus, it represents a useful clinical marker in terms of
its ability to stratify lesions requiring treatment. Use of p16 as a biomarker for cervi-
cal disease has been considered in multiple contexts including stratification - primary
screening, triage of screening results and cell-line cytology discrimination; diagnosis
following colposcopy, and prognosis. This reflects the potential for use of p16 in dif-
ferent formats dependent on the patient management strategy chosen.
In a stratification context, it has been shown to be superior to conventional cytol-
ogy in a trial of 1137 women when coupled with HPV testing [46]. A dual test for
p16 and HPV E4 expression has been suggested for sample stratification [47, 48], but
p16 is typically paired with Ki67. Several studies have demonstrated the utility of
p16/Ki67 dual staining in enhancing cytology sensitivity [38]. Conflicting data has
arisen elsewhere: no alteration in p16 expression was observed in ten cervical cell
lines (8 HPV+ive, 2 HPV-ive) as a result of mutational inactivation of p16, although
this is deemed to be a rare event [49] compared with many other studies indicating
correlation of overexpression with increasing CIN grade.
Following colposcopy, staining of tissue sections with p16 has been shown to sig-
nificantly improve interobserver agreement for diagnosis of CIN2, 3 and high-risk
HPV CIN1 [50], and to be associated with all high-risk HPV infected lesions [43]. It
has also been shown to be present in the majority of cases of invasive disease but not
morbidities such as chronic cervicitis [51]. Conversely, a meta-analysis of p16 stain-
ing trials suggested that p16 staining positively associated with better prognosis in
certain settings (no lymph node metastasis, disease-free survival) but did not signifi-
cantly correlate with tumour size or grade [52].
Due to evidence of excess patients referred to colposcopy following both HPV- and
cytology-based primary screening, it is considered that p16 staining, preferably with
Ki67, is most beneficial as an adjunct to or replacement for cytology-based triage of
hrHPV samples.
1.1.6 Alternative biomarkers for triage of hrHPV primary screening
Besides p16/Ki67 many classes of non HPV-specific biomarker are available, although
none have been trialled in large-scale studies. These include proliferation and cell cy-
cle control markers (p53, cyclin dependent kinases (CDKs)) and differentiation (CD44)
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markers [53]. Other potential markers for cervical carcinoma include cancer stem cell
markers such as SOX2 and TRA-1-60 [54] and host chemokine signatures including
CCL2 [41], although such pro-inflammatory markers may be compounded by sample
variability due to co-morbidities or hormonal changes.
HPV-specific markers of disease have been considered to a greater extent in the
triage context. HPV genotyping provides another layer of information regarding the
progression risk associated with a given type, but such information still has poor pos-
itive predictive value, which is compounded by the use of vaccination programmes
which protect against the highest risk strains. The global variation in high-risk strains
would also prevent implementation of a broadly applicable test.
Of greater promise are markers of self- and HPV-related markers of methylation,
which have been shown to be directly correlated with cervical disease and do not
require morphological study. Markers such as MAL and CADM1 have been shown to
provide sensitivities of 84% for CIN3 when considered simultaneously, approaching
sensitivities previously found for p16/Ki67 classification of CIN3 [38]. It is not clear
how many methylation markers would be required to constitute a robust test, and
there have been no examples to date of direct comparisons between the accuracy of
methylation and dual-staining based triage approaches.
With the appropriate application of technology to promote automated, potentially
high-throughput classification as investigated in this thesis, p16 has the potential to
fulfil all of the triage test requirements as outlined in Section 1.1.5. As a surrogate
marker it provides a particular advantage over type-specific HPV testing. A direct
comparison of dual p16/Ki67 expression with promising methods such as methyla-
tion assays which also considers cost and resource burdens (i.e. the possibility of self-
taken samples, automated or non-specialist cytological analysis or triage of residual
sample from the primary screen) would be of use. Whilst new combinations of mark-
ers may established as superior and adopted in the future, p16 is a robust, widespread
and clinically useful marker in the screening process whether used alone or in conjunc-
tion with Ki67, and thus represents an ideal candidate for technological development.
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FIGURE 1.5: Progression from HPV infection to cervical cancer, characterised by an in-
crease in proliferating cells (light blue) and eventual loss of HPV replication. The ar-
rows and their relative colour intensity denote the expression levels of E6/7 (pink), E4
(green), viral DNA (blue) and L1 (yellow). The primary categorisation is that of Cervical
Intraepithelial Neoplasia (CIN1,2,3), and the bracketed value is of the Bethesda system
(High/low-grade Squamous Intraepithelial Lesion, H/LSIL). Modified from J.Doorbar
2006 [16].
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FIGURE 1.6: Cytologic and histologic images of low-grade SIL (A, B) and high-grade SIL
(C, D). SIL indicates squamous intraepithelial lesion. Reproduced from Kim et al. 2018
[19].
FIGURE 1.7: Former UK clinical pathway used for cervical screening. Dyskaryosis is
typically defined by an increased nuclear to cytoplasmic ratio and abnormal chromatin
pattern.
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1.2 Molecular pathology
The use of biomarkers such as p16 or HPV DNA in diagnosis can be described as
molecular pathology. In 2018 Coleman described molecular pathology as the applica-
tion of the principles of basic molecular biology to the investigation of human disease
processes [55]. It shares aspects of both anatomical pathology and molecular biology,
and so is fundamentally interdisciplinary in nature. Differing pathologies and visual
phenotypes typically used for diagnosis in this field are driven at a submicroscopic
level by cellular machinery responding to genetic and environmental cues. Through
consideration of the molecular content of cells, tissues and bodily fluids, a diagnosis
can be made on the basis of genuine drivers or markers of disease rather than visual
phenotypes which may be conflated by the most skilled pathologist.
Molecular pathology can be conducted alone or in combination with traditional
histopathology or cytology approaches (morphomolecular pathology). Far from sound-
ing the death knell for classical pathology, the knowledge gained from established ap-
proaches will be critical in ensuring that molecular diagnostics are suitably robust for
clinical use [56, 57, 58]. Three challenges have been identified for the modern pathol-
ogist: the assertion of traditional pathology as a now-enriched practice; the integra-
tion of new molecular technologies into existing workflows; and the dissemination of
molecular pathology knowledge amongst training and practising pathologists [59].
1.2.1 Global and targeted approaches
The different approaches to molecular pathology can be broadly grouped into two cat-
egories: ‘global’ or signature-based methods, and target-specific methods. Briefly, the
signature-based approach relies on unspecified molecular differences between disease-
positive and -negative samples, whereas the targeted approach chooses a likely bio-
logical marker for disease and quantifies target levels in the same samples.
Established examples of global approaches to molecular pathology include next-
generation sequencing (NGS) and mass spectroscopy, and tend to act within a ‘systems
biology’ framework, comparing populations of relevant molecules in the genome,
transcriptome, proteome or metabolome [60]. These may represent either preliminary
biomarker discovery processes to elucidate relevant targets, or methods of analysis in
their own right. Mass spectrometry has been used to identify 55 dysregulated proteins
[61] as well as potential metabolomic biomarkers for cervical cancer from plasma [62]
and tissue lysate [63]. Thus far, NGS has only considered cervical cancer from an HPV
perspective and therefore cannot be considered truly global in nature. It has been used
1.2. Molecular pathology 15
to consider HPV testing for self-sampled cytology [64] and in comparison with PCR
and other methods [65].
Targeted approaches are currently the most familiar methods in the molecular
pathologist’s toolkit, though that may change as whole-sample sequencing and subse-
quent global bioinformatic analysis becomes steadily more accessible to non-specialist
research groups. Immunohistochemistry (IHC) and immunofluorescence (IF) multi-
plexing is typically limited by the number of antibody host species available (unless
directly labelled antibodies are made) but their use in biomedical research is almost
ubiquitous. Hybrid capture and PCR or isothermal amplification-based methods can
be used to detect the presence of HPV types by the highly conserved L1 gene [66].
This has been combined with liquid biopsy but with low detection rates (61.6%) [67].
Fluorescence in-situ hybridisation (FISH) allows for specific DNA or RNA strands to
be localised. Other established targeted molecular pathology techniques are too nu-
merous to mention here but are described by Best et al. 2016 [68].
1.2.2 Advantages and disadvantages of molecular pathology
Some of the advantages and disadvantages of using molecular pathology apply gen-
erally, but many are specific to the global or targeted contexts. Overall, molecular
testing methods give the advantage of typically offering higher specificity, results in-
dependent of poorly preserved or altered morphology, and a biochemical signature
for disease which may predate what can be detected through morphologial changes.
The latter is particularly critical for reliable early-stage diagnosis which will not only
reduce patient burden but also cost of treatment.
Global methods allow the full complexity of a given disease to be considered,
which is useful from a clinical perspective when multiple mechanisms of disease result
in the same treatment pathway. They also allow for unsupervised analysis of sample
‘-omics’, thereby circumventing the need for time-consuming biomarker discovery.
However, these methods typically require more expensive and time-consuming anal-
ysis. Targeted methods are typically cheaper and easier to analyse, which may have
greater applicability in point-of-care or low resource settings.
As mentioned above, the use of molecular pathology alone does result in the loss
of spatial data from traditional pathology, and so may have to be used as an adjunct to
established methods especially in designation of tumour margins. There is suggestion
that global methods such as NGS have resulted in ‘information overflow’ [69] which
does not necessarily result in clinically useful information. As these methods often
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inform biomarker discovery, they lead to potential issues with the specificity and bi-
ological relevance of targeted molecular techniques - if a single indicator is used, the
diagnostic test may well omit patient populations. Too many indicators can lead to
issues over cost effectiveness.
As will become clear, the Raman spectroscopy-specific approaches to global and
targeted molecular pathology are largely shared with their non-optical counterparts.
Global approaches are typified by data richness which is slow to acquire and analyse
but capable of classifying multiple disease types. Targeted approaches are comple-
mentary - analysis and acquisition are much more rapid due to streamlining of data
collection, but rely upon a robust marker or small panel of markers.
1.2.3 Current examples in clinical practice
Molecular pathology is now commonplace in some areas of clinical practice. Examples
in oncology include ERBB2 (HER2) gene amplification in breast cancer [70], and mu-
tation of EGFR, BRAF and BCR/ABL1 in lung cancer, melanoma and chronic myeloid
leukaemia respectively [71].
Viruses [72, 73], bacterial infections [74] and sexually transmitted diseases [75, 76]
have all been targeted for molecular diagnostic tests. There are currently four FDA-
approved HPV tests available for cervical cytology samples which use PCR DNA am-
plification of HPV L1 (Roche Cobas), hybrid capture of whole HPV genome (Qiagen
Digene), hybridisation protection assay of HPV E6/E7 mRNA (Hologic Gen-Probe)
and unspecified DNA extraction (Hologic Cervista) [76].
A dual staining kit for p16 and Ki67 has been released by Roche (CINtec Plus Kit),
with clinical utility confirmed in several studies [77, 78, 79, 80, 81]. It is designed
for use in conjunction with the Cobas HPV test, ideally for samples which are HPV
positive for non-HPV16 or 18 types. The patient management strategy for hrHPV
primary testing is described in Figure 1.8. Although more effective than standard Pap
cytology, staining protocols are still time-consuming and require laboratory apparatus
and pathology expertise not available in areas of high unmet clinical need.
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FIGURE 1.8: The patient management strategy for cervical cancer through molecular
pathology methods, introduced in England by the end of 2019 and Scotland in April 2020.
Cytology is aided by p16/Ki67 dual-staining. Adapted from resources by Public Health
England [82].
1.3 Raman spectroscopy as a tool for molecular pathology
It is clear that a screening method able to employ quantitative molecular pathology in
an automated fashion would greatly improve diagnosis, as well as reducing the cost
burden through superior patient management and reduced resource requirements.
Based on the inelastic scattering of light from molecular bonds, Raman spectroscopy
is ideally placed to offer a more objective measurement of cervical cancer progression.
1.3.1 Fundamentals of Raman spectroscopy
Raman scattering is the inelastic counterpart to the Rayleigh scattering of light by
molecules. In spontaneous Raman scattering, a photon with a given wavelength
λincident interacts with a molecule in a real energy state. The molecule is promoted to
a higher vibrational energy and emits a photon in order to relax back to a real energy
state. Elastic (Rayleigh) scattering occurs when λincident = λscattered. Stokes and anti-
Stokes photons are emitted if the molecule relaxes to a higher or lower vibrational en-
ergy respectively (Figure 1.9). The shift in frequency of these Raman scattered photons
indicates the energy difference between the intrinsic vibrational states of the system.
This allows vibrational bonds of all the molecules in the laser focus to be characterised
simultaneously, and broadly grouped into biomolecular categories (Figure 1.9).
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FIGURE 1.9: A) The energy level diagram for Rayleigh and spontaneous, non-resonant
Raman scattering. Light of energy hν interacts with a molecule in a real vibrational state.
This promotes the molecule to a higher energy state, which typically is virtual. B) Ra-
man spectral peaks can be broadly grouped into biomolecule categories based on unique
vibrational modes occuring within these moieties [17].
Classically, spontaneous Raman scattering can be described by an electric field E
which induces a time-dependent polarisability in a molecule. Undisturbed, the per-
manent dipole moment of a diatomic molecule oscillates at its natural frequency as
the atoms vibrate. If the molecule is subject to an incoming photon with an oscillating
electric field ~E(~r, t) = ~E0i cos(~ki ·~r−ωit), a dipole moment is induced, as the nuclei are
attracted to the negative pole of the field, and the electrons to the positive [83]. Here
~E0i is the electric field amplitude, which includes the polarisation of the field. The inci-
dent wavevector and angular frequency are ~ki and ωi respectively. The induced dipole
is then
~µinduced = α~E = α~E0i cos(~ki ·~r−ωit) (1.1)
where α is the polarisability of the molecule. The magnitude of α varies as the molecule
oscillates, and so can be written as
α = α0 + (∆α) cos(~q ·~r−ω0t) (1.2)
where ∆α is the maximum variation and~q is the vibration (phonon) wavevector. Sub-
stituting Equation (1.2) into Equation (1.1),
µinduced = α0~E0i cos(~ki ·~r−ωit) + (∆α)~E0i cos(~q ·~r−ω0t) cos(~ki ·~r−ωit). (1.3)
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Using the trigonometric identity cos(θ) cos(φ) = 12 [cos(θ + φ) + cos(θ − φ)] and col-
lecting terms, the induced dipole moment is thus




(∆α)~E0i [cos((~ki −~q) ·~r− (ω0 −ωi)t) (1.5)
+ cos((~ki +~q) ·~r− (ω0 + ωi)t)]. (1.6)
Expression 1.4 is the Rayleigh scattering term, where the dipole oscillates and emits at
the frequency ωi of the incoming wave. Expressions 1.5 and 1.6 are the Raman scat-
tered Stokes and anti-Stokes photons, which have a lower (ωi −ω0 = ω f ) and higher
(ωi +ω0 = ω f ) energy than the incident photon respectively. The incident wavelength
can be scattered by any molecule within the focus of the laser, meaning that informa-
tion from all molecular species can be collected using the same laser frequency. The
rarity of spontaneously occurring inelastic transitions results in a weak signal. This
is especially the case for biomolecules, whose small Raman cross-sections (10−29cm2)
result in just one in every 10 million incident photons undergoing Raman scattering
[84]. The small number of Raman scattered photons means that long acquisition times
are required to reach a reasonable signal to noise ratio (SNR).
Surface-enhanced Raman spectroscopy (SERS) overcomes the problem of inher-
ently low Raman signal through amplification of the electric fields of incident and
emitted light. This enhancement is provided by placing the molecule of interest in
the vicinity of a metal surface, which is subject to the same laser source as in con-
ventional Raman spectroscopy. The oscillating electric field of the laser photons pro-
duces a collective oscillation of conduction electrons (plasmons) in the metal surface.
This is known as dipole localised surface plasmon resonance (LSPR). The incoming
wavelength can be tuned to the resonant frequency of plasmons on a particular metal
surface in order to maximise this effect [85], designated as surface-enhanced resonant
Raman spectroscopy (SERRS). This localised electric field contributes to the intensity
of both incident and Raman scattered light. LSPRs and the SERS effect are discussed
in greater detail in Chapter 4.
Another modification to Raman spectroscopy to improve SNR involves reduction
of non-vibrational background as opposed to amplification of the vibrational signal.
There are multiple approaches to this which are described in Chapter 3, including
wavelength-modulation of the incident laser light as first published by Shreve et al. in
1992 [86].
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1.3.2 Raman spectroscopy in molecular pathology
Owing to the advantages of Raman spectroscopy as outlined above, the technique
has become of increasing interest in biochemical analysis and medical imaging. It
is capable of providing some of the specificity of established techniques such as im-
munofluorescence or mass spectroscopy but with a reduced need for sample prepa-
ration. The following section considers Raman spectroscopic progress in a general
molecular pathology context, before cervical cancer screening is considered in more
detail below.
Global approaches
A global Raman spectroscopy-based approach to molecular pathology is characterised
by the use of intrinsic biochemical properties of the sample. Changes to the biochem-
ical content of the sample, which accompany changes to disease state, are reflected in
the Raman spectra. This ‘intrinsic’ measurement boasts the considerable advantages
of being truly non-invasive and requiring negligible sample preparation. However,
analysis of acquired data can be complicated. Fractional spectral differences between
disease states, and the confounding influence of patient inter-variability, can expose
the technique to overfitted data models and subsequent difficulties in the clinically rel-
evant stratification of samples. The global approach typically makes use of ‘standard’
spontaneous Raman spectroscopy, or its label-free derivatives such as coherent anti-
Stokes Raman spectroscopy (CARS) or stimulated Raman spectroscopy (SRS). SRS is
considered in greater detail in Chapter 5.
The non-invasive nature of Raman spectroscopy and its ability to probe samples
with vibrational specificity has resulted in an increasing interest in its use in a biomed-
ical context, and particularly in the field of molecular oncology. Raman spectroscopic
analysis has been employed extensively for the grading of both histology and cytol-
ogy samples in a variety of cancer types [87], as well as for the determination of breast
tumour margins in animal models [88]. Excellent reviews in this area are provided
by Austin et al. [89], Krafft et al. [90], Kong et al. [91] and the Xie group [92]. In
addition to cancer discrimination in tissue, Raman microspectroscopy has been used
to consider cellular status, including for apoptotic and necrotic cells [93] and stem cell
differentiation [94, 95]. Its label-free nature has provided significant progress in in-vivo
imaging applications [96, 97].
Owing to the signal strength limitations of Raman spectroscopy, groups have sought
to combine the technique with other global modalities. This has included optical
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coherence tomography, mass spectrometry and somewhat surprisingly, autofluores-
cence [98].
Targeted approaches
Unlike the global approach, targeted Raman molecular pathology makes significant
use of the understanding of specific biochemical changes within cells and tissues in
order to diagnose disease. Disease markers, such as overexpression of a particular
protein, are chosen for the target pathology and used to stratify disease state. This has
the advantage of providing a more specific diagnosis, as levels of known markers can
be quantified more easily than a ‘blind’ spectrum of vibrational changes. However, it
does require significant sample preparation, as well as testing of appropriate markers
and probes, in order to guarantee a true and repeatable diagnosis in clinical samples.
The targeted approach is particularly suited to surface-enhanced Raman spectroscopy
(SERS), which provides signal increases on the order of 1010 compared to spontaneous
Raman spectroscopy [99]. Critically, this means that the acquisition time for a compa-
rable SNR is greatly reduced.
In order to produce plasmonic field enhancement at levels practical for spectro-
scopic applications, the available surface area can be increased by the use of either
rough surfaces or particles with nanoscale features. The improvement of nanoscale
production and measurement techniques in recent years has seen an increased inter-
est in the use of metal nanoparticles in solution with the analyte. This is known as
‘conferred enhancement’ of the SERS phenomenon. Both direct and indirect signal en-
hancement have been explored using nanoparticles. The former enhances the Raman
signal of an endogenous compound in the sample and has been used to detect viral
pathogens [100, 101, 102] and to image intracellular components [103, 104]. How-
ever, the enhanced Raman spectra in this case are as complex as their spontaneous
predecessors. Reviews judge that the clinical translation of direct SERS methods will
be extremely challenging, as clinical samples are characterised by both low ratios of
target-to-irrelevant species and a high background [105, 106].
Indirect SERS involves generation of ‘functionalised’ nanoparticles containing an
exogenous Raman label, a process which is described in detail in Chapter 4. Due
to its ability to provide excellent acquisition times and a technique for quantifying
marker levels which is similar to current immunocytochemistry methods, SERS has
recently attracted a great deal of interest from the cell biology and disease diagnosis re-
search communities. SERS also provides advantages over other mainstream targeted
molecular methods, including fluorescence spectroscopy and immunological assays,
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through sharper spectral features and greater detection sensitivity respectively. SERS
has been used to discriminate lung, breast and leukaemia cell pathology, as well as
glucose levels in animal models [99]. Studies by Chou et al. of the β-amyloid peptide
found in Alzheimers-related plaques suggested that different secondary protein con-
formations could be detected using SERS with unfunctionalised gold nanoparticles
[107]. The use of a nanofluidic device in this and other studies [108] for trapping and
visualising nanoparticles and analytes is something that may be considered for auto-
mated diagnosis, alongside flow cytometry techniques. Endocytic uptake and internal
transportation studies have taken advantage of the stealth properties of indirect gold
nanoparticle-based imaging [109, 110].
Marker-specific SERS approaches have been employed in normal and cancer cell
discrimination. Yang et al.s’ study on epidermal growth factor receptor 2 (HER2) in
breast cancer cell lines (SKBR3 and MCF7) used silver nanoparticles with p-mercaptobenzoic
acid acting as Raman reporter and antibody conjugation agent [111]. This removes a
step from the nanoparticle fabrication process. The sensitivity of SERS with antibody
conjugated nanoparticles is such that Wang et al. were able to detect pancreatic cancer
marker MUC4 in human sera at levels which could not be resolved by conventional
formats such as ELISA [112]. This may prove to be a critical advantage for early detec-
tion methods, which could also be developed into a less time-consuming alternative
to immunohistochemical techniques.
1.3.3 Raman spectroscopy in cervical cancer diagnosis
Global approaches
The first cervical cancer diagnostic investigations to employ Raman spectroscopy were
executed by the Mahadevan-Jansen group in 1998, using both in vivo and ex vivo sam-
ples [113]. In vivo sampling was performed using a fibre-optic probe in the near in-
frared, indicating the primary interest in generating an endoscopy-like diagnostic tool.
It was hypothesised that the ratio of peaks 1659:1321cm−1 and 1659:1452cm−1 could
be used as an indicator of disease state. Although the probe was able to collect in
vivo Raman data successfully, the unassigned peaks were used as a disease indicator
instead of the full spectrum with multivariate analysis. This could potentially lead to
misinformation due to inter-patient variability, which could not be verified due to only
one abnormal and one normal patient being investigated. It must also be noted that
as in other cervical sample investigations peak intensity differed between in vivo and
ex vivo sampling. This suggests that analytical techniques developed for one sampling
methodology are unlikely to be directly translatable. Further in vivo investigations of
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tissue samples by the same group in 2001 suggested that peaks assigned to phospho-
lipids and DNA undergo change with lesion progression [114]. However, difficulties
were experienced with the heterogeneous nature of tissue, as well as spectral contri-
butions from vibrational modes not specific to a particular pathology. This can lead to
problems in training the algorithms used to analyse data, as a peak for one mode can-
not be assigned uniquely to a marker of disease. The problem of tissue heterogeneity
has been raised in reviews as a major barrier to the use of Raman spectroscopy as a
‘digital histopathology’ technique [87, 84].
The complexity of tissue signal analysis suggests that it would be beneficial to con-
sider cytology samples, not simply as a precursor to in vivo Raman histopathology, but
as a useful research outcome in its own right. This becomes even more relevant in the
context of current cervical screening techniques. To date, five cell line [1, 115, 116, 117,
118] and two acquired cytology studies [1, 119] have been performed. The Jess et al.
2007 study [117] investigated the ability of confocal Raman spectroscopy to discrimi-
nate between the nuclei of primary human keratinocytes (PHKs), those expressing the
E7 gene of HPV-16, and the cervical carcinoma-derived cell line CaSki. Up to 100%
sensitivity was achieved for normal vs. carcinoma discrimination, although speci-
ficity values were marginally lower. Both live and 70% ethanol-fixed samples were
investigated using a 785nm diode laser at 120s acquisition time per cell. The fixed
cells demonstrated higher peak discrimination than the live cells, which is a helpful
result for LBC sample consideration. The resulting spectra were analysed with the
commonly used Principal Component Analysis (PCA) technique, which is described
in Chapter 3. All peak differences for each cell type save 720, 1129 and 1452cm−1 were
found to exceed the standard error and therefore be statistically (and diagnostically)
significant. The paper also provides a full analysis of the individual vibrationally as-
signed peaks used in the PCA training algorithm as well as an explanation of their
potential pathological significance. Such analysis lends greater specificity to the ac-
quired data (as opposed to ‘blind’ analysis), which may potentially lead to a greater
understanding between the imaging technique and underlying biochemistry of the
disease. The main practical drawback of this experiment is the acquisition time re-
quired for each cell using standard Raman spectroscopy. A single abnormal cell in
one cervical smear of 10,000 cells is sufficient to provide a positive diagnosis, meaning
that a single slide would require approximately two weeks to image fully using point
sampling.
Further cell line experiments by Ostrowska et al. investigated cervical cell recog-
nition in relation to HPV type and viral copy number in C33A (HPV-negative), HeLa
(HPV-18, 20-50 copies), SiHa (HPV-16, 1-2 copies) and CaSki cells (HPV-16, 60-600
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copies) [115]. The results suggest that more significant spectral change (particularly
of protein, DNA and lipid peaks) does correlate with increasing HPV copy number,
but that PCA categorisation is more significantly affected by type. This highlights
the potential of Raman spectroscopy to diagnose HPV type as well as cancer status,
but does raise questions of how the diagnostic algorithm would approach a sample
containing multiple infections. The analysis appears to be significantly affected by
peaks assigned to Amide I and III, indicating a change in secondary protein struc-
ture. Increases in amino acids tryptophan, proline, tyrosine and phenylalanine could
also constitute markers, as the same changes were seen in the 2007 Herrington group
investigation for other cervical cell lines [117].
The move to clinical samples has only occurred for cervical cancer in recent years,
with Rubina et al. publishing one of the first studies in 2013. 79% classification effi-
ciency [119] was achieved. After spectral acquisition, the cells were stained and inde-
pendently examined by two cytopathologists to give 45 normal and 49 abnormal spec-
imens. An initial test of 17 normal and 20 abnormal samples considered using Prin-
cipal Component-Linear Discriminant Analysis (PC-LDA) suggested that the main
spectral differentiation could be attributed to the presence of blood components in the
samples. Although blood contamination can accompany positive pathologies it can-
not be exclusively attributed to disease. Thus, the remaining samples were subjected
to red blood corpuscle (RBC) lysis buffer. The resulting difference spectra, calculated
by subtracting the mean normal spectrum from mean abnormal spectrum, provides an
initial indication of which peaks change with disease state. Although this differs from
the cell-line spectral results of the Herrington group [117], the significant increase in
Amide III seen in all of the above studies suggests that a more in-depth investigation
of changes to secondary protein structure as a marker of cancer progression may be
worthwhile from a global diagnosis perspective.
The potential problem of inter-patient variability has been investigated in two pa-
pers by the Mahadevan-Jansen group. The first focused on the effects of hormonal sta-
tus on the biochemical fingerprint of cervical smears [120]. It found an increase from
88% to 94% in classification accuracy when diagnosis of normal, metaplasia, LGSIL,
and HGSIL samples was limited to a single hormonal status (pre-menopausal). The
second considered the effect of normal variation on disease classification in 172 pa-
tients[121]. These were categorised as ‘true normal’ (no history of disease); previous
disease normal (disease history but presently normal); adjacent normal (spectral ac-
quisition from normal area neighbouring diseased area); LSIL and HSIL. A Raman
spectroscopic analysis of the effects of acetic acid used to highlight diseased areas
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during colposcopy was also carried out. This was found to have no statistically signif-
icant repercussions for Raman analysis, which is a positive result for practical sample
acquisition. Only four of the 146 classified spectra were misdiagnosed, providing a
classification accuracy of 97%.
Further in vivo studies have yielded diagnostic accuracies of 82.9% using genetic
algorithm-partial least squares-discriminant analysis and double cross-validation [122].
Higher diagnostic sensitivities were achieved by the same group using both low- and
high-wavenumber spectral regions [123].
The first paper devoted to the use of SERS with cervical cancer was published in
2013, but used the enhancement method to improve spectral quality in a global ap-
proach. Here, Feng et al. investigated the use of blood serum samples from 60 cancer
patients (38 stage 1-2, 22 stage 3-4) and 50 healthy volunteers for diagnosis of cervi-
cal cancer with direct (non-functionalised) SERS[124]. The prospect of using blood
samples for diagnosis is appealing due to the ease of collection and transportation.
PCA-LDA was used to discriminate between serum samples with 96.7% sensitivity
and 92.0% specificity. These results are promising, but the major drawback of this
approach is the specificity of non-functionalised SERS when applied to clinical screen-
ing. Diagnosis of cervical cancer using blood samples from the general population is
likely to be confounded by other disease markers.
Targeted approaches
To date only one study considering p16-targeted SERS-active conjugates has been
published [125]. Here, synthesised squaraine dyes were used as Raman labels on
PEG-encapsulated gold NPs (40nm). Antibodies for epithelial growth factor receptor
(EGFR) and p16/Ki67 were conjugated to these nanotags. HeLa cells were incubated
with the nanotags and SERS spectra were recorded for live cells in PBS, with an acqui-
sition time of 0.5s per cell. The nanotags for EGFR and p16/Ki67 bind to cell surface
receptors and nuclear receptors respectively. This ability to introduce nanotags to the
cell nucleus could be a significant advantage for the investigation of cervical cancer
due to the importance of viral oncoprotein expression location. This has been shown
to vary between high and low-risk HPV types [126]. As a proof of concept this investi-
gation is a critical step in the use of SERS for marker quantification, but other cell lines
and controls will have to be used in order to test its diagnostic capability.
More recent publications, specific to the studies undertaken, are reviewed in the
introductions of Chapters 3 to 6. Overall, Raman spectroscopy has been shown to be a
valid diagnostic tool, but one which is currently hindered by several factors. Overall,
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there are a lack of sufficiently sized clinical trials to provide the necessary data for
cost-benefit analysis and clinical translation. In the global case, slow acquisition times
and sampling methods are barriers to progress. In targeted approaches, there appears
to be a lack of collaborative research between basic scientists and research clinicians,
resulting in well-characterised labelling systems which demonstrate novel optics or
chemistry but have low clinical utility.
1.4 Exploring Raman spectroscopy as a tool for improved cer-
vical screening practice
Cervical cancer screening in its current form is a successful programme but one which
would greatly benefit from a molecular pathology approach in order to reduce work-
load and cost, increase objectivity and accuracy, and make screening more accessible
to the demographics which need it most.
The fundamentals of Raman spectroscopy and previous studies in general bio-
chemical and cervical carcinoma-specific frameworks demonstrate its potential to pro-
vide a sensitive and objective molecular pathology test, but one which requires the
addition of enhanced Raman approaches to be clinically useful. This may take the
form of a diagnostic capable of co-testing for HPV and cytological abnormalities, or
one which replaces or provides objective guidance for current cytology practice.
The data presented above suggests that cervical cancer provides an ideal case
study for the development of Raman-based spectroscopic tests, as a disease which
requires greater diagnostic sensitivity in cytologic screening and also has the benefit
of a robust surrogate marker. The decision to approach the project in terms of global
and targeted approaches to diagnosis aligns with the current clinical reality and is
therefore best placed to produce a practical test.
The aim of this thesis is to produce an objective, quantifiable and hopefully auto-
mated method of diagnosing cervical cancer and its early precancerous progression
stages. This will use Raman spectroscopy as a form of molecular pathology analysis.
In the first instance, the global (Chapter 3) and targeted approaches (Chapter 5) will
be studied through the use of wavelength-modulated and surface-enhanced Raman
spectroscopy respectively, following production of a functional SERS-active conjugate
(Chapter 4). This overview data will provide the basis for selection of a clinically use-
ful method for further development (Chapter 6).
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Chapter 2
General materials and methods
General Materials and Methods comprises techniques which feature in more than one
chapter. The majority of methods used in this project are specific to each aspect and
so are detailed in the relevant chapter for ease of reference.
2.1 Cell culture
Operations involving cells prior to fixation were performed in a biosafety cabinet with
laminar flow hood (TriMAT2 Class II Microbiological Safety Cabinet) using standard
aseptic procedures. Molecular biology grade reagents and plasticware were used, oth-
erwise autoclaving was carried out. All maintenance and procedural incubation steps
were at 37◦C in 5% CO2 using Cellstar culture vessels from Greiner Bio-One.
2.1.1 Primary cells
Primary cells and culture reagents were purchased from Lonza unless otherwise stated.
The recommended culturing procedure for Normal Human Epithelial Keratinocytes
(NHEKs, neonatal foreskin) resulted in reduced cell viability due to poor disassoci-
ation, cell clumping after centrifugation, and low cell adherence. The protocol was
modified as described below to mitigate for this. NHEKs were subcultured for no
more than 20 passages using ReagentPack Subculture Reagents from Lonza (Cat #
CC-5034).
75cm ventilated culture flasks were washed once with 5ml 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) Buffered Saline Solution before adding 2ml
0.25% Trypsin/ethylenediaminetetraacetic acid (EDTA) at room temperature (RT). Plates
were incubated at 1min intervals until 90% cell disassociation was confirmed with
brightfield microscopy. Trypsinisation was neutralised with 4ml RT Trypsin Neu-
tralising Solution and the cells counted using a 10µl sample prepared with 1:1 0.4%
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Trypan Blue Stain (Sigma) and a Luna Automated Cell Counter. New plates were pre-
pared with an appropriate volume of KGM-Gold medium at 37◦C, and cells plated
at the recommended seeding density of 10,000 cells/cm2. KGM-Gold medium was
supplemented with 0.1% hydrocortisone, 0.1% transferrin, 0.05% epinephrine, 0.1%
gentamicin sulfate/amphotericin (GA-1000), 0.4% bovine pituitary extract, 0.1% re-
combinant human epidermal growth factor (rhEGF) and 0.1% insulin (all [v/v]) as
provided with the media kit (Cat. # 00195769). 90% media replacement was carried
out on alternating days.
2.1.2 Established cell lines
All procedures described are for 10cm culture plates using Gibco reagents unless oth-
erwise stated. Cell stocks from established lines were maintained in the appropriate
medium as described in Table 2.1, supplemented with 10% foetal bovine serum [v/v]
(FBS) and 1% penicillin-streptomycin solution [v/v] (‘Pen Strep’ 10,000 U/ml, Thermo
Scientific). All lines were subcultured 1-2 times per week as described below, depen-










CaSki RPMI-1640 0.25% HPV16 positive
squamous cell carcinoma,
adult cervix (metastasis to
small intestine)
ATCC




TABLE 2.1: The cell lines cultured for all aspects of the project. See (1) for details of
abbreviations.
Cell culture
For subculturing, culturing medium was removed and the cells washed with 2ml ster-
ile phosphate-buffered saline (PBS) before 2ml RT Trypsin/EDTA at appropriate con-
centration was added (see Table 2.1) and the plates incubated for no more than 5min at
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37◦C. Dissociation was confirmed using brightfield microscopy before 8ml appropri-
ate warmed medium was added. The resulting cell suspension was diluted into pre-
pared culture plates containing the required volume of warmed medium. The plates
were swirled to promote seeding uniformity and maintained for at least 24h before
further treatment.
Cell freezing and recovery
For cell storage, confluent 10cm plates were incubated at 37◦C for 5min with 1ml
Trypsin/EDTA after washing with 2ml PBS to remove residual medium. Disassoci-
ated cells were mixed with 4ml appropriate serum-free media, transferred to a 15ml
Falcon tube and centrifuged at 200g for 5min at RT. The supernatant was discarded,
replaced with 3ml freezing media (50% FBS, 20% dimethyl sulfoxide (DMSO, Sigma),
30% serum-free media [v/v]) and the suspension aliquoted into 3 labelled CryoTube
Vials (Thermo Scientific). The vials were transferred to a prepared freezing container
and stored at -80◦C overnight before long-term storage in liquid nitrogen.
For recovery, culture plates were prepared with 8ml appropriate medium and in-
cubated at 37◦C. Cryo vials were thawed at 37◦C and the cell mixture immediately
combined with 1ml warmed media before transferring to the prepared plate. 90% me-
dia replacement was carried out the following day to remove dead cells and residual
DMSO. Following recovery, cells were monitored daily to assess viability and growth
rates.
2.2 Production of his-tagged p16
2.2.1 Transfection
Histidine-tagged vector pcDNA3.1(+) containing a 524bp gene insert for p16 was or-
dered from Invitrogen GeneArt and amplified in competent bacteria (DH5α) using
the GeneJET Plasmid Maxiprep Kit (Thermo Scientific) to produce 1ml purified DNA
(589.4ng/µl). For a 6-well culture plate containing 50-70% confluent wild-type cells,
DNA vector was added to 100µl appropriate serum-free medium at RT for each well.
Transfection agent was added for 15min to allow for complex formation. Cell medium
was aspirated from the culture plates and replaced. The transfection complex was
added dropwise and the plates maintained as described above for 24h before harvest-
ing. Initial experiments suggested that Lipofectamine resulted in lower transfection
efficiency and cell viability than Attractene, and so the latter was used for all further
experiments.
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SiHa and SAOS-2 (osteosarcoma) wildtype (w/t) cells were transfected with the
target vector or a green fluorescent protein (GFP) control insert in pcDNA3.1(+) in or-
der to optimise DNA and reagent levels (Figure 2.1). These cell lines were chosen for
their disrupted pRb pathway, thus permitting overexpression of p16 without initia-
tion of cellular senescence and subsequent difficulties in culturing. Reduced levels of
Attractene were found to have no adverse effects on transfection efficiency. SiHa cells
are capable of producing larger quantities of protein from the same levels of DNA
compared to SAOS-2, and so were chosen for further protein purification work. Both
p16 expression and controls suggest that optimal reagent and plasmid concentrations
can be seen in Table 2.2.
Plate type DNA (ng) Attractene (µl) Media volume (µl)
96 well 0.2 0.5 50
24 well 0.4 1.0 60
6 well 1.2 3.0 100
10cm 4.0 10.0 300
TABLE 2.2: The optimised levels of DNA, Attractene and serum free media used for trans-
fecting His-tagged p16 in pcDNA3.1(+) vector into SiHa wildtype cells.
2.2.2 Purification
Plate capture
Production of his-tagged protein in SiHa cells was confirmed by capture on a nickel-
coated 96-well plate (Pierce, Thermo Scientific) with binding capacity of ≈9pM per
well. Transfected SiHa cells were lysed with Triton buffer (see Table 2.3) and the lysate
(0.8ng/µl or 0.8M) diluted 1:1000 in PBS. 50µl was added to each well required and in-
cubated on a plate shaker at 500rpm for 1h at RT. Wells were washed three times with
PBS-Tween and 100µl primary antibody in PBS added at dilutions of 1:2000, 1:1000
and 1:500 in duplicate for 1h at RT. After washing, secondary antibody at 1:1000 in
PBS was added for 1h, the plate washed and visualised immediately upon addition of
enhanced chemiluminescence (ECL) solution using a photometric plate reader (Fluo-
roskan Ascent FL, Labsystems). The results can be seen in Figure 2.2.
Bead capture
His-tagged p16 was captured on Ni2+ Agarose beads (Ni-NTA Agarose, Qiagen) with
400µl lysate supernatant combined from four confluent 10cm plates of transfected
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SiHa. After washing, cells were lysed with NP-40 lysis buffer for 30min on ice and
sonicated. The resulting lysate was filter-sterilised with 0.22µm membrane to remove
larger molecules or residual cellular debris. Ni2+ Agarose beads were washed, pel-
leted and resuspended three times in Wash Buffer I before suspending in 1ml lysis
buffer. The lysate was incubated with the beads for 1h at 4◦C on a rotating incubator.
The bead-protein complex was run through a prepared 10ml column with 5x Wash
Buffer I washes and 3x Wash Buffer II washes before eluting wih 2ml Elution Buffer
for 30min at 4◦C on a rotating incubator. The elutant was added to a Zeba Spin De-
salting Column (7K MWCO, Thermo Scientific) and centrifuged at 1000g for 2min at
4◦C to remove salts and other small molecules. The concentration was determined by
spectrophotometry of the 260/280nm absorbance ratio to be 33.3µg/ml averaged over
three measurements. The purified protein was diluted 4:1 with 80% glycerol in PBS
[v/v], aliquoted and snap frozen in liquid nitrogen for storage at -80◦C.
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FIGURE 2.1: GFP positive controls in SiHa for a) 1.2 µg DNA, 3.0 µl Attractene, b) 1.8 µg
DNA, 3.0 µl Attractene, c) 1.2 µg DNA, 4.5 µl Attractene and d) 1.8 µg DNA, 4.5 µl At-
tractene. Reduced Attractene does not affect transfection efficiency. e) Demonstration of
effective transfection of His-tagged p16 (higher molecular weight) into SAOS-2 and SiHa
cells alongside endogenous WT p16 expression in Western blot.
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FIGURE 2.2: Lumimetric intensity of nickel plate-captured his-tagged p16 protein from
crude cell lysate, demonstrating that the protein can be expressed and extracted using
this method. The blank control refers to a block-only plate with 1:1000 primary antibody
dilution.
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2.3 Western Blotting
For ease of reading, all buffer constituents and gel reagents are listed in Tables 2.3
and 2.4 respectively. All Western Blotting equipment originates from BioRad unless
otherwise stated.
Buffer type Conc. Constituents
NP-40 1x 0.1% NP-40 [v/v], 25nM HEPES, 150mM NaCl
50mM NaF, 1x PIM, 5mM DTT
Triton 1x 0.10% Triton x100 [v/v], 50mM HEPES (pH7.6)
0.1mM EDTA, 150mM NaCl, 10mM NaF
1x PIM, 2mM DTT
Urea 1x 7M urea, 25mM HEPES, 25mM NaCl
0.05% Triton x-100 [v/v], 5mM DTT
Sample buffer 2.5x 5% SDS [v/v], 25% glycerol [v/v], 0.3M Tris (pH6.8),
Bromophenol Blue
Diluted with 1:5 DTT/lysate
Running
buffer




10x 29g Tris, 144g glycine in 1l dH2O.
Diluted with 2:7 MetOH/dH2O
ECL I 1x 0.1M Tris-HCl (pH8.6), 1ml 250mM Luminol in
DMSO, 440µl 90mM p-Coumaric acid in DMSO, in
100ml dH2O
ECL II 1x 0.1M Tris-HCl (pH8.6), 64µl H2O2, in 100ml dH2O
TABLE 2.3: Constituents of lysis, sample and SDS-PAGE buffers used during the project,
particularly for Western Blotting. Lysis buffers were all made up to 2ml with dH2O. See
(1) for details of abbreviations.
2.3.1 Cell lysing and protein quantification
Harvesting
Cells were harvested from culture plates using a cell scraper after three washes with
PBS. The resulting 1ml suspension in PBS was centrifuged at 400g for 5min at 4◦C
and the supernatant removed. Cell pellets were lysed immediately or snap-frozen in
liquid nitrogen for storage at -20◦C.
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Gel type Constituents
Running gel 5.0ml dH2O, 6.0ml 30% acrylamide mix
3.8ml 1.5M Tris (pH8.8), 150µl 10% SDS [w/v]
150µl 10% APS [w/v], 6µl TEMED
Loading gel 4.1ml dH2O, 1.0ml 30% acrylamide mix
750µl 1.0M Tris (pH6.8), 150µl 10% SDS [w/v]
150µl 10% APS [w/v], 6µl TEMED
TABLE 2.4: Constituents of handcast SDS gels used to separate proteins. Volumes and
concentrations described produce 2 12% gels of 1.0mm thickness. See (1) for details of
abbreviations.
Lysing
Thawed pellets were resuspended in 100µl freshly prepared lysis buffer and incubated
on ice for 15min. The samples were transferred to a microcentrifuge at 16,100g for
15min at 4◦C, the protein supernatant transferred to a fresh Eppendorf tube and the
cellular debris discarded. Triton, urea and NP-40 lysis buffers were tested with SiHa
and CaSki cells (Figure 2.3). Use of urea buffer resulted in an additional band below
that associated with native p16, indicating degradation or cleavage. NP-40 lysis buffer
was used for all subsequent lysing steps.
FIGURE 2.3: Expression of p16 and house-keeping gene β-actin in p16-positive cell lines
SiHa and CaSki (both HPV16 positive squamous cell carcinoma of the cervix). The use of
urea lysis buffer leads to the appearance of lower molecular weight bands.
Bradford Assay
1µl of each lysate sample was added, in duplicate, to 200µl 1x Bradford Reagent (Bio-
Rad) in a clear 96-well plate. Protein standards were prepared in the same way using
samples of 4.000, 2.000, 1.000, 0.500, 0.250, 0.125, 0.068 and 0mg/ml Bovine Serum
Albumin Fraction V (BSA, Melford) in dH2O [w/v]. Preparations were thoroughly
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mixed in a plate shaker at 500rpm for 10min. Colorimetric response was measured us-
ing a microplate reader (Wallac Victor3 1420-050 (Perkin Elmer) or Spark 20M (Tecan))
and the resulting values plotted against the standard BSA curve to give average total
protein content per sample in duplicate. Normalised protein volumes were diluted
1:1 with dithiothreitol (DTT) sample buffer and the finalised samples heated at 70◦C
for 4 minutes to denature the proteins. Samples were stored on ice until loaded.
2.3.2 Gel electrophoresis and imaging
Gel, tank and membrane preparation
12%T (total monomer concentration) SDS gels were produced in gel casts and stored at
4◦C for no more than two weeks before use. Upon addition of tetramethylethylenedi-
amine (TEMED, Thermo Scientific) the running gel mixture was pipetted rapidly into
the gel casts and left to set. This was repeated for the loading gel, with a well comb of
appropriate size and thickness inserted for sample loading. Finished gels were loaded
into gel cassettes and placed in a Mini-PROTEAN tank filled with SDS running buffer
to the height of the gel cast. Loaded protein samples were separated on the gel at 160V
for 1h.
Nitrocellulose membrane and blotting paper were soaked in transfer buffer prior
to use. The protein bands were transferred to the nitrocellulose membrane using a
Mini Trans-Blot Cell at 100V for 1 hour or at 25mA overnight. An ice block was added
to the transfer tank to prevent voltage fluctuations due to overheating.
Antibody incubations and visualisation
Transferred membrane was fixed and stained with 4% paraformaldehyde (PFA) in
PBS [v/v] and black ink (Pelican) for 15min. Unbound areas of the membrane were
blocked using 5% fatless milk powder (Marvel, ‘milk solution’) in PBS-Tween [w/v]
for 1h at RT. The membrane was partitioned using a scalpel according to the weight
of the proteins of interest. The relevant sections were incubated for 1h with primary
antibody (to protein of interest or housekeeping gene) diluted in milk solution. The
membranes were then washed in triplicate with PBS-Tween to remove unbound anti-
body. This step was repeated for horseradish peroxidase (HRP)-conjugated secondary
antibody (Polyclonal Rabbit Anti-Mouse HRP, DAKO). Chemiluminescence was acti-
vated by 1:1 ECLI/ECLII blotting for 1 minute, and the bands visualised on Hyperfilm




2.4.1 Cell and slide preparation
Cells were seeded onto ethanol-sterilised glass cover slips at appropriate dilution to
reach 50-80% confluency after 24 hours (typically 1:4 in 6-well culture plate) unless
transfection was required. After washing in triplicate with PBS, cells were fixed for
15min in 4% PFA in PBS [v/v], washed again with 0.1% PBS-Tween [v/v], perme-
abilised with 0.1% PBS-Triton X100 [v/v] for 15min and blocked for 30min with 3%
BSA in PBS-Tween (‘blocking buffer’). Cover slips were transferred to a dark box and
incubated for 1h at RT with 1:250 primary antibody to p16 (BD Pharmingen Mouse
Anti-Human mAb 0.5mg/ml) in blocking buffer, washed with PBS-Tween and incu-
bated under the same conditions with fluorescent secondary antibody (AlexaFluor 488
Goat Anti-Mouse 2mg/ml). Cover slips were then incubated with 4’,6-diamidino-2-
phenylindole (DAPI, Thermo Scientific), 1:2500 in PBS for 5min for nucleus visuali-
sation, before washing once with PBS-Tween and twice with dH2O to remove resid-
ual saline. Cover slips were mounted on glass slides using Fluorescence Mounting
Medium (DAKO) and stored at 4◦C overnight before imaging.
2.4.2 Fluorescence imaging and analysis
Images were recorded using the fluorescein isothiocyanate (FITC) and DAPI chan-
nels of a Zeiss upright epifluorescence microscope with micrometre stage. The DAPI
channel was used for focus, and the FITC channel of target-positive samples auto-
exposed first to determine an exposure time which would not cause image saturation.
Tiled images were compiled in MicroManager using Multi Acquisition with 10% im-
age overlap. Individual exposures were stitched together in FIJI (ImageJ) using image
position metadata and the Grid/Collection Stitching plugin.
Nuclear expression of p16 protein was assessed over cell populations by mapping
a thresholded nuclear mask from the DAPI channel onto the FITC channel and using
particle analysis to assess the mean 16-bit greyscale value of each nucleus. The size
(µm2) and circularity of the assessed nuclei were adjusted until all non-overlapping
cells were incorporated. Relative p16 expression was visualised using expression his-
tograms, produced in Origin 2016 - a typical example can be seen in Figure 2.4.
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FIGURE 2.4: Tiled immunofluorescence images with p16 expression in green and nuclear
staining in blue of a) HaCaT cells, b) SiHa cells. c) A population histogram of the cor-
responding nuclear expression of p16 in both cell types across the full 16-bit grayscale
range.
2.5 Enzyme-linked immunosorbent assay (ELISA)
ELISAs were used to calculate the assay detection sensitivity of antibodies to p16 (BD
Pharmingen mAb, mouse anti-human 0.5mg/ml). Purified p16 (p16-INK4a, Recom-
binant Human, RayBiotech) was reconstituted at 10ng/µl in PBS and the protein so-
lution incubated in 0.1M sodium carbonate buffer such that the total mass per well
was 100.00, 50.00, 25.00, 12.50, 6.25, 3.13, 1.56 and 0.78ng in a 50µl volume. Once in-
cubated for 1h at RT on a plate shaker at 500rpm, the wells were washed three times
with 0.1% PBS-Tween [v/v] and blocked with 200µl 3% BSA in PBS-Tween [w/v] for
1h at RT. An additional block-only row was used for an average blank value. Blocking
buffer was replaced with primary antibody diluted 1:1000 in blocking buffer, incu-
bated for 1h, washed again and the process repeated for HRP-conjugated secondary
antibody (Polyclonal Rabbit Anti-Mouse HRP, DAKO). After washing, expression was
visualised immediately using 50µl ECL solution on a photometric plate reader. The
initial ELISA for BD Pharmingen mAb 0.5mg/ml can be seen in Figure 2.5. This was
repeated in triplicate in Chapter 4 Section 4.5.2.
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FIGURE 2.5: Lumimetric intensity of BD Pharmingen mAb to p16, diluted 1:1000, when
visualised with HRP-conjugated secondary antibody. The ELISA indicates an antibody
limit of detection in the region of 0.125ng/µl for this assay format. Antibody detection
sensitivity is an important consideration for conjugated nanoparticles.
2.6 Paper-based immunoassays
2.6.1 In-house dipstick assays
Basic in-house dipstick assays were produced by cutting a nitrocellulose membrane
(HiFlow Plus, 130µm membrane thickness) into 5mm by 35mm strips (Assay type
‘A’). Paper-based devices were also constructed using a nitrocellulose membrane with
adhesive backing (Hi-Flo Plus 180 Membrane Card, Merck Millipore) attached to a
cellulose wicking pad (C083 Cellulose Absorbent Sample Pad Roll, SureWick, Merck
Millipore) at the top and absorbent glass fibre pad (GFDX Glass Fiber Conjugate Pad
Roll, SureWick, Merck Millipore) at the base (Assay type ‘B’). In both cases, 0.5µl puri-
fied protein (p16-INK4a, Recombinant Human, RayBiotech) in PBS was spotted onto
the centre of the strips and air-dried for use in testing for antibody binding activity
(Figure 2.6).
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FIGURE 2.6: A) A simple flow device consisting of a backed nitrocellulose membrane.
B) An improved architecture which facilitates conjugate uptake and storage through the
glass fibre pad, and increased volume and capillary force through the addition of a cellu-
lose wicking pad.
2.6.2 Commercial conjugation assays
Commercial dipstick assays (‘Conjugate Check & Go!’, Expedeon) were used to test
for successful conjugation. In addition to a nitrocellulose sample strip (400µm mem-
brane thickness) and cellulose wicking pad these assays have a printed test line of Pro-
tein A/G mix which binds to the fragment crystallizable (Fc) region of most species
of monoclonal antibody, including non-reactive isotype controls. Commercial assays
were also used as a vehicle for purified protein spotting where stated.
In all cases, the base of the prepared dipstick assay was placed in a clear 96-well
plate containing a homogeneous mixture of 20µl nanoparticle sample and 20µl ‘con-
jugate buffer’ + 1% BSA [w/v] (Figure 2.7). Conjugate buffer 10x concentrate was
supplied with the assay kit, prepared according to the recommended method and
stored at 4◦C. Paper assays were placed backing down at a slight angle from the ver-
tical to prevent uncontrolled solution wicking caused by surface contact with the well
chamber. These were left for 10-20 minutes until the assay was saturated and no liquid
remained in the well. Assays were photographed using a dSLR camera (Nikon D3300)
or scanned with an Epson 4490 Photo for colorimetric inspection.
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FIGURE 2.7: A pictorial representation of the dipstick method. A) Conjugates are applied
to a buffer solution, either in isolation (for testing purposes) or to cell lysate. B) The
solution is drawn up an inserted nitrocellulose assay strip (Figure 2.6 by capillary action.
C) The conjugates interact with a dried target line (either purified p16 protein or a binding
ligand for the same, when using lysate). Excess unbound conjugates dry into the wicking
pad.
2.7 Nanoparticle blotting
Nitrocellulose membrane (BioTrace NT) of thickness 101.6µm and pore size 0.2µm was
blotted with purified protein (p16-INK4a, Recombinant Human, RayBiotech) in PBS
and left to dry. The membrane was then blocked with 5% BSA or fatless milk pow-
der in PBS-Tween for 1h at RT or overnight at 4◦C. After rinsing with PBS-Tween, a
conjugate solution was applied to the surface for 1-2 hours. In the case of blank nitro-
cellulose membrane, typically 2ml conjugate would be applied to a 6x8cm surface and
left on a rocking plate to prevent solution pooling. For wax-printed 96 well plate de-
signs on membrane, 20µl conjugate was added to each circle (Figure 2.8). Membranes
were then soaked in PBS-Tween for 1h to remove non-specifically dried conjugates,
before being photographed for colorimetric inspection.
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FIGURE 2.8: A) Plan view of the wax-printed ‘96-well’ assay, in which resistive wax is
patterned onto a nitrocellulose membrane. B) The target or capture ligand is dried into
the exposed ‘wells’ of the membrane, before the conjugates are applied. Conjugates may
either bind to the target in question or flow through to a blotting layer underneath.
2.8 SERS mapping
SERS mapping with conjugate-incubated cells was carried out using a Renishaw inVia
confocal Raman microscope equipped with a 500mW 785nm laser and 50x magnifica-
tion lens. Brightfield images were recorded for hotspot co-registration. Spectra were
acquired using a 1200l/mm grating, 10% laser power with edge filter and no pinhole,
spectra centred on 1400cm−1 and a step size of 2µm unless otherwise stated. Prior to
sample measurement, a silicon standard was measured using 100% laser power and
1s single acquisition. The characteristic vibrational peak at 520cm−1 was manually
calibrated as required.
After acquisition, spectra were smoothed using a 7-point Savitzky-Golay filter and
baselined using the proprietary automated baseline tool in Wire 4.0 or 4.2. Normali-




spectroscopy for cell classification
3.1 Introduction
One of the major technical barriers to the introduction of Raman spectroscopy as a
clinical tool is the rarity of inelastic photon scattering events. The acquisition of high-
quality spectra is further compounded by the presence of autofluorescence in samples,
which is a particular problem for biological interrogation and can often lead to the
loss of smaller Raman peaks behind a fluorescent background. Several approaches for
reducing the background have been explored previously, including post-acquisition
baseline correction, stimulated Raman spectroscopy (SRS) and time-, frequency- and
wavelength-domain methods [127].
Time-domain methods are based on the lifetime differences between emitted fluo-
rescent and Raman scattered photons, on the order of nanoseconds and picoseconds
respectively. As such it is a multimodal analogue of fluorescence lifetime imaging
(FLIM). The use of an ultrafast laser pulse and temporal gate allows the almost instan-
taneous Raman scattering event and slower fluorescence relaxation to be separated in
time. Temporal gates include Kerr gates [128], intensified CCD or CMOS devices [129,
130] and streak cameras [131]. Such methods, which require high-energy laser sources
to generate a detectable signal in short pulses, are typically not suitable for use with
biological samples due to the risk of photodamage [129].
Frequency or phase-modulated approaches include frequency demodulation [132]
and phase-nulling approaches [133]. In the former, a high-frequency sinusoidal wave-
form applied to the laser source causes differences in the phase shift and subsequent
amplitude of Raman and fluorescence events. This results in a suppression but not
necessarily complete removal of the autofluorescent background.
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Wavelength modulated Raman scattering (WMRS) is a wavelength-domain ap-
proach, along with shifted excitation Raman difference spectroscopy (SERDS) [134]
and subtracted shifted Raman spectroscopy (SSRS) [135]. WMRS has been used to in-
vestigate single living Chinese Hamster Ovary cells (CHO-K1) [136] as well as T lym-
phocytes (CD4+, CD8+), killer T cells (CD56+) and dendritic cells (CD303+, CD1c+)
[137]. It has also been shown to provide high specificity and sensitivity for the char-
acterisation of human urothelial (SV-HUC-1) and bladder cancer (MGH) cell lines cul-
tured normally [138] or exposed to urine [139], which represents another step towards
an automated optical platform for cancer screening. However, molecular markers of
pathologies vary from disease to disease, necessitating for this thesis an in-depth study
of cells specific to the cervical cancer context.
3.2 Concept: wavelength modulation
During a WMRS measurement, the laser wavelength is modulated throughout the ac-
quisition process using a tunable laser [138]. This causes the Raman spectral peaks to
shift fractionally when measured in terms of scattered wavelength. When this shift
is measured across several wavelengths, a ‘differential spectrum’ can be generated
which demonstrates the true Raman peaks in wavenumber shift from the incident
wavelength. This wavelength modulation does not affect the position of autofluores-
cence from the sample and substrate, allowing the background to be automatically
removed.
Automatic autofluorescence removal is conducted on the basis that fluoresence
background is static in reference to a shift in incident wavelength. An individual
spectrum Sj measured at a wavelength shift ∆λi of the tunable laser can be repre-
sented by the superposition of the Raman SR and fluorescent SF parts, where Sj(λi) =
SF(λi) + Mik(∆λi)SR(λk). Mik is the fractional shift matrix, determined by the mod-
ulation of wavelength. The separation of the Raman and fluorescence components is
achieved by representing Mik using a lock-in procedure [136], where the modulated
Raman spectrum can be elucidated from a ‘noisy’ fluorescence spectrum. Numer-
ous methods have been tested with wavelength modulation for the removal of this
static fluorescence background, including standard excitation Raman difference spec-
troscopy, standard deviation, Fourier filtering, least-squares fit and principal compo-
nent analysis (PCA), with PCA providing the best signal-to-noise ratio (SNR) [140].
Using Principal Component Analysis (see Section 3.3.3), the differential Raman spec-
trum is formed from the first principal component of the modulated data set, corre-
sponding to the component which captures the greatest variance in the data.
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In this study, the principle of background-free global Raman interrogation and
multivariate analysis was applied to the automatic classification of cervical smear ana-
logues, fixed in PreservCyt to reflect clinical practice. The primary aim was to test the
classification capability of the technique, with additional consideration for the practi-
calities of sample acquisition time and setup.
3.3 Materials and methods
3.3.1 Cell sample preparation
A total of five established cell lines from squamous epithelial tissue were used for this
project, reflecting the intention to investigate WMRS as a method of classifying cer-
vical smear samples. CaSki, SiHa, C33A (all squamous cell carcinoma, adult human
cervix), HaCaT (immortalised squamous epithelium, adult human skin) and NHEK
(normal squamous epithelium, neonatal human skin) were cultured to 80-90% conflu-
ency. Culture methods can be found in Chapter 2, Sections 2.1.1 and 2.1.2. These were
harvested by trypsinisation, washed in triplicate by centrifugation and resuspension
in sterilised phosphate buffered saline (PBS), and fixed in the clinical methanol-based
fixative PreservCyt Solution (‘PreservCyt’, Cytyc). Samples were stored in PreservCyt
at -20◦C until use. All centrifugation steps were executed at 400g for 5 minutes at 4◦C.
Prior to interrogation, fixed cell samples were washed in triplicate by centrifuga-
tion and resuspension in sterilised PBS in order to remove traces of fixing solution, as
methanol produces strong Raman signatures. 20µl of PBS cell suspension was then
transferred to a quartz cavity slide (Figure 3.1), carefully sealed with a 150µm quartz
coverslip and inverted. The quartz assemblies were rested for at least 20 minutes prior
to interrogation in order to promote cell adherence to the quartz coverslip, which was
placed face down on the inverted microscope assembly for measurement.
3.3.2 Spectral acquisition
A confocal Raman spectrometer built and modified for acquisition of both standard
and modulated spectra (Figure 3.2) was used to evaluate the fixed cell samples. Ra-
man spectra were generated from individual cells inside the quartz cavity assembly
using a ‘SolsTis’ tunable continuous wave Ti-Sapphire laser (M Squared, maximum
power 6W), delivering 150mW power to a 1µm spot in the sample plane through a
40x oil immersion objective (Nikon, NA1.3). The signal was resolved with a Sham-
rock SR-303i spectrometer (400 lines/mm grating, Andor Technology) and collected
with a CCD camera (Newton, Andor Technology) thermoelectrically cooled to -70◦C.
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FIGURE 3.1: The cavity slide assembly used for all acquisitions. Slides were sterilised
with ethanol, air-dried and polished in between measurements.
‘Standard’ (spontaneous) and wavelength modulated Raman spectra were acquired
using Solis (s) Software (Andor Technology) along with a brightfield microscope im-
age (Imaging Source USB Camera) of each cell.
Standard acquisitions were conducted at 785nm, using 5 accumulations of 2s laser
exposure for both the cell and adjacent background. In the modulated acquisitions, 5
accumulations of 2s exposures were performed with five different cycles of excitation
wavelengths over a total range 785±0.5nm. No background acquisition was necessary
in the modulated case due to the inherent autofluorescence removal. This approach
was justified on two premises. First, the use of five distinct modulated cycles as a
form of background removal does not improve the SNR of the raw modulated data
to provide an unfair advantage over the standard spectra, which have had their back-
ground removed in a different way. Second, the need to acquire two spectra in the
standard case (for cell and adjacent background) resulted in a practical acquisition
time equivalent to the total modulated acquisition time (50s per data point).
It has been shown previously that no significant phototoxicity was experienced by
the cells as a result of laser exposure at similar settings[137].
Reference spectra for laser calibration and spectral normalisation (Section 3.3.3)
were acquired from 1µm polystyrene beads in distilled water. These spectra, recorded
with a time-stamp either side of each dataset, were used to account for fluctuations
in laser power, wavelength and spot location due to heating, fibre-optic coupling or
mirror alignment.
3.3.3 Spectral processing and data analysis
All spectra were considered in the fingerprint region of interest, 800 to 1800cm−1. Nor-
malisation was conducted by linearly interpolating the intensity and Raman shift of
the characteristic 1001.4cm−1 polystyrene peak according to the sample measurement
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FIGURE 3.2: The optical diagram of the spectrometer designed for WMRS and standard
Raman spectral acquisition. Brightfield microscope images are acquired separately on
CCD1 and blocked from the spectrometer by secondary EF.
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time stamp. This accounts for laser power fluctuations over time, thereby prevent-
ing the PCA script from grouping cells according to laser power or wavelength drift.
Immediately prior to analysis, individual spectra were assessed and removed from
the analysis if a high spectral background was apparent. Such artefacts arise from
suboptimal focusing or cell movement during acquisition.
All spectra were analysed using Principal Component Analysis (PCA), a com-
monly used multivariate spectral analysis technique. PCA breaks spectra down into
orthogonal spectral components (‘loadings’ or ‘principal components’, PCs) which de-
scribe the variation in the dataset. The first principal component describes the greatest
variation, with higher components eventually describing noise [141]. Seven PCs were
used in all data analysis conducted but a maximum of three displayed for ease of visu-
alisation. Previous research with human immune cells with the same setup indicated
that the first seven PCs account for the major variation in the dataset [137], and so
this was used for all test models. The weighting or ‘score’ of these PCs (the extent to
which each PC represents a particular spectrum in the dataset) can be used to generate
PCA cluster plots, which may be used for diagnostic classification. The loadings and
scores represent, respectively, the eigenvectors and eigenvalues of the data covariance
matrix, consisting of samples and their spectra at each wavenumber.
3.3.4 Cross-validation of spectral classification
Sensitivity and specificity values can be generated through leave-one-out cross vali-
dation (LOOCV) also known as a jacknife [142], described visually in Figure 3.3. Here,
a single spectrum is retained and the remaining spectra used to form a training set.
The retained spectrum is then classified according to the first seven principal compo-
nent loadings of the training set using a k-nearest-neighbours (KNN) algorithm [137]
with a known number of clusters, equal to the number of cell types used. In a clinical
setting, this would require large training sets with clusters assigned to designated test
outcomes, for example normal, mild dyskaryosis, and so on.
This is repeated for each individual spectrum, with the collated data displayed as a
confusion matrix. In confusion matrices, correctly classified types appear on the lead-
ing diagonal, with mis-classifications appearing in off-diagonal positions. Matrices
are square with dimensions equal to the number of subsets. The off-diagonal popu-
lations indicate which subsets are more likely to be mistakenly classified as another
set, potentially allowing for conclusions to be drawn regarding biological similarity
or disparity.
3.4. Comparison of human papillomavirus (HPV) status 49
FIGURE 3.3: Pictorial representation of the leave-one-out cross validation method, used
to assess the accuracy of the PCA model for classification.
When performed for two datasets, the classifications can be quantitatively esti-
mated as sensitivity and specificity values by assigning the cell line as ‘positive’ or
‘negative’. Equations 3.1 and 3.2 determine the results.
Sample 1 (Predicted) Sample 2 (Predicted)
Sample 1 (Actual) True Negative (TN) False Positive (FP)
Sample 2 (Actual) False Negative (FN) True Positive (TP)
TABLE 3.1: The classification of assigned positive and negative samples used to generate
sensitivity and specificity data, based on actual and PCA-classified sample type.
Sensitivity =
Test true positive samples






Test true negative samples





Statistically significant variations between spectral intensities were also estimated
for each cell line pair using student’s t-test at a significance level of p < 10−12. The full
processing and analysis script used was written in MATLAB by the Dholakia group
(University of St Andrews).
3.4 Comparison of human papillomavirus (HPV) status
A preliminary comparison of standard and wavelength modulated Raman spectroscopy
as a classification tool was made using fixed C33A (HPV negative) and SiHa (HPV16
positive) cervical carcinoma cell lines, kindly donated by the Scottish HPV Archive
[143]. The samples were resuspended in PBS and prepared for analysis as described
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in Section 3.3.1. Initial tests with the C33A cell line found that an acquisition time of
2s over five accumulations yielded superior standard Raman spectra to a single acqui-
sition of 10s. The brightfield cell images were morphologically similar, consisting of
∼10µm diameter cells which were highly rounded due to the trypsinisation process.
The PCA plots for the standard and modulated Raman can be seen in Figure 3.4
and 3.5 respectively. Spectra can be seen in Figure 3.6. LOOCV was applied to the
datasets to yield pairwise sensitivity values of 88.0% and 100.0% for standard and
modulated Raman respectively, with specificities of 90.5% and 95.8% respectively. It is
clear from both PCA and classification accuracy that modulated Raman spectroscopy
provides an improved separation and classification of two cervical carcinoma cell lines
with differing HPV status. The main spectral disparities occur at approximately 730,
760, 890, 920, 1130, 1250, 1380 and 1480cm−1. In the scores plot, the PC1/2 projection
provides the most distinct separation of samples, as expected.
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FIGURE 3.4: Standard spectral datapoints represented as PC weightings for C33A (HPV
negative carcinoma) and SiHa (HPV-16 carcinoma) cells. 24 C33A and 22 SiHa spectra
were used for the comparison.
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FIGURE 3.5: Modulated spectral datapoints represented as PC weightings for C33A (HPV
negative carcinoma) and SiHa (HPV-16 carcinoma) cells. 21 C33A and 23 SiHa spectra
were used for the comparison.
FIGURE 3.6: Average A) standard and B) modulated spectra for C33A and SiHa cells.
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3.5 Comparison of transformation status
3.5.1 Comparison of standard and modulated spectral classification by PCA
The investigation of standard and modulated Raman spectroscopy was then extended
to four cell lines (one normal, one immortalised, two cancerous). A total of 163 cells
were interrogated using both standard and wavelength modulated Raman spectroscopy,
consisting of 42 NHEK, 40 HaCaT, 41 SiHa and 40 CaSki cells. As before, the estab-
lished cell lines in particular could not be discerned on a purely morphological basis,
which furthers the case for biochemical classification as a complementary technique.
It must be noted that the morphology of the primary NHEK cells varied significantly
in terms of both shape and size compared to the established cell lines. Following re-
moval of suboptimal spectra according to Section 3.3.3, Raman spectra and PCA plots
were generated as seen in Figures 3.7 and 3.8 respectively. The ability of PCA to act
as a classification algorithm was explored using cross-validation of the data. LOOCV
was performed on all four cell lines for both datasets; the confusion matrices for stan-
dard and modulated PCA can be seen in Tables 3.2 and 3.3 respectively, along with
misclassification statistics. For all three established cell lines, the modulated spectra
provide better discrimination. However, classification is slightly superior using stan-
dard Raman spectra for NHEKs.
3.5.2 Pairwise analysis of cell lines
In order to gain further understanding of both the efficacy of the test and the ma-
jor vibrational signals contributing to the analysis, each possible pair combination of
cell lines were analysed using the PCA script. The sensitivity and specificity values
for each of these tests are summarised in Figures 3.9 and 3.10 respectively. The av-
erage sensitivity was 84.8 ± 9.0% and 93.8 ± 5.2%, and specificity was 85.1 ± 10.7%
Predicted
Actual NHEK SiHa CaSki HaCaT Class acc.
NHEK 31 2 1 1 88.6
SiHa 2 25 6 7 62.5
CaSki 1 9 19 10 48.7
HaCaT 3 9 6 22 55.0
TABLE 3.2: The confusion matrix resulting from cross-validation of standard Raman PCA,
with accompanying percentage classification accuracy.
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FIGURE 3.7: (a) Standard and (b) modulated Raman spectral averages for the four cell
lines used, 800-1800cm−1
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FIGURE 3.8: (a) Standard and (b) modulated PCA weightings for the four cell lines used.
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Predicted
Actual NHEK SiHa CaSki HaCaT Class acc.
NHEK 29 4 0 1 85.3
SiHa 1 30 0 10 73.2
CaSki 1 1 38 0 95.0
HaCaT 0 2 0 38 95.0
TABLE 3.3: The confusion matrix resulting from cross-validation of modulated Raman
PCA, with accompanying percentage classification accuracy.
and 93.8± 4.3%, for standard and modulated PCA respectively, all given as standard
error of the mean (SEM). This demonstrates that, for both metrics, wavelength modu-
lated Raman spectroscopy provides superior discrimination as well as lower variation
between cell types.
The generated spectra were also marked with significance bands as described in
Section 3.3.4. Banded spectra for NHEK-SiHa, NHEK-CaSki and NHEK-HaCaT are
shown in Figures 3.11 and 3.12: the remaining combinations (SiHa-CaSki, HaCaT-
SiHa, HaCaT-CaSki) did not possess any bands under the t-test statistics used and are
omitted. The lack of statistically significant spectral differences for the latter pairings
explains the reduced sensitivity and specificity values for these three comparisons.
Prior to consideration of significance bands, it can be seen in the standard Raman spec-
tra that for each comparison of NHEKs to the three established cell lines, the same
peaks are demonstrating significant change. The peak at approximately 1590cm−1
(adenine/guanine) only appears for the immortalised and carcinoma cell lines. The
largest peak at approximately 1450cm−1 (CH2 deformation in lipids) is unusual in
that it is higher for NHEKs than SiHa or HaCaT cells. All remaining peaks show in-
creases for the cancerous and immortalised cells. The NHEK-CaSki comparison shows
a small increase in the C-C skeletal stretching in protein not seen in the remaining com-
parisons whereas, in the NHEK-SiHa and NHEK-HaCaT studies, the latter cell lines
show more pronounced increases in the ring breathing in tyrosine/C-C stretching in
proline.
The statistically significant bands and tentative peak assignments based on pre-
vious literature [117] are discussed in Section 3.8. Overall, it is clear that the use of
a differential spectrum in modulated Raman spectroscopy highlights different statis-
tically significant regions of the spectrum in comparison to standard Raman spectra.
This is because the differential method highlights the shape and relative position of
the peak, as opposed to just the intensity.
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FIGURE 3.9: The sensitivity values for each set of cell lines when cross-validated as a pair.
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FIGURE 3.10: The specificity values for each set of cell lines when cross-validated as a
pair.
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FIGURE 3.11: Standard Raman spectra for the pairwise comparisons demonstrating sig-
nificant spectral deviations (grey bands) under the t-test statistics used.
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FIGURE 3.12: Standard Raman spectra for the pairwise comparisons demonstrating sig-
nificant spectral deviations (grey bands) under the t-test statistics used.
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3.6 Considerations of sampling location
As discussed in Section 3.1, it was previously found that the Raman spectra for intra-
cellular locations in CHO cells cultured on glass slides were very distinct, with the nu-
cleus providing the optimum SNR. However, this data was generated from adherent
cells grown directly onto glass slides, giving the characteristic flattened morphology
associated with cells in culture (Figure 3.13). In the case of spectral acquisitions for
Sections 3.4 and 3.5, it was not always clear from a combination of camera resolution
and morphology whether the nucleus was being targeted.
To investigate the importance of intracellular location on characterisation, further
samples of the Section 3.5 cell lines were fixed and each cell interrogated multiple
times at locations designated as cell membrane (labelled wall for brevity), cytoplasm,
nucleus and nucleolus. Cells were rejected if the specified components could not be
discerned clearly. The nucleolus was identified as a high-density sphere within the
nuclear volume. All four datasets were recorded in the modulated setup only and
analysed as discussed previously.
Figure 3.14 shows the overall PCA plot from the cells, disregarding laser spot lo-
cation. The resulting confusion matrix classification accuracies are detailed in Table
3.4. Despite some misclassifications (particularly for NHEKs), the average predictive
accuracy is high at 91.2%. This confusion matrix can then be expanded to consider
location for each cell line in turn. This can be seen for the SiHa line in Figure 3.15,
with remaining cell lines in Figures 3.16, 3.17 and 3.18. The classification accuracies
for the location-specfic subset of each expanded matrix are summarised in Table 3.5.
These are much lower than both classifications by cell line and location-based results
from de Luca et al.’s experiment, suggesting that there is insufficient spectral disparity
FIGURE 3.13: Intracellular locations of A) the original experiment with CHO cells which
indicated classification could be made by the locations shown; B) typical morphology of
adherent cells in culture; C) typical morphology of fixed cells following trypsinisation.
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FIGURE 3.14: PCA weightings for the four cell lines classified without consideration of
sampling location.
to separate clusters by location.
Predicted
Actual CaSki SiHa HaCaT NHEK Class acc. (%)
CaSki 38 0 0 1 97.4
SiHa 0 36 2 1 92.3
HaCaT 1 0 37 2 92.5
NHEK 0 2 5 33 82.5
TABLE 3.4: confusion matrix resulting from cross-validation of the intracellular location
dataset before consideration of internal location. The average classification accuracy is
91.2%.
As such, the matrices were then considered by grouping points according to their
location inside (nucleus, nucleolus) or outside (cytoplasm, cell membrane) the nu-
cleus. The summarised classification accuracies shown in Table 3.6. The resulting
accuracies from this test indicate that there is sufficient spectral difference to separate
these location clusters from inside and outside the nucleus with an accuracy approach-
ing that of cell line classification. However owing to their rounded morphology, the
fixed cells do not provide sufficient spectral difference to distinguish between specific
cellular regions with the accuracy seen for cells in culture.
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FIGURE 3.15: PCA weightings for the four cell lines classified with consideration of sam-
pling location, subdivided into nucleus, nucleolus (‘inner’), cytoplasm (‘cyt’) and cell
membrane (‘wall’).
Classification accuracy
Location NHEK SiHa CaSki HaCaT Average
Nucleus 50 60 50 60 55±5
Nucleolus 50 20 50 80 50±21
Cytoplasm 44 88 44 80 64±20
Cell wall 60 50 60 80 63±11
TABLE 3.5: A summary of the classification accuracies resulting from cross-validation of
modulated Raman PCA of intracellular regions.
Classification accuracy
Location NHEK SiHa CaSki HaCaT Average
Inside 93.3 90.0 90.0 94.1 91.9±1.9
Outside 88.9 86.7 77.8 100.0 88.4±7.9
TABLE 3.6: Classification accuracies resulting from cross-validation of intracellular sam-
pling with reduced spatial sensitivity.
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FIGURE 3.16: CaSki modulated PCA plot expanded by intracellular location.
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FIGURE 3.17: HaCaT modulated PCA plot expanded by intracellular location.
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FIGURE 3.18: NHEK modulated PCA plot expanded by intracellular location.
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3.7 Spectral variation due to sample storage
Finally, the potential effects of storage time on spectral classification were investigated.
This is an important consideration for cervical smears as samples are stored indefi-
nitely for archive in PreservCyt and may have to be revisited for clinical trials or in
the case of ambiguous diagnoses.
Work by Hobro et al. considered spectral differences between live mouse embry-
onic fibroblast (MEF) cells and those fixed with different agents, including methanol
[144]. Methanol acts as both a fixing and permeabilisation agent which dehydrates
cells and precipitates proteins. In that case, a significant loss of overall Raman signal
was observed in cells fixed with methanol, which were mostly associated with lipid
bands. The effects of storage in fixative were not considered by Hobro et al. Based
on the routine morphological and genomic analysis of stored smear samples without
alterations to data, we hypothesised that changes over time after initial fixation would
not be significant. If such changes do occur, it would have considerable impact on the
use of Raman spectroscopy as a tool for clinical sample classification where samples
may be archived in fixing solution for long periods of time either before analysis, for
revisiting borderline samples or for comparing with new samples for disease progres-
sion.
A total of 150 cells were interrogated from SiHa cell samples which had been stored
at −20 ◦C for three days, one month or six months in PreservCyt before following the
same protocols described previously. The average Raman spectra are in Figure 3.19 -
variation can be seen in the 1200-1500cm−1 region as well as for the Amide I (α-helix)
peak at 1680cm−1. Figure 3.20 shows the corresponding PCA plot, where grouping
can be seen for the three day and six month clusters in the PC1/PC2 and PC2/PC3
projections, but not for the one month cluster. The confusion matrix (Table 3.7) shows
considerable variation in classification accuracy, which indicates that there are suffi-
cient spectral differences to ‘classify’ cells from the samples used. However, there is
no trend according to storage time, which indicates that other sources of variation are
present. It is posited that the variation seen may be due to different subculturing ages
of the established cell line samples, which would not be an issue for clinical samples.
However, the sensitivity of the technique here highlights the potential challenges that
may arise from non-specific variation of cervical smears.
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FIGURE 3.19: Variation of average Raman spectra of fixed SiHa cells with storage time
after fixing. Cells were stored in PreservCyt at -20◦C.
FIGURE 3.20
Predicted
Actual 3 day 1 month 6 months Class acc.
3 day 29 0 21 58.0
1 month 1 47 2 94.0
6 months 17 1 32 64.0
TABLE 3.7: The confusion matrix resulting from cross-validation of the fixed cell storage
time dataset, with accompanying percentage classification accuracy.
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3.8 Analysis of significant vibrational modes
The direct interrogation of vibrational modes with this method can yield biologically
relevant data regarding global changes to cell molecular populations. Although Ra-
man is mode- rather than molecule-specific, conclusions may be drawn relating to
alterations in the proteome, lipidome, epigenome and so on.
In Table 3.8, pairwise comparisons are made of the transformed cell lines versus
NHEKs, in both the spontaneous and modulated acquisition modes. The wavenum-
ber regions shown in bold refer to comparisons in which the NHEK spectrum is of
higher intensity - this was not usually the case. Regions shown in italics refer to the
statistically significant region being in the shoulder of the peak. Differences in shoul-
der position and intensity occur as the result of the molecular environment in which
the vibrational bond is found.
As discussed in Section 3.5.2, the modulated differential-like analysis highlights
different areas of the peak structure. The increased classification accuracy of WMRS
may be due, in part, to the use of this spectral profile, which suggests that it may be a
beneficial approach for standard acquisition.
The only regions which were statistically significant for all standard Raman spec-
tral comparisons were those corresponding to Amide I: α-helix and Amide III: β-sheet,
adenine and cytosine. It is posited that the increased density of protein conformational
changes may arise from histones[117]. Many of the remaining significant peak differ-
ences also result from DNA-associated structures, including DNA O-P-O backbone
stretching and polynucleotide chains.
The only differential region which demonstrated statistically significant variations
in each case was that of the symmetric ring breathing mode of phenylalanine/tryptophan.
There was also statistically significant reduction in the CH2 deformation in lipids for
CaSki and HaCaT cell modulated spectra compared to NHEKs. In the modulated
case, the HaCaT cells also demonstrated a significant reduction in the ring breathing
in tyrosine, and the C-C stretching modes in proline, but an increase in Amide I and
III. Interestingly, there were no modes in the modulated case that distinguished the
spontaneously transformed line (HaCaT) from the two cervical cancer lines (SiHa and
CaSki), though in the standard case they could be distinguished with the concentra-
tion of DNA bases.
70 Chapter 3. Wavelength modulated Raman spectroscopy for cell classification





























































Amide III: α-helix & collagen,
























































TABLE 3.8: Statistically significant Raman spectral regions for used for classification of
cell lines. Vibrational modes are assigned based on previous literature (Jess et al. 2007,
Talari et al. 2014). Regions shown in bold represent those for which the NHEK signature
was higher than that of the comparator. Regions shown in italics refer to peak shoulders
rather than the peak itself (shown in normal text).
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3.9 Conclusions
In this Chapter, fluorescence-free wavelength modulated Raman spectroscopy has
been used to consider the benefits and practicalities of such a system in the context
of label-free classification of fixed squamous epithelial cells in suspension, such as
those produced during a cervical smear test.
The use of wavelength modulation in Raman spectroscopy and the resulting re-
moval of autofluorescence provides clear benefits to its ability to automatically clas-
sify cells over conventional Raman scattering, without the requirement for manual
baseline fitting, additional lasers or optical gates. Direct comparison with standard
Raman spectroscopy shows marked improvement of sensitivity and specificity when
considering both HPV (sensitivity +12.0%, specificity +5.3%) and transformation sta-
tus (sensitivity +10.3%, specificity +11.1%). WMRS is able to provide superior cell
classification accuracy, not just overall but in every case except CaSki/NHEK sensi-
tivity. The ability to discriminate between HPV positive and negative cervical carci-
noma cell lines is an encouraging step towards the potential integration of HPV and
smear testing using optical discrimination. However, it must be noted that these car-
cinoma lines represent different mechanisms of origin, and by extension molecular
pathologies. The ability to also identify HPV status in normal cervical cells would be
a requirement of an integrated platform and so this will require consideration.
The investigation of location impact for spectral sampling provided important data
regarding the expected differences between sampling particular cell morphologies or
methods of collection. It is suggested that the lower specificity of sampling location in
this dataset compared to previous experiments is due to the superposition of spectral
data from different components of the cell, as the surface area occupied by the cell is
lower. This lower margin of error could provide benefits for coupling the spectrom-
eter with automated cell sampling capabilities. Translation to clinical samples would
require additional studies into sampling spot size and locational sensitivity to account
for the morphological differences which arise from cell provenance and harvesting
technique.
Finally, the cell spectral data does not appear to be directly affected by fixed cell
storage time which is a positive result in the context of long-term archive classifica-
tion. The data does suggest however that other factors involved, such as biochemical
changes which occur with the level of cell confluency. If this is the case, such in vitro
artefacts are unlikely to affect clinical samples. However, the sensitivity of the tech-
nique to these changes suggest that similar issues with sample heterogeneity will have
to be addressed with large clinical datasets.
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The major technical barrier to this technique becoming clinically relevant is the
acquisition method, which must be progressed beyond point sampling in order to
achieve feasible sampling times. It is entirely feasible that the technique could be com-
bined with other imaging methods such as Optical Coherence Tomography (OCT)
[145] or Digital Holographic Microscopy (DHM) [146] in order to provide a cell ‘to-
pography’ map for automated point sampling. The use of a digital guidance system
could highlight unusual morphologies, thereby reducing the number of cells assessed
per sample. It is hoped that such a system could be introduced to clinical settings in
order to reduce the burden on manual cytological diagnosis, as well as increasing the






As discussed in Chapter 1 of this thesis, the introduction of noble metal nanostruc-
tures into Raman environments allows for signal amplifications up to the order of
109 [99] compared to standard inelastic scattering events, dependent on the substrate-
analyte complex. The mechanism of this surface-enhanced Raman scattering (SERS)
phenomenon is discussed in Section 4.2. As such, SERS represents a way of overcom-
ing the issues of acquisition times discussed at the conclusion of Chapter 3 without
the need for alternative optical setups. Indeed, silver nanoparticles have been used
directly with healthy and cervical cancer patient blood samples to amplify the Raman
spectra and carry out PCA-based classification [124].
The ability of plasmonic nanostructures, and in particular nanoparticles (NPs) to
preferentially interact with Raman scattering events at close proximity means that
they may be used as a specific label as well as a general amplifier, becoming a ve-
hicle for functional molecules. In the context of cervical cancer diagnosis, NPs may be
conjugated to antibodies specific for a known marker of disease such as p16, allow-
ing for expression of this target to be assessed in biological systems. Label-free SERS,
in which metal nanostructures are used for direct enhancement, is well documented
[147] but not suitable for this project: biological moieties would be preferentially am-
plified in areas of greater uptake, which is likely to vary depending on the morphology
and orientation of slide-based cytology samples.
The development of antibody-conjugated nanoparticles or ‘nanotags’ for SERS ap-
plications is multifaceted. It requires not only the optimisation of the individual as-
sembly components as seen in Figure 4.1 - namely the substrate, Raman label, blocking
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layer, conjugation method and binding ligand - but also consideration of the poten-
tially complex interplay between these elements and their surrounding environment,
which often may only be inferred from optical data due to the size of the system.
FIGURE 4.1: Schematic representations of A) bare gold nanoparticles (AuNPs) which ab-
sorb strongly in the green region of the visible electromagnetic spectrum and amplify lo-
cal Raman signals. B) Reporter AuNPs or R-NPs which provide known Raman labelling.
C) Blocked AuNPs which prevent non-specific interaction with the environment and im-
prove in vivo circulation time. D) Targeted AuNPs which attach to molecules of interest
via a binding ligand.
Nanoparticle substrates
SERS can be achieved with any nanoscale metallic structure as described in Section 4.2,
and has also been shown with organic and inorganic semiconductors [148, 149, 150].
Noble metal nanoparticles (AuNPs and AgNPs) are most common owing to mini-
mal oxidation and the ability to support electromagnetic enhancement in the visible
and near-infrared regions, which are more relevant to biomedical imaging applica-
tions owing to their non-ionising effects. AuNPs demonstrate narrower wavelength
tunability and less pronounced SERS enhancement owing to a lower Q-factor, but are
more widely used in current clinical applications [151, 152]. Both types can be fab-
ricated by a number of methods including metal salt reduction techniques [153, 154],
etching and lithography [155, 156], laser ablation [157, 158] and biosynthesis [159, 160]
amongst others.
Examples of colloidal solid nanostructures can be seen in Figure 4.2 and include
spheres, rods, plates, wires, stars and pyramids amongst others [161]. More complex
structures may be hollow [162], contain cores of different materials [163] or be delib-
erately aggregated within a solid dielectric [164]. Solid plasmonic substrates were not
appropriate to this project but are discussed elsewhere [165].
The wavelength of laser excitation of localised surface plasmon resonances (LSPRs)
should be close to the resonant peak of the substrate, which changes with size, shape
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FIGURE 4.2: AuNPs with (a) rod-like, (b) triangular, (c) cubic and (d) octahedral shape. Ag
NPs with (e) rod-like, (f) triangular, (g) cubic and (h) octahedral shape. AuNPs fashioned
as (i) Au decahedra, (j) nanostars and (k) rods with sharp tips. Reproduced from Romo-
Herrera et al. 2011 [161].
and material (Figure 4.3). Theory and experiment indicate that the greatest plasmonic
enhancement is achieved when the nanoparticle resonance wavelength (λNP) is equal
to the average wavelengths of the laser excitation (λexc) and Raman vibrational peak
of interest (λRS), such that λNP = 1/2(λexc + λRS) [166].
Raman labels
In principle, any suitably soluble Raman-active molecule can be adsorbed onto a plas-
monic substrate for electromagnetic enhancement. In practice Raman labels or ‘re-
porters’ fall into three groups as seen in Table 4.1: small molecules, bio-orthogonal
molecules and fluorescent dyes. Small Raman-active molecules such as 1,2-di(4-pyridyl)ethylene
(BPE) or 4-mercaptobenzoic acid (MBA) can be adsorbed or covalently bound by high-
affinity sulphur (thiol) groups onto metallic surfaces with little impact on the hydro-
dynamic diameter of the structure. Bio-orthogonal molecules [168] such as alkynes,
nitriles and stable isotopes of carbon and hydrogen produce peaks in the cellular silent
region, reducing the need for complex signal processing. Fluorescent dyes with Ra-
man activity are often used in development work so that activity can be confirmed
through multiple imaging modalities. Small Raman molecules have the dual benefit
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FIGURE 4.3: (Left) Calculated extinction spectra of single Au/Ag nanoshells with a radius
of 27.5nm and varying shell thickness (d). (Right) Calculated extinction spectra of silica
core/gold shells NPs (core radius 60 nm) with varying shell thickness. Reproduced from
Wang and Schlucker 2013 [167]
of ease of spectral processing due to a lower number of vibrational peaks as well as
their size.
Blocking layers
Additional coatings may protect the nanoparticle from adverse interactions with the
surrounding environment which may lead to uncontrolled aggregation. This can hap-
pen as the result of changes in pH or opsonisation, where biomolecules (typically
charged proteins) in the surrounding environment form unwanted coronae on the
substrate [169]. Common protective layers include passivating proteins such as bovine
serum albumin (BSA), silica (SiO2) shells [170], polymers such as polyethylene glycol
(PEG), glycans and lipid bilayers [171]. Polymer layers can also be used as spacers or
modified with functional groups for conjugation as seen in Section 4.6. Spacer length
is typically optimised so that both steric hindrance of functional molecules and overall
particle size are minimal.
Binding ligands
Conjugated nanoparticles have been applied to a vast array of biosensing and biomed-
ical applications as described previously, with target binding ligands including com-
plementary DNA [172, 173, 174], siRNA [175], naturally occurring protein complexes




Small polarisable molecules Thiol groups; MBA, MP, BT, BPT, ATP.
Adsorbing molecules; BPE, PPY, PYOT, AZPY.
Bio-orthogonal molecules Alkynes; phenylacetylene, propargyl glycine.
Diynes; polyynes (‘carbon atom wire’).
Nitriles; MBN, phenylthiocyanate.
Stable isotopes; carbon-13, deuterium.
Fluorescent dyes Fluorone dyes; Rhodamine 6G, fluorescein.
Isothiocyanates; FITC, MGITC and TRITC.
Cyanine dyes; DTTC iodide (Cy7)
Triarylmethane dyes; Crystal Violet, Brilliant
Blue
TABLE 4.1: Raman-active molecules used as nanoparticle labels, grouped by molecule
type. See Abbreviations (1) for full names.
For this project, quantification of p16 expression was carried out with commer-
cially produced monoclonal antibodies. Antibody-conjugated nanoparticles have been
used previously for cell separation [179] although these use cell surface markers which
are rarely disease-specific. Such systems may be used for separating cell types in het-
erogeneous clinical samples. They have found use as EGFR-specific contrast agents
in MRI imaging of oesophageal cancer [180], though this approach suffered from low
sensitivity.
Gold nanoparticles conjugated with antibodies have been used extensively with a
number of imaging techniques [181] including multiphoton plasmon resonance spec-
troscopy [182], optical coherence tomography [183] and surface-enhanced Raman spec-
troscopy, as well as through the simple use of the light scattering properties of AuNPs
incubated with cells [184, 185].
The National Science and Technology Development Agency, Thailand, have pro-
duced AuNPs passively conjugated with both monoclonal and polyclonal antibodies
to p16 for use in electrochemical [186] and paper-based immunoassays [187] respec-
tively. At the time of writing only one other SERS-active conjugate to p16 has been
produced [125], using a functional PEG linker, squaraine dye and p16/Ki67 mono-
clonal antibody (mAb) mix. It is not known how the levels of these two common
stains for cervical intraepithelial tissue were quantified given the resulting heteroge-
neous NP population.
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Conjugation methods
Interactions between antibodies and gold nanoparticles may be passive or supported
with additional binding ligands. In the passive case, antibodies interact with the gold
surface through hydrophobic or electrostatic attraction, or through co-ordinate (dative
covalent) binding of sulphur atoms in the antibody to the gold surface.
Functional linkers may be used to mediate covalent binding of antibodies to col-
loidal gold. One of the most popular general methods is the use of a thiolated polymer,
typically polyethylene glycol (PEG), which adheres to the metal surface with an addi-
tional functional group at the opposing end. The length of the polymeric spacer can
be varied depending on use and also acts to sterically block non-specific interactions
with the charged surface. The functional group can take multiple forms including
carboxylate, aldehyde, hydrazide, thiol, hydroxyl and amide groups [188].
Biological linkers may also be used for antibody conjugation. Unmodified anti-
bodies can be attached via Protein A or G presented on the surface of Staphylococ-
cus aureus and Streptococcal bacteria respectively [189]. They both interact with the
heavy chains of antibodies (typically the Fc region) and have varying binding affini-
ties for the Fc portion of mammalian immunoglobulins. Native Protein G contains
an albumin-binding site which is removed in the recombinant form to prevent non-
specific binding in BSA-blocked environments. Finally, streptavidin-coated AuNPs
may be used to immobilise biotinylated antibodies. This requires careful titration of
the degree of biotin labelling so that antibodies do not bind to multiple streptavidin-
coated NPs [190].
The three methods investigated during this project - passive, covalent and biocon-
jugation - are summarised schematically in Figure 4.4 and discussed in greater detail
in Sections 4.6.1 , 4.7.1 and 4.8.2 respectively.
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FIGURE 4.4: Schematic of the conjugation processes in A) covalent conjugation using a
functionalised PEG linker with carboxyl group, B) passive conjugation and C) bioconju-
gation using Protein G’ (shown in red).
4.2 Concept: SERS and nanoparticle conjugates
As discussed in the Introduction, spontaneous Raman scattering is an intrinsically rare
occurrence which takes place as the result of anisotropic alterations in the polarisation
of a molecule with the electric field of an incident photon. In the phenomenon of
surface-enhanced Raman scattering by electromagnetic enhancement, this molecular
polarisation is amplified by the presence of additional electric fields from surface plas-
mons. Surface plasmons are the collective oscillations of conduction electrons, excited
by electromagnetic radiation at a metal-dielectric junction.
FIGURE 4.5: A) Schematic of localised surface plasmons induced by the electric field E of
an incident laser. The free electron cloud (blue) of the gold sphere (yellow) is subsequently
displaced, generating a localised electric field, simulated in B) as E2 for a sphere, cube and
triangular pyramid (reproduced from Kahraman et al. 2017) [191].
If the metal interface is continuous, plasmonic oscillations propagate between 10
and 300nm as surface plasmon polaritons (SPPs): on a surface such as a sphere or
at sharp edges, the oscillations are limited to localised surface plasmon resonances
(LSPRs) as shown in Figure 4.5. Additional chemical enhancement may occur as the
result of charge transfer between the metal substrate and certain adsorbed molecules,
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and coupling with LSPRs from neighbouring structures can result in ‘hotspots’ at par-
ticle junctions[192]. The magnitude of the electric field at the surface of a spherical





where εm is the wavelength-dependent dielectric constant of the metal surface, and
ε0 is the dielectric constant of the local environment around the sphere [193].
Nanostructures can be fabricated which support LSPRs and therefore act as Raman
scattering amplifiers at close range (typically 0-4nm). The SERS enhancement factor
is directly proportional to the fourth power of the plasmons’ electric field intensity,
with the magnitude of supported plasmons directly proportional to a characteristic




/2(ε i)2, where ω is the excitation frequency of the laser, and εr and ε i are
the real and imaginary parts of the structure’s dielectric function respectively [191].
Q depends then on the size, shape and material of the nanostructure but also on the
dielectric used, corresponding to the solvent or blocking agent for colloidal systems.






where IRS is the Raman intensity produced by the average number Nvolume of
molecules within the scattering volume and ISERS is the SERS intensity of the aver-
age number Nsur f ace of molecules adsorbed onto the substrate within the same volume
[194].
For this project, spherical gold nanoparticles were chosen as the substrate ow-
ing to ease of production, plasmonic anisotropy and lower toxicity and aggregation
probability than silver NPs in the instance that they be transferred to topical in vivo
studies. In practice, gold nanoparticles ranging from 5-150nm can be used for SERS
applications: any larger and the optical enhancement deteriorates due to decreasing
surface/volume ratio. Choice of diameter involves balancing optical enhancement
favoured by smaller particles and diagnostic sensitivity supported by particles with
larger surface areas, dependent on the application. A nanoparticle diameter of 40nm
was chosen as the most common size for potential lateral flow applications, repre-
senting a compromise between optical contrast and antibody coverage. Small Raman
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molecules were chosen for their stability and minimal disruption to nanoparticle di-
ameter, which was an important consideration for the use of conjugates in fixed cells.
Commercially available antibodies were chosen as well-characterised binding ligands
- the conjugation method is explored in the remainder of this chapter.
4.3 Materials and methods
All reagents were purchased from Sigma Aldrich unless otherwise stated. Ultrapure
water (‘dH2O’, MilliQ) was used for all experiments. All nanoparticle centrifugation
(‘pelleting’) steps were carried out at 3400g for 20 minutes in the first instance unless
otherwise stated. All shaking steps were carried out using a benchtop plate shaker
(IKA MS 3) at 500rpm. It should be noted that as this chapter consists largely of
method optimisation work, the protocols outlined below represent an initial starting
point. Modifications are outlined in the main text.
4.3.1 Nanoparticle production
A 1l Erlenmeyer flask and magnetic stirrer were cleaned with aqua regia (HNO3+3HCl)
for two hours, rinsed and dried. 60.5mg sodium tetrachloroaurate (III) dihydrate was
dissolved in 500ml dH2O (equivalent to 304.17µM solution) and heated at 100◦C and
stable stirring conditions on a magnetic hotplate until boiling. 57.5mg sodium cit-
rate tribasic dihydrate dissolved in 7.5ml dH2O (equivalent to 26.07mM solution) was
added and mixed for 15 minutes. This was left to cool with continuous stirring before
transferring to a clean glass container.
4.3.2 Raman spectroscopy
Raman spectra of nanoparticle samples in bulk solution were made using a Sierra Se-
ries desktop Raman spectrometer (Snowy Range Instruments) with 100mW 785nm
laser at full power. All spectral acquisitions were made for one second unless other-
wise stated, with an undiluted 500µl sample stored in a cylindrical glass vial cleaned
using aque regia. When direct sample comparison was required between measure-
ment batches, spectra were normalised with reference to the characteristic 884cm−1
peak of ethanol to account for small fluctuations in laser power over time, with a nor-
malising multiplication factor of 10000/intensityEtOHpeak.
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4.3.3 Covalent conjugation
A method diagram for both approaches is shown in Figure 4.6.
On-NP method
In the standard protocol, 40µl 1mM carboxy-PEG12-thiol (‘CT-PEG’, ThermoFisher Sci-
entific) was added to 960µl reporter-AuNPs and shaken for 2 hours. Samples were
pelleted and resuspended in 74µl EDC (1mg/ml), 217µl NHS (1mg/ml), 709µl 10mM
MES buffer (pH6.0), and shaken for 30 minutes. Following centrifugation, the pellet
was resuspended in 980µl 10mM HEPES buffer (pH7.0) and 20µl antibody or blank
control (dH2O) and shaken overnight. The completed conjugates were pelleted and
resuspended in 980µl 10mM phosphate buffer (pH7.6) unless otherwise stated.
Off-NP method
In the standard protocol, 40µl 1mM CT-PEG and 74µl EDC (1mg/ml) were added to
one 1.5ml Eppendorf, and 217µl NHS (1mg/ml) and 20µl antibody or blank control
(dH2O) to another. Both were shaken for 5 minutes before combining and adding
709µl 10mM HEPES buffer (pH7.0). This solution was shaken overnight, added to 1ml
reporter-AuNPs and left to shake again for 2.5 hours. The completed conjugates were
pelleted and resuspended in 980µl 10mM phosphate buffer (pH7.6) unless otherwise
stated.
4.3.4 Passive conjugation
In the standard protocol, Raman reporters were adsorbed onto bare colloid by shaking
10µl appropriately diluted reporter solution with 990µl AuNPs for 30 minutes. Fol-
lowing centrifugation for 15 minutes at 2300g and resuspension in 980µl phosphate
buffer (pH7.6), antibody solution (1-30,000ng/µl) was added to 1ml reporter-NPs and
shaken for 15 minutes. 10µl 10%[w/v] BSA solution was added, shaken for 30 min-
utes and the solution pelleted and resuspended in 10mM phosphate buffer (pH7.6)
unless otherwise stated.
4.3.5 Bioconjugation
Raman reporters were adsorbed onto bare colloid by shaking 10µl appropriately di-
luted reporter solution with 990µl AuNPs for 30 minutes. Following centrifugation
for 15 minutes at 2300g and resuspension in 980µl MES buffer (10mM, pH4.8), 100µl
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FIGURE 4.6: The two approaches used for covalent conjugation of antibody using EDC
and sulfo-NHS linker chemistry. In the ‘on-NP’ method, the moieties are added in order
to the nanoparticles with centrifugation steps in between to remove excess reagent. In the
off-NP method, the carboxylated PEG and EDC, and NHS and mAb, are assembled in
isolation. The ligand complex is then formed in an overnight step before it is added to the
NP surface.
Protein G in 10mM phosphate buffer (pH7.6) at the required concentration was added
and the solution left to shake for 30 minutes. The resulting solution was pelleted
again, resuspended in 980µl MES buffer, added to 10µl mAb solution (mAb diluted
1:10 in PBS) and left to shake for 30 minutes. The completed conjugate was pelleted
and resuspended in 980µl 10mM phosphate buffer (pH7.6).
4.4 Production of Raman-active nanoparticles
4.4.1 Gold nanoparticle characterisation
Gold nanoparticles were produced according to a modified Turkevich method, de-
scribed in Section 4.3.1. The citrate reduction agent also caps the particles, producing a
negative surface potential which allows them to remain in suspension. These colloids,
nominally spherical and 40nm in size, were characterised using dynamic light scatter-
ing (DLS) and zeta potential measurements, extinction spectroscopy and transmission
electron microscopy (TEM). Two batches of nanoparticles were produced during the
project, with some variation in physical properties. The average diameter in nanome-
tres of the nanoparticles for both batches was calculated from TEM measurements to
give 48± 9nm and 41± 9nm for the first and second batch respectively (Figure 4.7).
From this the particle number density and concentration were generated using
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FIGURE 4.7: A; TEM image of nanoparticles, taken using a Tecnai TF20 cryo-TEM (FEI)
and thresholded in ImageJ (FIJI) to provide a mask for particle sizing; B) population his-
togram of the Feret diameter of the second batch of NPs, demonstrating a modal diameter
between 40-45nm as expected, and an average of 41± 9nm; C) the variation in absorbance
profile between the first and second batch of nanoparticles used for the project.
N =
A450 × 1014
d2[−0.295 + 1.36 exp(−( d−96.878.2 )2)]
(4.3)
where A450 is the absorbance at 450nm, and d is the particle diameter in nanome-
tres, to give the values summarised in Table 4.2 [195].
The gold nanoparticles (AuNPs) had a localised surface plasmon resonance (LSPR)
peak of 532nm and 526nm for Batch 1 and 2 respectively, with a full width half maxi-
mum (FWHM) of 60nm and 46nm for the same. Monodispersed solutions of AuNPs
typically have a FWHM of less than 100nm, with narrower peaks corresponding to
higher monodispersity.
4.4.2 Investigation of Raman reporters
Raman reporters, or strongly Raman active small molecules, were chosen for inves-
tigation over Raman-active fluorescent dyes in order to reduce the overall size of the
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Specification Batch 1 Batch 2
Number density (particles per ml) 5.38× 1010 7.39 × 1010
Molar concentration (nM) 8.9 12.3
Feret diameter by TEM (nm) 48± 9 41±9
Hydrodynamic diameter in dH2O (nm) 62.8±1.9 48.0±0.3
Zeta potential (-mV) 37.7±1.1 37.4±0.9
LSPR peak (nm) 532 526
TABLE 4.2: Characterisation of the two gold nanoparticle batches produced. Errors corre-
spond to a single standard deviation from the mean.
Raman-active conjugate. This is an important consideration for fixed cell incubation,
as cellular uptake mechanisms are limited to passive diffusion and electrostatic inter-
actions.
Initially BPE, PPY, PYOT, MBA and AZPY were investigated (see Figure 4.8 for de-
tails). This was done by diluting a stock concentration of reporter (typically 10mM in
ethanol) in dH2O before adding 5µl diluted reporter to 495µl bare AuNPs (or equiv-
alent ratio at larger volumes) and shaking for 30 minutes. The resulting reporter NPs
were microcentrifuged at 3400g for 20 minutes, 480µl supernatant removed to elimi-
nate non-adsorbed reporters, and the pellet resuspended in 480µl dH2O for character-
isation.
Further experiments were then carried out with the most reproducible reporter-NP
combinations. Serial dilutions of BPE, PPY and PYOT indicated that BPE provided the
most stable coverage of AuNPs up to a micromolar limit, and so this was chosen for
use with the targeted conjugate (Figure 4.9). Potential candidates for a physicochemi-
cally identical dummy particle were also considered (Table 4.3), although this strategy
was revised in Sections 4.8 and 4.10 owing to the masking effects of antibody conjuga-
tion on the reporter layer.
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FIGURE 4.8: The structures, names and abbreviations of the five Raman-active molecules
initially chosen for the project.
Sample Hydrodynamic diameter (nm) Zeta potential (-mV)
AuNP 62.8±1.9 37.7±1.1
BPE 10−5M 62.9±2.8 9.07±7.1
BPE 10−6M 62.8±2.8 37.3±0.8
BPE 10−7M 54.4±1.5 31.0±6.8
PYOT −510M 57.2±0.6 40.5±4.4
PYOT −610M 54.9±0.4 24.8±5.5
PYOT −710M 55.0±0.5 27.4±3.2
PPY −510M 75.8±2.2 20.1±2.1
PPY −610M 59.4±0.7 31.0±3.5
PPY −710M 89.8±1.3 28.7±5.3
TABLE 4.3: Characterisation of the Raman reporter-coated particles produced at different
initial concentrations. Zeta or surface potential is shown in negative electron volts, with
higher values corresponding to greater solution stability due to electrostatic repulsion.
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FIGURE 4.9: A) Absorbance spectra of the three chosen reporters indicating an order-of-
magnitude concentration operating window for adsorption onto 40nm gold nanoparti-
cles; B) BPE concentrations compared to bare AuNP absorbance spectra (10−5 M not seen
due to low absorbance from aggregation); C) PPY concentrations compared to AuNP ab-
sorbance spectra (10−5 M not seen due to low absorbance from aggregation); D) PYOT
concentrations compared to AuNP absorbance spectra.
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4.4.3 Optimisation of BPE-AuNP stability and signal
More sensitive concentration experiments indicated that, under the centrifugation
conditions outlined in Section 4.4.2 and when suspended in dH2O, an initial reporter
concentration of 1.25µM was the maximum which could be stably achieved. Ab-
sorbance measurements and surface potential dropped rapidly at 1.50µM (Figure 4.10).
Optimum surface charge (zeta) potential, possibly corresponding to monolayer cov-
erage, was achieved at 0.75µM. Samples produced in triplicate supported this con-
clusion, with considerably less variation in optical characteristics compared to other
samples (Section 4.7.4).
FIGURE 4.10: A) Absorbance peak of bare AuNPs and reporter-NPs between 0.50 and
1.50µM initial BPE concentration, showing an aggregation-induced reduction in ab-
sorbance at 1.50µM; B) variation in hydrodynamic diameter with addition of reporters,
indicating a change in interaction of the colloidal structures with their solvent as a result
of reporter addition; C) zeta potential of the same in three technical replicates, showing
optimum charge stability of the colloidal solution at 0.75µM; D) the average absorbance of
three sample replicates of initial BPE concentrations 0.50, 0.75 and 1.00µM, with a single
standard deviation from the mean shown in grey. Again, this suggests that 0.75µM initial
BPE concentration corresponds to monolayer coverage for 40nm AuNPs.
The Raman spectra for BPE at different concentrations can be seen in Figure 4.11.
The major peaks are at 1019, 1202, 1340, 1608 (principal peak) and 1637cm−1. Gaussian
peak fitting of the resulting data following baseline removal indicated that a detection
minimum of 4nM BPE in solution could be achieved under the conditions used above.
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This was calculated using a linear extrapolation of each Raman peak at the concentra-
tions produced until the axis intercept was reached (Figure 4.12).
FIGURE 4.11: The fingerprint-region Raman spectra of bulk reporter-NP samples at initial
BPE concentrations between 0.50 and 1.50µM, as well as bare AuNPs. Acquired over 1.00s
with a 100mW 785nm laser.
Further optimisation of Raman signal from the SERS conjugates is considered in
Section 4.8.4 once a conjugation method was chosen.
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FIGURE 4.12: Intensity at each major Raman peak compared to initial BPE concentration.
The linear relation between intensity and concentration for standard Raman spectroscopic
measurements indicates that the spectral limit of detection (the point at which any of the
primary peaks would be fitted with a zero-intensity Gaussian peak) is 0.40µM initial BPE
concentration, equivalent to 4nm in solution with AuNPs.
4.4.4 Effect of buffers on signal and stability
Typically, reporter-NPs must be suspended in buffers other than distilled water so
that subsequent reactions do not cause significant pH shift and particle aggregation.
Reporter-NPs were prepared at three concentrations as described in Section 4.4.2 but
with a final resuspension solution of one of the following:
– dH2O
– MES buffer (pH4.8, 10mM)
– Phosphate buffer (pH7.6, 10mM)
– HEPES buffer (pH7.0, 5mM)
MES (2-(N-morpholino)ethanesulfonic acid) is a buffer with minimal salt effects
whose useful pH range is lower than that of other common biological solvents. It was
used for bioconjugation experiments at pH4.8 (see Section 4.8) to passively adsorb
Protein G onto the surface of the reporter-NPs. Phosphate buffer was used for passive
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conjugation, as its high buffering capacity reduces likelihood of pH-dependent NP
aggregation. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) is used in
the preparation of EDC-NHS antibody complexes in the covalent conjugation method.
The effect of buffers on the Raman signal of the nanoparticles can be seen in Figure
4.13. It is clear from this that a BPE-NP solution stored in phosphate buffer degrades
considerably compared to others, and so should be avoided for conjugation protocols.
This has not been seen in any published material but is posited to be due to differ-
ences in the dielectric constant of each buffer, which makes a contribution to SERS
enhancement.
FIGURE 4.13: A comparison of Raman spectra of BPE-AuNPs at a range of concentra-
tions in the buffers relevant to chosen conjugation chemistries. A) 0.50µM comparison;
B) 0.75µM comparison; C) 1.00µM comparison; D) comparisons organised by buffer type,
indicating a clear deterioration of Raman signal with phosphate buffer use.
It was unclear whether phosphate buffer was causing permanent dissociation of
reporters from the surface, or if the effect was due to temporary interaction of buffers
with the colloid. NPs stored in phosphate buffer for 30 minutes before centrifugation
and resuspension in MES for overnight storage were found to maintain their signal,
as were samples stored in MES briefly before phosphate buffer (Figure 4.14).
Further buffer conditions for storage of final conjugates are considered in Section
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FIGURE 4.14: The Raman spectra of BPE-AuNPs (0.75µM) stored in MES then phosphate
buffer (black line), and phosphate then MES buffer (red line). This was done to explore
whether the spectral deterioration was a permanent or temporary effect.
4.9. Having synthesised a SERS-active AuNP substrate, the binding mechanism had
to be characterised.
4.5 Antibody characterisation
4.5.1 Stability and sensitivity of commercial antibodies
Initially, a monoclonal antibody by BD Pharmingen (Purified Mouse Anti-Human p16,
Clone G175-405) was used to assess p16 expression in the cell lines chosen for this
project. The antibody is supplied as 31.25µg/ml in an aqueous buffered solution con-
taining BSA, goat serum and sodium azide. Despite being advertised as routinely
tested with Western Blotting, no publications were available. Western Blots for SiHa
cells, which express p16 strongly, did not produce any signal when tested with anti-
body diluted to 1:1000, 1:500 and 1:200 in milk solution.
The antibody was then tested against purified p16 in a dot blot, where the pro-
tein was spotted down in either its native form as provided, or after denaturation
by adding 20% [v/v] DTT and heating to 70◦C as per the Western Blotting protocol
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in Chapter 2. As seen in Figure 4.15, this antibody binds with much lower affinity
to the denatured form of p16 which makes it much less versatile as a candidate for
nanoparticle conjugation. Additionally, the supplied format is comparatively dilute -
requiring much higher concentrations for a Western Blot than used previously - and is
mixed with BSA which would compete for nanoparticle surface coverage.
Santa Cruz antibody (sc-9968), supplied as 0.2mg/ml in PBS with sodium azide
and gelatin, was then tested and found to be suitable for Western Blotting (also Figure
4.15). This was used for conjugate development work as discussed in Section 4.6.3
before discovering that it was a discontinued product. As such, a newly released
antibody from BD Pharmingen (Clone G175-1239) was tested and found to have a high
affinity for p16 in Western Blot format, as well as being suitable for immunofluorescent
work. All antibodies were diluted 1:1000 in milk solution for the blots shown in Figure
4.15. This is supplied as 0.5mg/ml in aqueous buffered solution containing sodium
azide. The new G175-1239 clone was used for all subsequent experiments.
FIGURE 4.15: A) Dot blot of BD Pharmingen mAb against purified human recombinant
p16 at different concentrations, native and denatured. B) Western blots with Santa Cruz
antibody, now discontinued, and a newly available BD Pharmingen mAb. Note that the
concentrations are different so a direct comparison cannot be made.
4.5.2 Antibody limit of detection
Following an initial test of the protocol (Chapter 2), the sensitivity of BD Pharmingen
mAb Clone G175-1239 was tested in triplicate by ELISA at final concentrations from
2.000 to 0.031ng/ml in 1:1 serial dilutions with PBS. The lumimetric results can be seen
in Figure 4.16, and are shown as a function of both p16 concentration and absolute
protein content. Error bars are given as a single standard deviation from the mean
value. Protein concentration values were fitted with a third-order polynomial to give
the fit shown, with an adjusted coefficient of determination (COD, R2) of 99.4%. The
linear fit of absolute protein content yields a slightly poorer fit but can be used to
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determine the limit of detection (LoD) of the antibody for this given format, which is
a useful consideration in nanotag production to ensure sufficient binding sensitivity.
FIGURE 4.16: Lumimetric response of BD Pharmingen mAb Clone G175-1239 to purified
p16 in an ELISA format, conducted in triplicate and shown in terms of protein concentra-
tion and absolute content.
The limit of blank (LoB), defined as the highest concentration of analyte which
may appear as a blank signal[196], is given by
LoB = µblank + 1.645σblank (4.4)
for a Gaussian distribution with 90% confidence interval where ‘blank’ is the lumi-
metric value for N=8 empty wells with µ = 0.0108 and σ = 0.0104. Thus, LoB = 0.028
by luminosity, which is negligible by protein concentration. The limit of detection,
LoD, is given by
LoD = LoB + 1.645σsamples (4.5)
where σsamples was calculated as an average of the sample standards deviations,
equivalent to 0.4209 luminosity. This gives LoD = 0.692 luminosity, equivalent to
1.80±0.25ng or an initial concentration of 36±5ng/µl, where the error was calculated
as the maximum deviation from the linear fit.
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4.6 Covalent conjugation of antibody
4.6.1 Covalent conjugation scheme
Following primary optimisation of Raman reporter concentration to achieve a stable
colloid carried out in Section 4.4.3, antibody conjugation methods were investigated.
Covalent antibody conjugation is often considered the most robust approach owing
to its chemical permanency, particularly when introduced to biological or pH-variable
environments. As such it formed the basis of attempts to conjugate antibodies to p16
in the first instance.
Antibodies are commonly conjugated via their primary amine (-NH2) groups. Typ-
ically the positive charge of the group causes amines to present at the outer surface of
the protein structure, theoretically leading to minimal functional disruption through
protein denaturing following conjugation. Multiple amine-reactive groups exist with
different functionalities, including NHS-esters, imidoesters and carbodiimides.
Taking advantage of the different reactive species available, molecular spacers can
be introduced to the covalent conjugation scheme. This reduces the effects of stearic
hindrance on antibody capture efficiency when immobilised in large numbers on the
surface of a nanoparticle and can also double as a surface blocking agent, although it
also increases conjugate size (Figure 4.17).
In this context, a functionalised polyethylene glycol (PEG) molecule acted as a
spacer between the nanoparticle surface and the binding ligand. It consists of a 12-unit
PEG chain (47.8Å) that is thiol- and carboxyl-terminated (Figure 4.17). The carboxylic
acid group is covalently bound to amine groups on the antibody via a carbodiimide ac-
tivator, N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC). Water-
soluble N-hydroxysuccinimide (sulfo-NHS) is added to this reaction scheme to create
a more stable intermediate (Figure 4.18).
4.6.2 Comparison of EDC/NHS methods
Conjugation of primary amines using EDC/NHS chemistry can take two forms: ‘on-
NP’ conjugation in which the spacer, conjugation moieties and binding ligand are
added layer by layer to the NP surface; and ‘off-NP’ conjugation where the spacer
and ligand are assembled separately before binding to the NP via the thiol group.
On-NP conjugation samples were produced using the method detailed in Section
4.3.3. A commercial monoclonal antibody to human p16 (Santa Cruz, see Section
4.5.1 for details) was used with BPE-coated NPs (1.25µM initial concentration) and
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FIGURE 4.17: Schematic of the covalent conjugation system, in which antibodies are at-
tached by their amine groups to the gold spheres via a 12-mol PEG spacer with carboxy-
lated and thiolated end groups.
another IgG1 antibody specific for MDM2 (in-house product, ‘4B2’) used with PYOT-
NPs (2.50µM initial concentration). In both cases, the full conjugate was compared
to a reporter-only NP solution and a PEG-only control, which followed the full con-
jugation procedure using distilled water instead of antibody (Figure 4.19). The 4B2
antibody acted as a non-p16 specific isotype control until a genuine IgG1 control was
acquired. The ‘isotype’ sample demonstrated a similar hydrodynamic diameter to the
PEG-only control as well as evidence of successful conjugation through a red-shift in
the absorbance spectrum compared to bare gold. However, the p16-targeted sample
partially aggregated at the same concentration, indicating that the optimised covalent
method cannot be applied universally to antibodies of the same isotype. This aggre-
gation took the form of small but visible strands of particles in a near-transparent
solution.
The on-NP method was then trialled again with the Santa Cruz monoclonal anti-
body, introducing variation of antibody concentration. The absorbance measurements
and physicochemical characteristics can be seen in Figure 4.20 and 4.21 respectively.
Again, all three antibody-coated samples aggregated, with the highest concentration
of antibody producing strands of particles.
At this stage, the off-NP method was investigated on the basis that the strand-like
aggregation could indicate optimal reagent concentrations with excessive centrifuga-
tion. The resultant clumping effect could be mitigated by the use of a method with
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FIGURE 4.18: The reaction scheme for EDC/sulfo-NHS coupling of primary amine
groups (antibody) to carboxyl groups (PEG chain). EDC produces an active ester with
the carboxyl group which is stabilised by the addition of sulfo-NHS. The introduction
of an amine group results in a stable amide bond and sulfo-NHS by-product which is
removed with the supernatant after centrifugation.
fewer centrifugation steps (see Figure 4.6). At this stage, a new monoclonal antibody
to p16 was released by BD Pharmingen and assessed for efficacy in Section 4.5.1. For
continuity both this and the Santa Cruz antibody, now discontinued, were assessed
for conjugation stability using the concentrations given in the original protocol (Figure
4.22). The zeta potential measurements in particular suggest that the off-NP method
is indeed more stable. Having established that this method was less prone to induc-
ing particle aggregation, a comparison of the antibody types was made and the new
ligand found to be more stable. In addition, its increase with size compared to the
PEG-only control indicates antibody coverage.
Lower concentration studies with the p16-specific antibody indicated that a re-
duced antibody concentration results in greater stability. A direct comparison of the
lowest concentration was made using the on-NP method, which aggregated into vis-
ible strands as before despite demonstrating a higher absolute zeta potential than the
off-NP method. Repeats of the off-NP approach with both the BD Pharmingen mAb
and genuine isotype control also partially aggregated. At this stage, passive conjuga-
tion was adopted as a technique to ascertain the order of magnitude of antibody con-
centration which could be applied stably to the nanoparticles without consideration of
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covalent conjugation kinetics. Optimisation of the passive conjugation technique and
accompanying concentration measurements are detailed in Section 4.7. These results
indicated that the IgG1 molecules in question should be conjugated in concentrations
over an order of magnitude lower than that suggested originally.
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FIGURE 4.19: Targeted and dummy covalent conjugate characteristics at each stage of
layering using on-NP EDC-NHS chemistry. Absorbance properties of the A) target (p16
mAb) and B) dummy (IgG1) conjugates; hydrodynamic diameters of the C) target and
D) dummy conjugates; zeta (surface charge) potentials of the E) target and F) dummy
conjugates.
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FIGURE 4.20: Absorbance characteristics of on-NP covalent conjugates with Santa Cruz
p16 antibody and PEG-only control, showing aggregation of the particles.
FIGURE 4.21: A) Hydrodynamic diameter and B) zeta potential of the covalent conjugates
shown in Figure 4.20, which indicate a lower stability of particle and subsequently larger
particle aggregation for the lowest and highest concentrations of antibody used.
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FIGURE 4.22: A) Hydrodynamic diameter and B) zeta potential of covalent conjugates
produced using both methods and the Santa Cruz and BD Pharmingen antibodies using
the original protocol as stated in Section 4.3.3. Both sets of measurements indicate that
the Santa Cruz antibody produces a less stable conjugate than the new BD Pharmingen
ligand.
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4.6.3 Optimisation of reagent concentration
As a result, twelve conditions were produced to investigate the effects of individual
reagent variation on covalently conjugated particles. As seen in Table 4.4, the con-
ditions were chosen in order to explore the effects of antibody concentration varia-
tion, equimolar variation of all reagents, coupling reagent variation without antibody,
and coupling architecture with a constant carboxyl-terminated PEG layer. These were
compared with bare nanoparticles, BPE-NPs and a PEG control. All Raman-active
samples used an initial concentration of 1.25µM BPE, equivalent to 12.5nM in NP
bulk solution. All conjugation reagents were produced in solution immediately prior
to conjugation and stored on ice until required to reduce likelihood of hydrolysis. The
absorbance data, peak-to-650nm and wavelength shift values of all samples are repre-
sented in Figure 4.23.
Conditions 1 and 10, which represented repeats of the original protocol, both ag-
gregated immediately upon combination of the reporter-NPs with the PEG-mAb com-
plex.
In the first set, the concentration of antibody was varied, with PEG coverage and
cross-linking compounds kept constant. In the second, an equimolar variation of all
reagents was considered, with ‘1:1’ representing the original protocol. In the third set,
the cross-linking compounds were varied ratiometrically with antibody, with the PEG
layer kept constant (Figure 4.24).
The absorbance data from the antibody-free controls (Figure 4.24 D) indicate that
the original concentration of PEG, and indeed EDC/NHS, provides a greater stability
and monodispersity of conjugates than lower concentrations. However, the addition
of equal concentrations of monoclonal p16 antibody to that used in the original pro-
tocol induced aggregation. This suggests that the stability of the particles is strongly
affected by the specific antibody to be conjugated, not merely its type. Out of the con-
jugation reagents, concentration of PEG appears to have the greatest impact on LSPR
wavelength shift (Samples 7, 8, 9), which is amplified by the addition of antibodies
(Samples 1, 5, 6).
These same samples were then introduced to commercial dipstick assays (see Sec-
tion 2.6.2), used to assess the correct conjugation of antibody onto the surface. The
assays are printed with a Protein A/G mix which binds to the Fc portion of the anti-
body, causing collection of any successfully conjugated nanoparticles onto the capture
strip which can be seen by eye due to the absorbance properties of the NPs them-
selves. The variation of antibody alone results in a high background with no signal at
the capture line, indicating that the non-conjugated activated PEG is interacting with
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Condition CT-PEG (µM) EDC/NHS (µg/ml) mAb (µg/ml) HEPES (mM)
AuNP - - - -
BPE - - - -
1 1000 1000 500 10
2 1000 1000 5 10
3 1000 1000 0.5 10
4 1000 - - 10
5 10 10 5 1
6 1 1 0.5 0.1
7 1000 1000 - 10
8 10 10 - 1
9 1 1 - 0.1
10(1) 1000 1000 500 10
11 1000 10 5 10
12 1000 1 0.5 10
TABLE 4.4: The concentrations of CT-PEG (blocking polymer and functionalised linker),
EDC/NHS (functionalisation reagents), antibody (binging ligand) and HEPES (conjuga-
tion buffer) used for an experiment investigating covalent conjugation stability with the
antibody in question.
the nitrocellulose membrane. The pure AuNP and PEG-constant particles do not pro-
duce any colorimetric signal, showing that a positive lateral flow test is the result of
successful antibody conjugation and not activated carboxyl groups or non-specific in-
teraction of the Protein A/G mix with a bare metal surface. The ratiometrically varied
samples produce a relatively clean background and signal at the capture line (Figure
4.25).
None of the above samples produced a visible colorimetric signal with a purified
protein dot blot, indicating that the technique used successfully conjugates the anti-
body but disrupts its functionality. Multiple attempts to reproduce the successful con-
jugation conditions above failed, with no signal seen on commercial dipstick assays at
the test line.
A set of samples representing a full investigation of equimolar reagent concen-
tration was then produced, using 0.75µM BPE as the initial concentration of Raman
reporters. The reagent concentrations and dipstick assay results can be seen in Fig-
ure 4.26. Unlike the higher-concentration samples produced previously, this repeat
remained stable and produced a strong positive signal at the Protein A/G capture
line. This drops off for the tenfold dilution and then increases again for Conditions 5
and 6 as seen previously. This indicates that the positive test line seen previously may
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FIGURE 4.23: A) Schematic of the conditions explored for this experiment, including an-
tibody concentration, all reagents, and all reagents except PEG; B) the extinction char-
acteristics of the samples; C) ratio of peak height to extinction at 650nm, providing a
concentration-free indication of aggregation status; D) extinction peak wavelength, which
shifts fractionally (1-4nm) with successful surface modification but significantly with un-
wanted aggregation.
be the result of insufficient blocking on the particle surface rather than the number of
antibodies successfully conjugated. However, despite the indication of successful con-
jugation for Condition ‘3’, dot blots with purified p16 did not yield a positive signal
as they did for passive and bioconjugated nanoparticle-antibody complexes.
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FIGURE 4.24: Extinction spectra of conjugates with different concentrations of A) anti-
body; B) all reagents; C) all reagents except PEG; D) all reagents with no antibody.
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FIGURE 4.25: The commercial dipstick assay results for conditions where antibody was
used. Conditions 1 and 2 varied mAb only, 5 and 6 varied all reagents equally, and condi-
tions 11 and 12 varied all reagents except PEG.
FIGURE 4.26: The commercial dipstick assay results for covalent conjugation conditions
where the original ratio of reagents (EDC/NHS, CT-PEG and mAb) were retained but
serially diluted.
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4.6.4 Variability of binding functionality
Following the optimisation of reporter signal seen in Section 4.8.4, a new set of co-
valent conjugates were produced as a final assessment of their use in Raman-based
diagnostic applications. Both on-NP and off-NP methods were trialled, with 0.75µM
BPE as in the previous set of samples as well as 5µM BPE which was found to provide
stable, highly Raman-active conjugates.
1ml samples of 1:1, 1:10, 1:100 and 1:1000 dilutions of the protocols described in
Section 4.3.3 were produced in addition to a 1:1 antibody-free control with both re-
porter concentrations, where the antibody volume was replaced with distilled water.
Prior to the final centrifugation and resuspension in pH7.6 phosphate buffer, the sam-
ples were split into two 500µl volumes. Following centrifugation and supernatant
removal, one of the samples was resuspended in 480µl phosphate buffer for optical
characterisation (Figure 4.27) and the other in 80µl phosphate buffer for interrogation
with commercial dipstick assays (Figure 4.28). The assays were prepared with 0.5µl
purified p16 protein spots (100ng/µl in PBS) and left to dry prior to assay use.
Both sets of on-NP samples produced at 1:100 and 1:1000 reagent dilution aggre-
gated following resuspension in HEPES and addition of antibody, as can be seen from
the heavily reduced absorbance characteristics in Figure 4.27. For these measure-
ments, acquired immediately after production, the off-NP samples demonstrate the
same trend but not to the same extent of aggregation. However after two days stored
at room temperature, the off-NP 1:100 and 1:1000 samples also aggregated.
The dipstick assays appear to demonstrate stronger target binding characteristics
for the off-NP conjugates despite a lower test-line signal. This suggests that the ori-
entation of antibodies in this case is more ‘outward-facing’ or that this method is less
functionally disruptive.
The Raman spectra of these conjugates, acquired after off-NP sample aggregation
had taken place, can be seen in Figure 4.29. The off-NP method produced a stronger
Raman signal than on-NP for both concentrations of reporter. However, this technique
still yields a lower Raman signal than stable bioconjugates and uses much higher
quantities of antibody.
Owing to the intrinsically inconsistent nature of this technique, the lower Raman
signal which can be achieved using the same concentration of reporter, and the in-
creased cost of reagents which must be considered in the context of population health
applications, the covalent conjugation method was not chosen for production of SERS
conjugations for cell-based diagnosis.
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FIGURE 4.27: Extinction spectra for covalent conjugates produced using A) on-NP
method with 0.75µM BPE-NPs; B) off-NP method with 0.75µM BPE-NPs; C) on-NP
method with 5.00µM BPE-NPs; D) off-NP method with 5.00µM BPE-NPs. Comparison
of E) on-NP samples; F) off-NP samples.
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FIGURE 4.28: Dipstick assay binding sensitivity of 5x concentrated EDC/NHS conjugates.
A) On-NP method. B) Off-NP method. C) Bare AuNPs. Faint binding spots can be seen
for all of the non-control items (left).
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FIGURE 4.29: Raman spectra of the samples produced and shown in Figure 4.27.
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4.7 Passive conjugation of antibody
4.7.1 Passive conjugation scheme
Passive antibody conjugation is widely considered to be the simplest of conjugation
methods as it does not require additional coupling moieties beyond the binding lig-
and and nanoparticle surface. Instead the technique relies upon electrostatic, van der
Waals and hydrophobic interactions between the two components. The basic premise
is that by altering the pH of the nanoparticle buffer to match the isoelectric point (pI) of
the antibody so that it carries no net charge, attractive forces will cause the antibody to
passively adsorb onto the nanoparticle surface (Figure 4.30). As such, conjugates can
be produced rapidly and inexpensively without iterative optimisation of additional
components.
FIGURE 4.30: Schematic of the passive conjugation mechanism, in which the pH of the
surrounding medium is shifted so that proteins may overcome the negative surface po-
tential of the gold spheres and adsorb onto the surface.
Despite its theoretical advantages the reality of this interaction can be complex.
Both nanoparticles and antibodies are sensitive to changes in pH. It is difficult to as-
certain the exact pI of a commercial antibody with a protected amino acid sequence.
Successful passive conjugation can lead to disruption of the tertiary protein structure,
leading to a loss of biological functionality. The aggregation of nanoparticles is also
dependent on the relative coverage of Raman reporters and binding ligands - insuf-
ficient coverage and the bare NP surface will be subject to the aggregating effects of
buffer ions, but too high a concentration and they may clump together. The use of
blocking agents such as bovine serum albumin (BSA) to passivate the bare surface
must not interfere with the active sites of the ligand or interact non-specifically with
the environment. Reporters and antibodies compete for space on the surface and must
112 Chapter 4. Development of antibody-conjugated nanoparticles
be finely tuned to ensure that the final conjugate is both optically and biologically ac-
tive.
4.7.2 Optimisation of antibody coverage and surface competition
Passive conjugation was initially explored as both a potential alternative to cova-
lent conjugation which may circumvent issues over binding non-functionality due to
reagent cross-linking, and as a way of rapidly ascertaining the optimal concentration
of antibody to use with 40nm AuNPs. The pH of the Raman active reporters used in
Sections 4.4.2 and 4.6.2 for 1.25µM BPE and 2.50µM PYOT was 8.5 and 7.9 respectively,
measured using a digital pH probe with three-point calibration (Eutech Instruments).
The isoelectric point of IgG1 antibodies is typically between 8.2 and 9.0. If the sur-
rounding environment has a lower pH than this, then the antibody will carry a net
positive charge. If higher then it will carry a net negative charge, causing electrostatic
repulsion between the ligand and negatively charged gold colloid. Passively conju-
gated ‘target’ (p16 mAb, BPE) and ‘dummy’ (IgG1 isotype, PYOT) particles were pro-
duced using the initial protocol detailed in Section 4.3.4 and found to be stable. The
conjugates were then applied to a dipstick assay as outlined in Section 2.6.2, prepared
with 0.5µl purified p16 protein. The assays appeared to indicate a positive line for the
target conjugates but not at the original application site of the protein, and so the re-
sult was deemed inconclusive. Additional samples produced to the same protocol and
tested using a dot blot method did not bind, and indeed appeared to aggregate into
the nitrocellulose membrane around the site of the protein spot, indicating a problem
with flow and blocking.
It was then suggested that I should investigate the application of antibodies to the
surface prior to the Raman reporter, as colleagues had seen greater success with this
approach. These were produced according to the following protocol:
1. Centrifuge 500µl AuNPs at 2300g for 15 minutes, remove 480µl supernatant and
resuspend in equal volume of pH7.9 phosphate buffer.
2. Add 5µl antibody or volume as desired and leave to shake for 15 minutes at
500rpm.
3. Add 5µl 10%[w/v] BSA in PBS and shake for 30 minutes.
4. Centrifuge at 2300g for 15 minutes, remove 480µl supernatant and resuspend in
equal volume of pH7.0 phosphate buffer.
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5. Add 5µl appropriately diluted Raman reporter solution and shake for 30 min-
utes.
6. Centrifuge at 2300g for 15 minutes, remove 480µl supernatant and resuspend in
equal volume of pH7.0 phosphate buffer.
These samples aggregated. At this stage sample production was focused down to
dummy particle production only in order to conserve reagents. Comparisons were
made with bare AuNPs and PYOT-NPs passively conjugated with IgG1 isotype con-
trol antibody (1.0mg/ml) using 1, 2, 3, 4 and 5µl antibody solution with 500µl particle
sample, equivalent to 2-10µg/ml in 2µg/ml intervals. Of the bare AuNP particles,
the addition of 1,2 and 3µl IgG1 resulted in complete aggregation, which indicated
insufficient coverage. Addition of 4 and 5µl caused only partial aggregation, whereas
all of the conjugated PYOT-NP samples remained stable. All samples were stored at
4◦C overnight, causing complete aggregation of all conjugates except the AuNP-only
5µl sample. Further samples up to 26µg/ml were produced, characterised optically
as shown in Figure 4.31. No trend could be found for this data - concentrations 6-
20µg/ml gave the greatest particle stability but where not found to bind to p16.
4.7.3 Effect of pH on passive conjugates
At this stage it was discovered that bare AuNPs, with an intrinsic pH4.0, aggregate
overnight when pelleted and resuspended in pH8.0 phosphate buffer as though for
conjugation. This was retested four times and found to be a consistent effect. As
a result of this, all further passive conjugation experiments were carried out using
manually pH-adjusted particles. Buffer exchange using dialysis tubing (Spectra/Por,
12-14kDa) was also found to aggregate the particles. The manually adjusted AuNPs
(now pH8.5 through dropwise addition of 0.5M NaOH) were used with ten-fold di-
lutions of both p16 mAb and IgG1 isotype control antibody to give characteristics as
shown in Figure 4.32. For both p16 mAb and its IgG1 isotype, the peak extinction
wavelength indicates an excess of antibody from 1000ng/ml and above. The aggrega-
tion shift across the range tested is more pronounced for IgG1 isotype control, with an
absorbance drop and wavelength redshift on the order of 0.5 and 10nm respectively,
compared to 0.1 and 5nm for p16 mAb.
Additional experiments using 10ng/ml final concentration of either p16 mAb or
IgG1 control were produced using AuNPs adjusted to pH7.1, 8.0, 9.1 and 10.0, along
with BSA-only controls. All were stable but none found to give a positive test-line
signal with the commercial dipstick assay ‘Conjugate Check & Go!’. Dot blot assays
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FIGURE 4.31: Extinction spectra for different concentrations of antibody (final concentra-
tion) passively conjugated onto 40nm gold nanoparticles.
with the same samples also failed. Bulk Raman measurements also indicated that no
Raman reporters were adsorbing onto the surface following passive conjugation of the
binding ligands. As such, a set of samples produced according to the above protocol
(AuNPs pH8.5) were compared to samples produced with simultaneous ligand and
reporter addition at both pH4.5 and pH8.5. All were stable but none found to produce
a signal with an in-house dipstick assay.
It was then calculated that for the stable passive conjugates (binding ligand at
100ng/ml or below, equivalent to 1:100 dilution ratio), conjugates would have to be
concentrated by at least five times to achieve a detectable bulk signal if compared to
the antibody-only ELISA performed in Section 4.5.2. This would explain the lack of
signal from the conjugates in dipstick assays, despite the optical characteristics indi-
cating successful adsorption of the antibody.
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FIGURE 4.32: A) Extinction peak height and B) wavelength for p16 mAb passively con-
jugated AuNPs. C) Extinction peak height and D) wavelength for IgG1 isotype passively
conjugated AuNPs.
4.7.4 Passive conjugates with reduced reporter coverage
In order to maintain conjugate stability it was then decided to reduce the concentration
of reporter used for the surface, as this would mitigate surface competition between
the two components. Reporter-coated AuNPs using initial concentrations of 0.50, 0.75
and 1.00µM BPE were produced in triplicate according to the following protocol:
1. Dilute 1mM stock (BPE in ethanol, 4◦C) in dH2O appropriately to give desired
initial reporter concentrations.
2. Add 5µl reporter solution to 495µl AuNPs and shake at 500rpm for 30 minutes.
3. Centrifuge at 2300g for 15 minutes, remove 480µl supernatant and resuspend in
equal volume of pH7.9 phosphate buffer.
4. Store at room temperature for 48 hours to account for mid-term stability and
characterise optically.
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FIGURE 4.33: Extinction spectra in triplicate with an AuNP reference for initial BPE con-
centrations of A) 0.50µM; B) 0.75µM; C) 1.00µM.
The absorbance profiles of the samples prior to antibody addition can be seen in
Figure 4.33, which indicate that 0.75µM BPE coverage provides the most consistent
result. The final conjugates also investigated antibody dilution in addition to reporter
coverage, and were introduced to commercial dipstick assays to test for successful pas-
sive adsorption of antibody. Antibody dilutions of 1:10, 1:100 and 1:1000 were used.
The 0.5µM BPE, 1:10 mAb (equivalent to 1µg/ml) sample aggregated, indicating that
adding an excess of binding ligand to particles without monolayer reporter coverage
can disrupt their stability. The remaining samples, shown in Figure 4.34, demonstrate
to an extent the relationship between reporter and binding ligand coverage. Assess-
ments of the greyscale intensity of the red channel of paper assays at the binding spot
and bare strip were made using ImageJ.
As expected, the signal strength produced at the test line increases with antibody
concentration, so that with 1:10 dilution a higher proportion of particles have anti-
bodies adsorbed onto their surface. As with experiments in Section 4.6.3, 1:1000 mAb
dilution results in an incredibly weak test-line signal. When compared to other 1:100
samples, the 1.00µM BPE, 1:100 mAb conjugate also seems to indicate that a higher
coverage of reporter requires higher antibody saturation in order to generate a signal.
This may be due to the fact that higher coverage of reporter leads to weaker attrac-
tive forces between the particle surface and protein, meaning that larger quantities of
protein are required to increase likelihood of contact between the two components.
The two optimal samples in terms of colorimetric contrast - 0.75µM and 1.00µM
BPE with 1:10 mAb dilution - were produced in triplicate and found to be consistent
(Figure 4.35). The 0.75µM BPE sample was also then used with a Western Blot mem-
brane (see Sections 2.3 and 2.7) to test whether it would bind visibly to native p16 from
SiHa cells. When compared to HCT116, a colorectal carcinoma cell line regularly used
as a negative control for the protein, it was found that the conjugates appear to bind
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FIGURE 4.34: A) Dipstick assays demonstrating antibody coverage of passive conjugates
at different concentrations of BPE and antibody; B) colorimetric assessment of the assays
showing test line intensity (SNR) and background accumulation compared to bare strip
(SWR).
non-specifically to all proteins on the membrane, possibly as the result of insufficient
blocking of the particle surface (also Figure 4.35).
FIGURE 4.35: A) The two best conditions from Figure 4.34 produced in triplicate; B)
non-specific binding to membrane-bound proteins for p16-positive (SiHa) and negative
(HCT116) cells.
4.7.5 Consideration of passive conjugate blocking on protein interaction
Conjugate samples were then produced according to the following procedure:
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1. Add 5µl desired reporter concentration to 495µl AuNPs and shake for 30 min-
utes at 500rpm.
2. Centrifuge at 2300g for 15 minutes to pellet. Remove 480µl supernatant and
suspend in equal volume of 10mM pH7.9 phosphate buffer.
3. Add 5µl desired antibody concentration (1:10 dilution in PBS) to reporter AuNPs
and shake for 15 minutes.
4. Add 10µl desired concentration [% w/v] BSA in PBS and shake for 30 minutes.
5. Centrifuge at 2300g for 15 minutes to pellet. Remove supernatant. Resuspend in
either 480µl 10mM pH7.6 phosphate buffer for normal concentration or 80µl for
a 5x optical density conjugate suitable for blotting.
The BSA content of the blocking solution was varied from 10 to 30% (equivalent to
solution saturation) in 5% intervals. The resulting conjugates, along with BPE-coated
AuNPs in phosphate buffer, were applied to a Western blot membrane. The non-
specific control did not bind to the protein content of the membrane, whereas all five
blocked samples did (Figure 4.36). The p16 band was clear in all cases, along with all
remaining proteins. There does not appear to be any trend in binding strength, either
for p16 or other proteins, related to the percentage weight of BSA in solution.
FIGURE 4.36: Different concentrations of BSA used to block passively conjugated
nanoparticles, from the standard concentration to solution saturation. Additional block
did not aggregate the particles but did not reduce non-specific binding.
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A conventional Western Blot (Section 2.3.2) was then run using wild-type SiHa
lysate, using 3% BSA in PBS-T (w/v) as a blocking agent instead of 5% fatless milk
solution. This resulted in a double-band for p16 in addition to an extremely high
background (Figure 4.37). A second Western blot directly comparing the two blocking
agents with both antibody and secondary-only control again suggested that BSA is
an inappropriate blocking agent to use in the context of blotting methods, due to the
high background. Two final Western blots were then produced. The first used BSA as
a protein sample and showed that there is no specific reaction between BSA and the
antibody used for this project (Figure 4.38). The second, in which passive conjugates
were blotted onto a milk-blocked membrane, showed that milk blocking significantly
reduces the non-specific background of the conjugates but also reduces the colorimet-
ric signal seen at the p16 band so that it is no longer detectable by eye (also Figure
4.38).
FIGURE 4.37: Western blots using A) BSA as a membrane block (in triplcate), B) BSA
and milk as membrane blocking agents, compared with secondary only control. Stringent
and identical washing procedures were used for each membrane, indicating a reaction
between BSA and the primary antibody.
Casein (VWR International), polyethylene glycol (average m.w. 8000, Sigma Aldrich)
and goat serum (Sigma Aldrich) were all investigated as alternative blocking agents.
The casein samples aggregated, and remaining samples produced a false positive sig-
nal on commercial dipstick assays owing to the need for BSA in the running buffer
solution for the assay (Figure 4.39).
Finally, dot blots were produced for the best conditions of all conjugate types to
test for binding strength in a colorimetric context. In each case 1µl spots of purified
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FIGURE 4.38: Western blot membranes showing that A) the reaction with BSA is non-
specific and that antibody sensitivity is reduced by storage in phosphate buffer; B) mem-
brane blocking with milk solution gives a marked improvement in non-specific back-
ground but does not remove it completely.
FIGURE 4.39: A) brief investigation of alternative blocking agents with dipstick assays; B)
demonstration of requirement for BSA in conjugate buffer as an assay-blocking measure.
p16 protein (100ng/µl and 10ng/µl) were applied to a PBS-wetted nitrocellulose mem-
brane and left to dry, before the membrane was blocked for 30 minutes at room tem-
perature using 1% [w/v] fatless milk powder in PBS. Conjugates were incubated for
two hours before being washed with milk solution for five minutes in triplicate. The
passive conjugates, shown in Figure 4.40, produced a faint spot for the higher pro-
tein concentration, but was clearly inferior to Protein G-based conjugates discussed in
Section 4.8.
As a result of the non-specific binding of the passive conjugates as well as the
reliance on BSA as a component of the commercial dipstick assay blocking solution
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FIGURE 4.40: Dot blots carried out for A) passive conjugates at different antibody con-
centrations; B) bioconjugates (Protein G’) with different antibody cconcentration.
for testing successful conjugation, it was decided to explore alternative methods for
conjugation as seen in Section 4.8.
4.8 Bioconjugation of antibody
4.8.1 Bioconjugation scheme
As explained in Section 4.1, bioconjugation to AuNPs takes two major forms: native
binding with Protein A or G and binding of biotinylated antibodies using avidin or
streptavidin. The primary advantage of the Protein A/G method in particular is that
by immobilising the antibody of interest onto a surface by its heavy chain within the
Fc region, the functional region of the antibody is automatically oriented to offer op-
timal binding (Figure 4.4). Much like functionalised PEG it can also act as a blocking
agent for the particle surface if titred properly. Given the issues discovered in Sections
4.6 and 4.7 with conjugate binding affinity in paper-based devices and the proven abil-
ity of Protein A/G mix to successfully bind the antibody of interest in a commercial
dipstick assay, this approach provides an obvious alternative to the more common
methods trialled in the remainder of the chapter.
4.8.2 Optimisation of Protein G’ coverage
Protein G’ (Proprietary Source, Recombinant, expressed in E. coli) was chosen as the
bioconjugation moiety for the project owing to its ability to strongly bind murine im-
munoglobulins compared to Protein A. Recombinant Protein G’ is a modified form of
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Protein G in which the albumin and cell surface binding domains have been elimi-
nated in order to reduce non-specific binding. The protein is supplied as a lyophilised
compound and was reconstituted in phosphate buffer (pH7.6), and is nominally stable
from pH2-10 with a pI of 4.5 and optimal binding pH of 5.0. In order to approximate
the concentration order of magnitude required for a monolayer on the AuNP surface,
the molecular footprint was calculated. Recombinant Protein G’ is 21.6kDa but ap-
pears as 31-34kDa by Western Blot. Assuming a spherical molecule its diameter is
then 4nm, giving a footprint of approximately 12nm2. The NP surface area is ap-
proximately 5050nm2. Thus, a monolayer requires 420 protein molecules per particle.
Given an AuNP concentration of 16nM, the Protein G’ solution should be 6.8µM. For
a 21.6kDa protein this is equivalent to 3.67µg in 25µl or 0.15mg/ml.
BPE-AuNPs (0.75µM initial concentration) were produced as outlined previously
and tested with resuspension in pH5.0 citrate buffer, which aggregated the particles
completely. A 10mM solution of MES buffer was then produced and adjusted to
pH4.8, in which the BPE-AuNPs remained stable without adverse effects on Raman
signal (Section 4.4.4). Small volume tests (250µl) were produced according to Section
4.3.5 and a simple salt aggregation test was used to assess the coverage of Protein G
on the surface. This was done by diluting the protein-coated particles with an equal
volume of 1.71M NaCl solution and measuring subsequent aggregation optically - the
absorbance characteristics before and after salt addition can be seen in Figure 4.41,
with physical characteristics in Figure 4.42. These indicate that a minimum concen-
tration between 0.038 and 0.075mg/ml is required to prevent aggregation in a strong
ionic buffer, and that a concentration of 0.300mg/ml results in an excessive drop in
absorbance. The sudden increase in zeta potential stability at 0.150mg/ml may in-
dicate monolayer coverage, which corroborates the molecular footprint calculations
seen above. Thus, the 0.075 and 0.150mg/ml sample protocols were carried forward
for antibody titration.
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FIGURE 4.41: Extinction characteristics of BPE-NPs coated with Protein G’ (solid red
line) at initial concentrations of A) 0.038mg/ml; B) 0.075mg/ml; C) 0.150mg/ml; D)
0.300mg/ml compared to samples prior to conjugation (solid black line) and conjugated
samples after salt aggregation (dotted red line).
124 Chapter 4. Development of antibody-conjugated nanoparticles
FIGURE 4.42: The A) hydrodynamic diameters and B) surface charge potentials of BPE-
AuNPs before and after Protein G’ adsorption at different concentrations. Protein concen-
trations 0.075mg/ml or lower result in a drop in zeta potential which was confirmed by
salt aggregation.
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4.8.3 Conjugation of antibody on Protein G’ coated particles
Undiluted antibody used with the initial protocol resulted in a positive dot blot signal
on milk-blocked membrane (1% fatless milk powder in PBS for 30 minutes, incubation
for two hours, washed for 5 minutes with milk solution in triplicate). Further samples
produced without centrifugation and resuspension after addition of Protein G found
a strongly reduced signal by dot blot, indicating that antibody was binding to excess
Protein G in solution.
Further samples produced according to the specifications shown in Table 4.5 were
also incubated on nitrocellulose membrane according to the same protocol. In each
case 1µl spots of purified p16 protein (100ng/µl and 10ng/µl) were applied to a PBS-
wetted nitrocellulose membrane and left to dry before blocking. The resulting colori-
metric signals can be seen in Section B of Figure 4.40, which demonstrates clearly visi-
ble binding for all samples at different intensities. As expected, higher concentrations
of antibody result in a greater colorimetric intensity, and so additional samples with
1:1 antibody dilution were produced and compared in Figure 4.43. Here the mem-
brane was not wetted before use. The most successful combination of reagent concen-
trations (Sample 3.1, 0.150mg/ml Protein G’, 1:1 mAb) were reproduced in triplicate,
tested with wetted membrane and found to be consistent. The conjugates were not
found to bind non-specifically to high molecular weight proteins in a Western Blot
format, as was the case with passive conjugates.
Previous experiments had shown that two hours was an optimal incubation time
for conjugates on blocked membrane (when compared with 1, 3 and 4 hour incuba-
tions). The optimised sample was also applied to a commercial dipstick assay which
had also been applied with 1µl spots of 100ng/µl and 1µg/µl and left to dry before
conjugate wicking. This produced clear positive colorimetric signals after just ten min-
utes, indicating that the dipstick approach is preferable to surface contact only (also
Figure 4.43). It was concluded that the two spots produce the same intensity of signal





TABLE 4.5: The concentrations of Protein G’ and antibody used for initial antibody con-
jugation experiments.
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FIGURE 4.43: Colorimetric reponses of A) different bioconjugate conditions against pu-
rified p16 dot blots at different concentrations and B) the best canditate in dipstick assay
format.
due to the expenditure of the majority of particles before the higher concentration spot
was reached. It is unclear, however, why a positive test line is still seen at the Protein
A/G line.
4.8.4 Storage and signal considerations
Having optimised a suitable protocol for conjugates which bind clearly and rapidly to
purified p16 in a paper-based assay format, the bulk solution was interrogated with
a Raman spectrometer (Section 4.3.2) and found to produce only small peaks, indicat-
ing that buffers used for the various conjugation stages and storage may need to be
altered. As such, six samples were produced according to the specifications in Table
4.6.
Samples 2, 3 and 6 aggregated after a 48 hour period, indicating that HEPES is
an inappropriate storage buffer for these conjugates. The remaining samples demon-
strated, again, weak Raman signals (Figure 4.44). The stability of the conjugates over-
all indicated that phosphate buffer could be preferentially used as an antibody conju-
gation medium. As such, all subsequent conjugates were produced according to the
following protocol:
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Sample mAb conjugation buffer Storage buffer
1 MES (pH4.8) Phosphate (pH7.6)
2 MES (pH4.8) PBS
3 MES (pH4.8) HEPES (pH8.0)
4 Phosphate (pH7.6) Phosphate (pH7.6)
5 Phosphate (pH7.6) PBS
6 Phosphate (pH7.6) HEPES (pH8.0)
TABLE 4.6: The conjugation buffer conditions used with optimised concentrations of Pro-
tein G’ and mAb.
1. Add 5µl desired reporter concentration to 495µl AuNPs and shake for 30 min-
utes at 500rpm.
2. Centrifuge at 2300g for 15 minutes to pellet. Remove 480µl supernatant and
suspend in equal volume of 10mM pH4.8 MES buffer.
3. Add 50µl desired concentration of Protein G (mg/ml in pH7.6 phosphate buffer).
4. Centrifuge at 2300g for 15 minutes to pellet. Remove 480µl supernatant and
suspend in equal volume of 10mM pH7.6 phosphate buffer.
5. Add 5µl desired antibody concentration to reporter AuNPs and shake for 30
minutes.
6. Centrifuge at 2300g for 15 minutes to pellet. Remove supernatant. Resuspend in
either 480µl 10mM pH7.6 phosphate buffer for normal concentration or 80µl for
a 5x optical density conjugate suitable for blotting.
It was found to be important that Protein G’ in particular is added at the volume
and concentration specified. A smaller volume of higher concentration providing the
equivalent mass of protein (5µl 1.5mg/ml instead of 50µl 0.15mg/ml) was found to
completely aggregate the nanoparticles.
A further set of conjugates investigating higher concentrations of reporter in con-
junction with other reagents was produced as seen in Table 4.7. Their absorbance,
Raman spectra and binding strength are shown in Figure 4.45. Samples 1, 5 and 8
produced the highest peaks, but Sample 8 also suffered from a high background. It is
possible that this is due to partial aggregation caused by incomplete surface coverage.
A final set of BPE-AuNPs investigating higher concentrations of BPE suspended in
MES buffer as though for bioconjugation are recorded in Figure 4.46. All were found
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FIGURE 4.44: Raman spectral variation with conjugation and storage buffer of the three
conditions in Table 4.6 which did not aggregate.
to be stable, demonstrating the importance of centrifugation and buffer conditions if
compared to the stability of initial reporter experiments in Section 4.4.3.
A final set of optimised conjugates with increased BPE concentration were pro-
duced in triplicate with hydrodynamic diameters in Table 4.8, and absorbance and
Raman spectra in Figure 4.47. These conjugates used initial concentrations of 5µM
BPE, 0.15mg/ml PrG’ and a p16 antibody dilution of 1:4, equivalent to 0.125mg/ml.
The addition of protein layers reduces Raman intensity, although the signal produced
for the particles in triplicate does vary for one sample. This conjugate method was
used for all further experiments as seen in Chapter 5.
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Sample BPE (µM) Protein G (mg/ml) mAb dilution Hydro. diameter (nm)
AuNP - - - 48.0±0.3
1 1.25 0.150 1:1 124.8±4.6
2 0.75 0.150 1:1 123.2±1.8
3 1.25 0.075 1:1 204.3±48.3
4 0.75 0.075 1:1 133.4±4.7
5 1.25 0.150 1:4 122.1±7.7
6 0.75 0.150 1:4 287.2±48.1
7 1.25 0.075 1:4 250.4±37.0
8 0.75 0.075 1:4 133.0±3.4
TABLE 4.7: Further bioconjugate conditions investigating higher concentrations of BPE
for improvement of Raman signal.
Sample Hydrodynamic diameter (nm)
BPE Conjugate 1 130.4±4.1
BPE Conjugate 2 141.9±7.1
BPE Conjugate 3 146.4±6.5
TABLE 4.8: Hydrodynamic diameters of the final bioconjugate condition produced in trip-
licate.
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FIGURE 4.45: A) Extinction, B) Raman spectral and C) colorimetric binding characteristics
of bioconjugate samples as detailed in Table 4.7.
4.8. Bioconjugation of antibody 131
FIGURE 4.46: Raman spectra of higher concentration BPE-AuNPs without protein cover-
age (MES buffer).
FIGURE 4.47: A) Extinction and B) Raman spectra of finalised bioconjugates produced in
triplicate.
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4.9 Conclusions
In this Chapter, a SERS-active antibody conjugate has been developed and optimised
which binds to purified p16 protein. The individual components of an antibody-
conjugated nanoparticle - metal substrate, Raman-active label, blocking moieties, bind-
ing ligand and conjugation method - have been characterised and optimised both in-
dependently and in conjunction with the other components. Three common conju-
gation methods were explored in order to produce the most effective conjugate for
quantification of p16 levels in cervical cancer cells.
Covalent conjugation, although typically considered the ‘gold standard’ of con-
jugation approaches, demonstrated issues with non-reproducibility which have been
documented previously and are most likely due to spontaneous cross-linking of the
conjugation moieties and antibody. This leads to the demonstration of successful an-
tibody conjugation onto the nanoparticle substrate but with disruption of antibody
binding functionality. Passive conjugation provided useful information for the rapid
optimisation of antibody concentration, but was found to produce weakly binding
conjugates, most likely due to the random orientation of ligand which is intrinsic to
the method. The Protein G bioconjugation method allowed not only for rapid optimi-
sation but also for conjugates where bound antibodies are guaranteed to be oriented
in a manner conducive to binding. The fact that the binding ligand acts as a protein
block on the nanoparticle surface when titrated to monolayer coverage helped to re-
duce the number of conjugation steps as well as issues experienced with the use of
BSA as blocking agent on passive conjugates. The final Protein G conjugate described
can be produced in 2.5 hours at room temperature at a material cost of £2.32 per 1ml
(unconcentrated), demonstrating baselined Raman intensity of 11530 ± 2650 counts
without concentration and a clear colorimetric and Raman response to 50ng purified
p16 in a paper-based assay.
An appreciation of the dynamics, competition and context of these critical com-
ponents is clearly essential for production of an NP conjugate which is stable, repro-
ducible and effective. Previously optimised covalent methods were ineffective for the
antibody used, even when of the same isotype. Antibody sensitivity and the subse-
quent required concentration for labelling has a significant impact on substrate avail-
ability for Raman labels. Conjugation approaches may disrupt the biological function-
ality of the antibody being conjugated. Certain conjugation buffers have demonstrated
capability to deteriorate SERS enhancement of Raman-active molecules. Spacers may
improve binding site access and reduce non-specific interactions but also increase the
size of the conjugate beyond usefulness. In order to capture the complexity of these
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interactions for the production of an effective gold nanoparticle-based conjugate from
scratch, a recommended general workflow has been produced and is shown in Figure
4.48.
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FIGURE 4.48: A recommended workflow for the development of SERS-active antibody-




Quantification of p16 in whole cells
5.1 Introduction
A targeted approach to molecular pathology allows for a diagnostically relevant marker
to form the basis of a rapid, quantifiable test, rather than relying on unknown cellular
changes as seen in Chapter 3. Using a targeted in-cell approach for cervical cytology
would be useful as an aid for pathologists, as smear samples are phenotypically het-
erogeneous. Technically, a single highly abnormal cell in a sample of approximately
10,000 may be sufficient for a positive diagnosis, although in practice larger abnormal
populations are required in order to be definitive.
A successful in-cell Raman diagnostic test has multiple requirements. The labelling
moiety must of course be specific for its target, but should also be sufficiently stable for
both consistent large-scale production and introduction into the cellular environment
of choice without loss of structure or functionality. A protocol must be developed
which minimises unwanted aggregation, residue or non-specific binding of the la-
bel. If multiplexing is used, the associated vibrational peaks must be suitably distinct
for straightforward analysis, even in the presence of spectral background or particle
aggregation. Finally, the label must be sufficiently well characterised to provide a con-
fident and meaningful reference when quantifying target expression.
These requirements necessitate the development of a targeted imaging approach
specific to each clinical application, including overall clinical goal, cell preparation
and fixation state, expression location of the target marker and imaging setup. This is
alongside the usual considerations of sample throughput and acquisition times.
This Chapter details the exploratory work performed in choosing a targeted imag-
ing approach which is appropriate to the cervical cancer diagnostic context. Three
approaches were investigated - conventional conjugate-based SERS imaging, SERS-
SRS hybrid imaging and global-targeted hybrid imaging. The first two make use of the
p16-specific nanoparticle conjugate produced in Chapter 4, whereas the third explores
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the use of directly Raman-labelled antibodies with SRS rather than SERS enhancement
mechanisms. Owing to limited data collection from the SERS-SRS method, this work
is detailed in Appendix B (Chapter 9).
SERS imaging with nanoparticle conjugates
A vast number of biomedical studies have been undertaken with SERS-active nanopar-
ticle conjugates, including live cell studies [197] not appropriate to this project - these
are reviewed elsewhere [198, 199]. Those specifically in the cervical cancer context
have investigated expression of human protein tyrosine kinase-7 (PTK-7) on HeLa
cells with dual SERS-fluorescent nanorods [200]. PTK-7 has been demonstrated as
a marker of cervical disease status and prognosis [201], but is not currently used in
clinical settings.
Global-targeted hybrid imaging
Targeted stimulated Raman imaging is emerging as a potential competitor for fluorescence-
based studies, owing to the small size of the labelling moiety (which is advantageous
for live experiments) and the ability to simultaneously undertake label-free ‘global’
imaging of Raman-active groups in the sample which would provide complementary
morphological and structural information [202, 168]. A number of publications have
either developed multiplexed, highly Raman-active vibrational tags for SRS imag-
ing [203] or demonstrated their use in drug discovery [204] and glucose uptake [205]
amongst others.
5.2 Concept: ratiometric imaging approaches
While Raman-active small molecule antibody tags are conceptually similar to the use
of radioactive or fluorescent labelling of antibodies for imaging purposes, the use of
nanoparticle-based systems requires consideration of additional parameters. Nanopar-
ticle conjugates are typically much larger (15-40×) than alternative labelling methods,
resulting in variations in uptake and retention of the probes dependent on the mor-
phology of the sample rather than target marker expression. Studies by Wang et al.
[206] indicated higher uptake of nanoparticle conjugates in normal versus xenograft
tumour, whereas Kircher et al. [207] and others [208] have observed enhanced pene-
tration and retention (EPR) in tumours, as one might expect.
Thus, a ratiometric system has been proposed previously in which a non-specific
control or ‘dummy’ conjugate population is introduced alongside the target-specific
5.3. Materials and methods 137
probe(s). This dummy conjugate has the same physical characteristics as the target
conjugate but is biologically inactive and carries a Raman reporter with at least one
distinguishing vibrational peak.
The level of target-specific binding can then be quantified once washing steps have
been carried out to remove unbound probes. As the system provides pure reference
spectra, direct classical least squares (‘DCLS’, also known as classical least squares,
direct least squares or Beer’s Law method) can be applied to analyse analyte con-
centration. Tested over large biological populations, this can eventually be linked to
disease status in individual cells within a given smear sample.
DCLS assumes that at each wavenumber, the spectrum is the sum of a linear
weighting of analyte reference spectra as shown in Equation 5.1. The algorithm it-
erates through spectral weightings until the sum of squared residual terms R is opti-
mally reduced, where R is determined by the difference between the experimental and
modelled value. The spectral weighting is proportional to the concentration of the an-
alyte; owing to the multiple parameters which influence the proportionality constant,
concentrations are compared ratiometrically between samples or determined using
an internal standard [209]. As seen in Equation 5.1, accurate DCLS requires spectral
preprocessing to remove cosmic rays and non-specific background contributions.
S = ΣnwnFn + kB + ΣmamPm + R (5.1)
where S is the raw spectral intensity, wn and Fn are respectively the weighting
and reference spectrum of nanoparticle type n, kB is the k-weighted average sample
background spectrum B, am is the weighting of polynomial term Pm used for baseline
correction and R is the residual term [210, 211].
5.3 Materials and methods
Sterilised phosphate-buffered saline (PBS) and ultrapure water (‘dH2O’, MilliQ) was
used for all experiments. All plate shaking steps were carried out at room temperature
(RT) on a benchtop plate shaker (IKA MS 3) set to 500rpm. All optical components
were supplied by Olympus unless otherwise stated.
5.3.1 Cell incubation with conjugates
Cells were seeded on 20mm diameter glass cover slips in six-well plates (Greiner Bio-
One) and allowed to proliferate for 24-48hr at 37◦C in 5% CO2 until 30% confluent
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for ease of individual cell imaging. For fixed cell incubation, growth media was aspi-
rated, the wells washed three times with PBS and 500µl ice-cold fixing solution (either
PreservCyt or 4% paraformaldehyde (PFA) in PBS) added for 30min. The fixative
was aspirated, the wells washed again and cells blocked using 2% BSA in PBS for
1hr at RT. The blocking solution was replaced with 100µl 5× concentrated conjugates
mixed with 400µl 0.1% BSA in PBS and the cells incubated for two hours at RT on a
plate shaker. The conjugate solution was then aspirated and the cells washed twice
with PBS and once with dH2O, before being left to dry and sealed with clear varnish
or mounted immediately using Fluorescence Mounting Medium (DAKO) onto glass
slides depending on the experiment.
For live cell incubation, growth media was aspirated, the cells washed with PBS,
100µl 5× concentrated conjugates added to 400µl fresh media in each well and the cells
incubrated at 37◦C for two hours. The cells were then washed, fixed and mounted as
described above.
All in-cell conjugate samples were imaged using an inVia Raman Microscope (Ren-
ishaw) with 785nm laser. Standard SERS mapping was used for several aspects of this
thesis and so is described in Section 2.8, General Materials and Methods.
5.3.2 Fluorescent antibody labelling
Unlabelled whole goat anti-mouse antibody (CAT A28174), 1mg/ml in PBS + 0.09%
sodium azide, was conjugated to Alexa Fluor 488 NHS ester (CAT A20000), succin-
imidyl ester, 1mg, molecular weight 643.4g/mol. This was compared to commer-
cial Alexa Fluor 488 goat anti-mouse (CAT A11001), 2mg/ml in PBS (pH7.5) + 5mM
sodium azide. For immunofluorescence, both secondary antibodies were bound to
p16 INK4A monoclonal mouse anti-human antibody (BD Pharmingen), 0.5mg/ml in
PBS.
The following protocol represents a slight variation of that described in ‘Amine Re-
active Probes’ (Molecular Probes, Life Technologies). An Antibody Concentration Kit
(ab102778, Abcam) was used to increase the concentration of the unlabelled antibody
from 1 to 5mg/ml and simultaneously buffer-exchange the protein into 0.1M sodium
bicarbonate buffer (pH8.3) for conjugation. Between 1.50 and 3.00µl amine-reactive
fluorophore (5 or 10mg/ml) was slowly added to 100µl concentrated unlabelled anti-
body whilst vortexing. The tube was wrapped in foil and incubated for 1hr at room
temperature with continuous stirring on a rotary incubator. The reaction was neu-
tralised with 10µl freshly prepared hydroxylamine (pH8.5, 1.5M and incubated for
1hr as before.
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To separate the conjugate from unreacted fluorophore, 500µl Sephadex-50 gel per
sample was prepared in PBS and left to hydrate overnight. The gel slurry was added
to a prepared filtration column and excess buffer left to run before the reaction volume
was added. The first fluorescent band to elute is the successfully conjugated antibody.
The absorbance spectrum of a 1µl volume of the sample was assessed, with values at
280nm and the absorbance maximum of the dye (495nm for Alexa Fluor 488) recorded





where Amax is the absorbance maximum of the conjugated fluorophore, MW is
the molecular weight of the protein, εdye is the extinction coefficient of the dye at its
absorbance maximum, and [protein] is the protein concentration in mg/ml. For IgG
antibodies, 1.4 Aprotein units is equivalent to 1mg/ml protein concentration. The ab-
sorbance Aprotein of the antibody is calculated from
Aprotein = A280nm − (Amax × CF) (5.3)
where CF is the correction factor of the dye contribution at 280nm, given by A280 f reedyeAmax f reedye
and quoted as 0.11 for Alexa Fluor 488.
The labelled antibody was stored in the dark at 4◦C and -20◦C for the short (less
than three weeks) and long term respectively.
5.4 Production of a physicochemical control particle
An isotype control or ‘dummy’ conjugate, which complements the finalised biocon-
jugate discussed in Chapter 4, was developed in order to assess the non-specific be-
haviour of nanoparticles in fixed cells. Initially, PYOT particles were produced due
to the similarities in hydrodynamic size and surface charge found in comparison with
BPE-coated AuNPs. However, the effect of such characteristics on a protein-coated
particle are negligible in comparison to the need for clearly discernible Raman peaks.
Two of the primary peaks for BPE and PYOT occur in the same region (1603-1606cm−1)
and so PPY was explored as an alternative.
5.4.1 Binding validation
Prior to use in cells, the specificity and binding affinity of target and dummy conju-
gates was tested using lateral flow assays. Paired conjugates were initially produced
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with parameters outlined in Table 5.1 and with the Protein G’ conjugation method de-
scribed in Section 4.8.4. Following the final centrifugation, 15µl of each conjugate was
used diluted 1:1 with conjugate buffer (with BSA), equivalent to a final concentration
of 25×. The low volume of conjugate required an additional ‘flush through’ with 15µl
conjugate buffer to prevent nanoparticles from becoming embedded in the membrane
prematurely. The experiment was repeated with 5x concentrated sample which pro-
vided a clear colorimetric response for target particles with 25ng purified p16 protein.
The experiment was then repeated with optimised concentrations of BPE and PPY as
discussed in Section 5.4.2, again demonstrating, as expected, a clear colorimetric re-
sponse from the target particles and blank response from the dummy particles. Both
tests can be seen in Figure 5.1.
Sample Reporter Antibody
Target Conjugate 1 - 1% 1:1 mAb
Dummy Conjugate 1 - 1% 1:2 mAb
Target Conjugate 1 1% 5µM 1% 1:4 mAb
Dummy Conjugate 2 1% 20µM 1% 1:8 mAb
TABLE 5.1: The reagent parameters used for preliminary and final ratiometric conjugates.
Volumes are given as a percentage of the initial sample volume, e.g. 10% refers to 50µl
reagent added to a 500µl sample. All samples used 10% 0.15mg/ml Protein G’ solution
for antibody conjugation. Binding validation is shown in Figure 5.1.
In both cases the isotype control ‘dummy’ particles did not produce a colorimet-
ric response other than a ’coffee ring’ effect for the high concentration sample with
high protein content. This is posited as being due to impeded flow through the mem-
brane - the effect is seen for both types of particles and indicates that the non-specific
responses of the conjugates are similar in this format.
5.4.2 Physical characteristics
As with BPE titration, a range of PPY inital concentrations from 10−3 to 10−6M were
tested through 1:100 dilution with AuNPs. Concentrations 10−3 to 10−4 aggregated
immediately. Further titrations of PPY at 10, 15, 20, 30, 40 and 50µM were charac-
terised by extinction and Raman activity as shown in Figure 5.2: samples degraded in
stability from 30µM onwards, producing large Raman peaks at 952cm−1 for the 40µM
sample as a result of aggregate hotspot formation.
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FIGURE 5.1: Binding validation of target and dummy conjugates by dipstick assay with
purified p16 protein. A) 50× and 1× concentrated target and dummy conjugates without
Raman reporters. B) The final conjugate designs tested at 5× production concentration.
Both were tested against 0.5µl spotted volumes of the protein content shown. As expected,
the dummy conjugate with isotype antibody control does not bind to the target.
FIGURE 5.2: The absorbance and Raman spectra of bioconjugates produced with varying
concentrations of PPY stock, used as a 1% volume of the sample. A) The colloidal solu-
tion is stable to 20µM, beginning to aggregate at 30µM and beyond. B) The conjugates
show high SERS activity at unstable concentrations due to aggregation-induced hotspot
junctions, but the stable concentrations still produce a high Raman signal at over 10000
counts for the primary peak.
PPY conjugates were then produced in triplicate using identical parameters to the
BPE target particles, but using an initial concentration of 20µM. The extinction spec-
tra can be seen in Figure 5.3, with physical characteristics summarised in Table 5.2.
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The variation in ratio of extinction peak to 650nm, a concentration-independent indi-
cator of stability, indicates variation in the PPY triplicate samples which may suggest
that 20µM PPY may not be fully stable. Smaller ratios correspond to less pronounced
absorbance peaks and therefore indicate aggregation.
FIGURE 5.3: Absorbance characteristics of PPY samples in triplicate. The variation is
partly caused by concentration variation but also due to reduced stability compared to
the BPE target conjugates (see Table 5.2).
Target and dummy conjugates were mixed in bulk at ratios from 0:5 to 5:0 in 20%
[v/v] increments and the combined Raman signals interrogated using 1.0s acquisi-
tions with a benchtop Raman spectrometer (Snowy Instruments) with 100mW 785nm
laser. The use of a 638nm laser line was found to significantly reduce Raman intensity.
The results can be seen in Figure 5.4.
Figure 5.4A shows a clear but non-linear increase of both of the unique principal
peaks for BPE (1201cm−1) and PPY (952cm−1) with relative volume. Figure 5.4B, how-
ever, shows that analysis can not simply be made on the basis of peak height. Frac-
tional variations in concentration can produce a significant effect on the proximity of
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Sample APeak A650 Ratio
BPE 1 0.7596 0.0721 10.55
BPE 2 0.6538 0.0611 10.70
BPE 3 0.5533 0.0557 9.93
PPY 1 0.6863 0.0849 5.17
PPY 2 1.1180 0.1327 8.43
PPY 3 0.8846 0.1024 8.64
TABLE 5.2: Absorbance characteristics of target and dummy conjugates. The ratio of
absorbance at the peak versus 650nm gives an indication of the aggregation status of the
sample, with higher numbers indicating higher stability.
FIGURE 5.4: Reference ladder of bulk ratiometric samples, mixed at 20% intervals. A)
The normalised Raman spectra of each sample. B) Intensity of principal peaks from each
sample showing some concentration-dependent error. C) A ratiometric reference curve of
the data, independent of concentration and showing a clear reciprocal trend.
particles within the acquisition volume and therefore the SERS signal. However, by
taking a ratio of the unique peaks for the two molecules and plotting against relative
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conjugate volume within the sample, a relationship can be found and potentially used
to predict ratios of target and dummy conjugates within a sampling volume (Figure
5.4C). A ‘Rational5’ Nonlinear Curve Fit was used in Origin, to reflect the ratiometric
(rational fraction) nature of the data. The potential instability of the 20µM PPY con-
jugate, combined with the steep slope of the ratiometric curve, suggest that a lower
concentration of the dummy reporter may be beneficial to reduce potential errors in
imaging data interpolation.
5.5 Ratiometric conjugates in whole cells
Having produced a complementary dummy particle for the established conjugate to
p16 protein, the ratiometric system was explored with SERS mapping in fixed cells to
test its ability to distinguish between expression levels in cell models and quantify the
relative concentrations of nanoparticles present.
5.5.1 Preliminary optimisation of conjugate incubation
Initially cell samples were prepared according to the protocol described in Section
5.3.1 and left to dry before inverting. Target (BPE 5µM) and dummy (PPY 20µM)
conjugate incubations were carried out with fixed HaCaT and SiHa cells, where p16
is respectively undetectable and overexpressed. Cells were fixed in either PFA (cross-
linking) or PreservCyt (dehydrating) as a comparator of the standard approach against
a clinically relevant model.
SERS mapping was carried out as described in Section 2.8 and mapping analysis
conducted with component-based DCLS using bulk reference spectra. Representa-
tive imaging maps and associated spectra are shown in Figure 5.5. Owing to the use
of drying for cell preparation, issues were encountered with salt crystal formation
that made cell membranes difficult to distinguish, particularly for PFA-fixed cells. Ta-
ble 5.3 shows the location of targeted conjugate hotspots, with signals designated as
True Positive or False Negative for inside or outside SiHa respectively. This labelling
convention was inverted for HaCaT cells. The SiHa and HaCaT cells incubated with
dummy conjugates displayed hotspots inside and outside cells.
Overall the results indicate that the use of PFA as a fixative results in lower speci-
ficity of measurement, as all of the HaCaT cells prepared in this way show false pos-
itive results. This is posited as being due to the cross-linking effects of PFA, which
are more likely to ‘trap’ conjugates non-specifically than cell dehydration. It is worth
noting here that for two of the HaCaT PreservCyt samples, a small Raman signal was
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FIGURE 5.5: Examples of SERS maps and corresponding hotspot spectra for PFA- and
PreservCyt-fixed wildtype SiHa and HaCaT cells, generated using Wire 4.2.
present barely visible above the fluorescent background. Use of this technique with
clinical samples would require careful thresholding to determine the level of SNR re-
quired to constitute a signal. Finally, the use of morphologically distinct cell models,
though appropriate in terms of p16 expression, do not give a comparable indication
of non-specific accumulation and general kinetics of conjugates inside fixed cells.
Conjugate incubation with fixed cells in suspension was also tested. For this, 100µl
aliquots of fixed HaCaT (p16 not detectable) and SiHa (p16 overexpressed) cells were
washed with PBS as described in Section 3.3.1 to remove PreservCyt residue, before
being blocked with 2% BSA in PBS for 1hr at room temperature (RT). Blocking solution
was removed by pelleting the cells at 6800g for 5min and removing the supernatant.
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Sample Fixative True False Sample Fixative True False
SiHa 1 PFA 1 - HaCaT 1 PFA - 3
SiHa 2 PFA 3 - HaCaT 2 PFA - 4
SiHa 3 PFA 6 - HaCaT 3 PFA - 4
SiHa 4 PFA - 1 HaCaT 4 PFA - 8
SiHa 1 PreservCyt - 2 HaCaT 1 PreservCyt - 2
SiHa 2 PreservCyt 2 - HaCaT 2 PreservCyt 0 -
SiHa 3 PreservCyt 4 - HaCaT 3 PreservCyt 1 -
SiHa 4 PreservCyt 6 - HaCaT 4 PreservCyt 2 -
TABLE 5.3: Labelling accuracy of target conjugates inside SiHa and HaCaT cells fixed
with either PFA or PreservCyt. ‘True’ and ‘false’ designations correspond to True Positive
and False Negative for SiHa (p16 expressed), and True Negative and False Positive for
HaCaT (p16 not expressed).
Cell samples were incubated with 100µl 50× concentrated target or dummy conju-
gates for 1.5hr on a plate shaker. The cells were pelleted again and the supernatant,
containing free conjugates, removed. The cells were suspended in 40µl PBS and di-
vided between two cavity slides for imaging under the same conditions as described
previously. This resulted in poor signal and issues with cell drift under laser interro-
gation due to lack of adherence.
On the basis of the experiments described above, several changes were made to
the method. First, the mounting medium used for immunofluorescent slide prepara-
tion was tested and found to be vibrationally silent. Thus, slides were then prepared
according to the immunofluorescence protocol described in Section 2.4 but using con-
jugate incubation instead of primary and secondary antibodies. Second, the dummy
conjugate reporter concentration was reduced from 20µl to 10µl to reduce likelihood
of aggregation. Finally, comparisons were made between SiHa w/t and transfected
with p16 in order to study SERS signal without complications from differing cell mor-
phologies.
5.5.2 Development of conjugate incubation and ratiometric method
A new set of conjugates was produced and incubated with SiHa cells in keeping with
the changes described above. SiHa cells were transfected with his-tagged p16 as de-
scribed in Section 2.2 for the highly expressing model. Initially, the conjugates were
tested separately so that minimal signal processing was required. DCLS was used
with the bulk reference spectra seen in Figure 5.6 to produce the false-colour hotspot
maps seen in Figure 5.7 - the corresponding raw spectra are in Figure 5.8. The maps
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themselves do not provide any visual indication of p16 over-expression. However,
the spectral data (and corresponding look-up values for the map) provide a clearer
picture. As hoped, the dummy conjugate signals vary slightly between samples but
not significantly between w/t and +p16 SiHa. The peak heights of the target conju-
gates show approximately a 2 to 5-fold increase in signal for the +p16 compared to
w/t SiHa.
FIGURE 5.6: Bulk reference spectra for target and dummy conjugates, used in Section
5.5.2. Spectra were acquired on a CBEx 785 hand-held Raman identification system.
For ratiometric mapping, a second set of conjugates were produced with the same
concentrations of reporter and incubated as a 1:1 volume mix with w/t and +p16 trans-
fected SiHa, fixed with PreservCyt before incubation. Individual incubations were
also produced. The cell maps can be seen in Figure 5.9, with spectra in Figure 5.10.
The elongated nature of the hotspots is an artefact of the use of a line profile for the
laser without a pinhole; this setup was found to significantly improve detectable sig-
nal. The white arrows indicate the pixels with maximum spectral intensity - for SiHa
w/t, these coincide, but for SiHa +p16 they are distinct. Most importantly, the target
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FIGURE 5.7: Examples of SERS maps and corresponding hotspot spectra for w/t and
transfected PreservCyt-fixed SiHa, which do not give any visual indication of a link be-
tween target signal and p16 expression.
conjugate intensity varies in keeping with the expected expression of p16 in the cells,
demonstrating a 2.2-fold average increase in 1201cm−1 BPE signal for the transfected
model, whereas the dummy signal decreased by 1.2-fold.
For analysis of conjugate ratios, a reference ladder of 5µl mixtures from 100% to
0% target in 10% increments was spotted down onto a glass microscope slide and left
to dry before imaging at 20× magnification. The two pure references were used to
create the DCLS component maps seen in Figure 5.9, but it was noted that the dummy
conjugate areas marked as high intensity by the DCLS analysis were not all genuine
hotspots when compared manually. This was partly due to the presence of the flu-
orescent background which could not be removed through automatic baselining or
substraction of a reference spectrum without altering central peak heights. The pri-
mary issue was that the principal PPY peak had deteriorated in the dried reference
ladder. As seen in Figure 5.11, the peak is convoluted with small peaks in the BPE
spectrum. Given the highlighted importance of signal quantification for progress to
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FIGURE 5.8: Raw hotspot spectral data for w/t and transfected PreservCyt-fixed SiHa,
corresponding to the equivalent maps in Figure 5.7.
be made in SERS mapping and the successful demonstration of conjugates presenting
in the expected levels in fixed cervical cancer cells, it was decided that signal process-
ing of the spectral data should be prioritised.
5.5.3 Establishing a signal processing technique
Having established that a SERS signal could be detected from conjugates inside cells,
efforts were focused on SERS signal processing and quantification. Dummy samples
produced at 20µM PPY initial concentration were revisited to account for the signal
crosstalk experienced with dried reference samples at 10µM PPY. A second ratiometric
reference ladder produced and characterised in bulk and via mapping. The bulk ratio-
metric ladder consisted of target and dummy conjugates mixed in 25% increments to
give 100:0, 75:25, 50:50, 25:75 and 0:100 ratios. Once bulk spectra had been acquired,
5µl aliquots of each sample were transferred to a glass slide to dry and then interro-
gated via Raman mapping. Bulk spectra were acquired over a single 1.00s acquisition
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FIGURE 5.9: SERS hotspot maps of w/t (left) and p16-transfected (right) PreservCyt-fixed
SiHa cells incubated with target (red) and dummy (blue) conjugates. A) Separate incu-
bations, which, as before, do not give any visual indication of p16 expression status. B)
Ratiometric incubation.
and mapped spectra acquired with HRStreamline on Wire 4.2 using a 2.00s acquisi-
tion and no pinhole. The normalised bulk spectra and associated peak height-based
ratiometric reference curves can be seen in Figure 5.12. For the mapped data, 9-point
spectral smoothing (third-order polynomial) was carried out and an automated base-
line subtracted. In initial tests, each spectrum was truncated to the region of interest
((850-1250cm−1)) to remove the fluorescent background, but this process was found to
crash the analysis software during mapping.
The processed spectral maps were then analysed ratiometrically using an in-house
MATLAB script, modified from code written by Catherine Lynch at the University of
Edinburgh and Lauren Jamieson at the University of Strathclyde. The commercially
available software, Wire 4.2, was not capable of either direct ratiometric mapping or
exporting matrices of DCLS weightings for further analysis.
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The mapping script allows for the ratiometric value of two peaks within the same
spectrum to be displayed as a false-colour pixel, allowing ratiometric maps to be gen-
erated. The resulting matrix of ratios corresponds directly to the percentage volume
data shown for the conjugates in Figure 5.12C and D.
Figure 5.13 shows maps of the dried reference spots and a visual representation
of the signal processing work flow. As the references progress through to 100% tar-
get, the number of red pixels (corresponding to high percentages of target) increases,
whereas blue (100% dummy) and black (approximately 1:1 mix) pixel numbers are
reduced. The granular nature of the reference data is due to the resolution of the tech-
nique, which can pick up locally dried areas of target or dummy conjugates not seen
with bulk imaging. This actually gives a better indication of what spectral process-
ing might look like for incubated cell samples. Calibration using the reference curve
would provide a more linear response for the false-colour map.
The preliminary data shown stands as proof of principle that the ratiometric ap-
proach could be used incorporated into established software platforms in an auto-
mated fashion. This would give more meaningful data than conventional SERS maps,
and could be applied to a fixed cell context.
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FIGURE 5.10: The baselined spectra from separate incubation SERS maps in Figure 5.9A.
A) SiHa w/t target hotspot spectra. B) SiHa +p16 target hotspot spectra. C) SiHa w/t
dummy hotspot spectra. D) SiHa +p16 dummy hotspot spectra.
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FIGURE 5.11: Reference spectra and corresponding ratios for target and dummy conju-
gates. A) Raw spectral responses of dried conjugates at the percentage volumes of target
(T) and dummy (D) conjugates shown, indicating that the pure dummy conjugate ref-
erence peak was not intense enough for ratiometric analysis methods. B) Baselined, av-
eraged spectral responses of dried conjugates at 10% volume intervals. C) Ratiometric
reference values for the two primary peaks, 1202cm−1 (BPE target) and 952cm−1 (PPY
dummy).
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FIGURE 5.12: Ratiometric spectral reference data capable of use with false-colour maps.
A) Pure baselined reference spectra of target (BPE-PPY 4-0) and dummy (BPE-PPY 0-4)
conjugates, acquired from bulk volumes. B) Intensity values of the reference peaks at 25%
interval mixed volumes of dummy and target conjugates. C) Ratiometric value against
percentage volume and the corresponding reciprocal fit. D) Graph C on a y-limited scale
to account for the near-asymptote of pure target spectra in a ratiometric format, which
serves as calibration data for false-colour maps.
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FIGURE 5.13: False colour ratiometric maps, generated using reference peaks 952cm−1
(dummy) and 1202cm−1 (target). A) Maps of the dried conjugate reference mixtures de-
scribed above, coloured according to peak ratio. B) Work flow of the signal processing
required to perform ratiometric analysis in this context.
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5.6 Optimising fluorescent labelling as an analogue for alkyne-
tagged antibodies
Following the inactivity of Raman labelled colloidal gold with stimulated Raman scat-
tering, direct antibody labelling with Raman molecules was explored as a vehicle for
hybrid stimulated Raman imaging. Investigating a small number of bands specific to
those peaks found to be significant in unlabelled cell classification, alongside those
associated with the antibody label in question, should allow for a Raman mapping
approach which rapidly images robust markers for the disease in addition to global
information and morphology for borderline samples.
The Raman-active molecule to be conjugated was N-4-(4-phenyl-1,3-butadiyn-1-
yl)benzyl (‘BADY’)-succinimide (Figure 5.14), synthesised by Dr Will Tipping in Pro-
fessor Alison Hulme’s research group in the Department of Chemistry (UoE). The
Raman molecule has been used previously when conjugated to anisomycin for SRS
imaging of drug kinetics and phosphorylation of JNK1/2 in breast cancer cell SKBR3
[212]. To optimise the succinimide conjugation protocol, a fluorescent label with suc-
cinimidyl ester was first conjugated to an unlabelled secondary antibody so that it
could be compared directly to a commercial equivalent.
FIGURE 5.14: Synthesis and structure of BADY-succinimide (bottom left), a Raman-active
molecule with vibrational peaks in the cellular silent region.
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5.6.1 Optimisation of NHS coupling using commercial labels
Preliminary investigations using a 10ml column resulted in a large number of exces-
sively dilute fractions which were not suitable for use with immunofluorescence (Fig-
ure 5.15). This was replaced with an 800µl column (35µm pore size, Mobicol #M1002).
The antibody was buffer-exchanged and concentrated as described in Section 5.3.2.
A 30µl volume of concentrated antibody was mixed with 1.50, 2.25 or 3.00µl fluores-
cent dye (10mg/ml as described in Section 5.3.2). Difficulty was experienced accu-
rately weighing small masses of unconjugated dye. The absorbance profiles of each
sample were collected using 1µl of each sample on a spectrophotometer (NanoDrop
2000c Spectrophotometer, Thermo Scientific). The results are in Figure 5.16 with cor-
responding degree of labelling (DOL) calculations in Table 5.4. The DOL values were
calculated using equations 5.2 and 5.3 in Section 5.3.2. The molecular weight of the
antibody is 144g/mol and the extinction coefficient of the dye is ε/1000 = 71.
FIGURE 5.15: Absorbance spectra of fluorophore conjugation fractions with 10ml column,
which required multiple flushes with PBS to extract the full reaction volume. Fractions 1
and 2 show the highest antibody concentration as expected.
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FIGURE 5.16: Absorbance spectra of the three conjugation optimisation samples produced
and used for storage experiments, with commercial Alexa Fluor 488 absorbance for ref-
erence. Sample 3 shows an excess of dye (absorbance maximum) in relation to protein
concentration (280nm).
Sample A496 A275 AmAb [protein] DOL
Commercial 5.302 3.353 2.769 1.978 5.4
1 1.863 1.619 1.414 1.010 3.7
2 3.972 1.315 0.878 0.627 12.8
3 6.321 1.986 1.290 0.922 13.9
TABLE 5.4: DOL calculations for the preliminary fluorophore conjugation samples pro-
duced, based on the absorbance at 496 and 275nm, and protein contribution and concen-
tration.
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5.6.2 Lifetime and storage considerations
One of the rationale quoted for the use of SERS as opposed to fluorescence imaging
is high photostability over time [167]. The conjugated fluorophores were tested for
storage-based signal deterioration on this basis to ensure that SERS offers advantages
beyond multiplexed or hybrid imaging in a cervical cancer context.
Wildtype SiHa cells were prepared for immunofluorescence (IF) using the labelled
secondary antibody samples produced in Section 5.6.1. The standard IF protocol is
described in Section 2.4 - in all cases, BD Pharmingen mouse anti-human antibody to
p16 was used as the primary antibody (1:250 dilution) and the produced goat anti-
mouse samples used as secondary under the same conditions. The cell slides were
imaged 1 day after production and stored at 4◦C in darkness for one month before
re-imaging. In both cases, the channel exposure times were 23ms for DAPI and 53ms
for FITC. The FITC fluorescence signal and population expression for both imaging
times can be seen in Figure 5.17.
For non-saturated samples, there is a dip in the normal distribution of fluorescence
expression after a month of storage, indicating that probing the intrinsic molecular vi-
brations of Raman-active tags may provide benefits for clinical samples which require
revisiting after storage. Sample 3 demonstrates the opposite trend, possibly related to
an excess of fluorophore in the sample.
5.6.3 Comparison of commercial and in-house conjugation using immunoflu-
orescence
The conjugation procedure was repeated with a full aliquot of unconjugated dye (1mg)
suspended in 100µl DMSO, before half was decanted and diluted 1:1 in DMSO to
ensure exact concentrations of 10mg/ml and 5mg/ml respectively. The absorbance
spectra and structure of the unconjugated dye can be seen in Figure 5.18. Eight sam-
ples were produced as summarised in Table 5.5 with the corresponding DOL calcu-
lations. Sample 8 used frozen dye from the previous experiment to test whether the
fluorophore remained stable following reconstitution. The results can be seen in Fig-
ure 5.19.
The samples were used to prepare wildtype SiHa for IF, as described in 5.6.2. A
comparison of the FITC signal from all 8 samples can be seen in Figure 5.20. Samples 1,
2, 5 and 7, being the closest in DOL to the commercial label, were also prepared with a
secondary-only control. These results and corresponding fluorescence histograms can
be seen on in Figures 5.21 and 5.22 respectively. Samples 2 and 5 provide the closest
DOL to the commercial sample, but the excess of labelling in Sample 2 also generates a
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FIGURE 5.17: Immunofluorescence imaging of SiHa w/t cells prepared with commercial
or in-house Alexa Fluor 488-conjugated goat anti-mouse secondary antibody. A) Fluores-
cence maps (FITC channel) of cell expression acquired 1 day and 1 month after prepa-
ration. B) Expression histograms of the above data taken from greyscale values of the
FITC channel with a nuclear mask, showing that the non-saturated samples (commercial,
Sample 2) undergo signal degradation with time.
strong background signal which renders the labelled antibody useless. As such, Sam-
ple 5 provides the best indication of labelling ratio for the antibody and succinimide
ester, which can be used as a starting point for optimisation of the antibody coupling
to BADY-succinimide.
Owing to time pressures, this body of work was passed on to collaborators in the
Hulme group so that efforts could be focused on the development of a low-cost, clini-
cally relevant tool.
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FIGURE 5.18: A) Absorbance profile of unconjugated Alexa Fluor 488 in DMSO at the two
concentrations used. B) The structure of the unconjugated succinimidyl dye.
Sample Dye (µl) A496 A275 AmAb [protein] DOL
Commercial - 1.881 1.318 1.111 0.794 4.8
1 1.50 1.324 0.678 0.532 0.380 7.1
2 2.25 1.876 1.113† 0.906 0.648 5.9
3 3.00 3.332 1.318 0.951 0.680 9.9
4 1.95 1.719 1.566 1.377 0.983 3.5
5 1.50 0.890 0.776 0.678 0.484 3.7
6 2.25 0.665 1.023 0.950 0.678 2.0
7 3.00 1.668 0.862 0.679 0.485 7.0
8 1.95 6.645 1.471 0.740 0.529 25.5
TABLE 5.5: DOL calculations for the optimised fluorophore conjugation samples pro-
duced, based on the absorbance at 496 and 275nm, and protein contribution and con-
centration. Samples 1-4 used 10mg/ml dye and 5-7 used 5mg/ml. Sample 8 used frozen
dye from the previous experiment. † No strong absorbance peak seen.
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FIGURE 5.19: A) Absorbance profile of the four fluorescent conjugates produced using
10mg/ml dye. B) Absorbance profile of the four fluorescent conjugates produced using
5mg/ml dye. See Table 5.5 for details.
FIGURE 5.20: FITC intensity of SiHa w/t using in-house Alexa Fluor 488-conjugated goat
secondary antibodies.
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FIGURE 5.21: Optimal in-house Alexa Fluor 488-conjugated goat secondary antibodies
compared with secondary-only control. Each FITC image (green) is followed beneath by
the accompanying DAPI channel to demonstrate cell position.
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FIGURE 5.22: Fluorescence histograms for optimal in-house Alexa Fluor 488-conjugated
goat secondary antibodies, as extracted from fluorescence microscopy images shown in
Figure 5.21. This clearly demonstrates Sample 5 as the best-performing conjugate in terms
of expression sensitivity and low non-specific binding capacity.
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5.7 Conclusions
In this Chapter, three approaches to targeted Raman spectroscopy have been explored
as a means of quantifying p16 expression in whole fixed cells.
In the typical SERS approach, a non-specific mimic or ‘dummy’ conjugate was de-
veloped as a complement to the p16-specific target conjugated developed in Chapter
4. Although some issues were experienced with the stability and reproducibility of
the dummy conjugate, in-cell experiments demonstrated a clear increase in target sig-
nal between wildtype and transfected p16 expression, combined with uncorrelated,
small variations in dummy signal as expected. The preliminary true-false analysis of
nanoparticle incubation indicated that the dehydrating methanol-based fixative typi-
cally used for smear sample preparation provides higher classification accuracy than
cross-linking PFA.
Well-fitted spectral reference data has been produced, allowing for the Raman sig-
nal from mapping experiments to be calibrated in terms of conjugate ratio. The es-
tablished signal processing workflow is ready for application with in-cell mapping
to generate data which can be quantified with the same confidence as fluorescence
microscopy data, rather than by presence of target signal alone.
Owing to the limited scale on which conventional SERS mapping can be applied,
SRS-based techniques were also briefly explored as detailed in Appendix B (Chap-
ter 9). Their rapid mapping capability, combined with additional global spectral in-
formation, would aid image-guided analysis of cytopathology slides through clearer
definition of cell membranes.
The conjugates produced, though biologically stable, were not capable of support-
ing surface plasmons with pulsed lasers, and so lose their SERS enhancement in an
SRS setting. As a result, Raman-active antibody labels were considered. Conjuga-
tion parameters were successfully established using a fluorescent analogue bearing
the same active group. The method is now ready for development with a synthesised
Raman label.
Overall, the global-targeted hybrid imaging approach, employing a strongly Raman-
active label in the cellular silent region but with the considerable additional benefit of
label-free imaging of cellular structures, offers the most promising approach from a
molecular pathology perspective. However, the associated costs of an SRS system
would potentially limit its use outside of research and development contexts, at least




Development of a sensitive
paper-based SERS diagnostic device
6.1 Introduction
Exploratory work performed in Chapter 5 demonstrated overall that while nanopar-
ticle conjugates are capable of indicating levels of p16 expression in individual whole
cells, this expression is difficult to quantify in real terms. Although SERS-based ra-
tiometric mapping offers imaging speeds at least an order of magnitude faster than
for global Raman interrogation and therefore provides additional spatial data, it lacks
both the spectral richness of global spectroscopy and the acquisition scale of other
protein-specific imaging techniques such as fluorescence microscopy. Overall, in-cell
SERS imaging is advantageous for either highly multiplexed ex vivo analysis due to
the narrow Raman peaks, or in vivo tumour discovery owing to the immune ‘stealth’
potential of AuNPs compared to other labelling systems [213, 214, 215, 216]. From
a molecular pathology perspective cervical smear analysis requires neither of these
properties, but rather a test capable of classifying the large and heterogeneous cell
population of a single smear according to its progression status.
Thus, a shift in imaging paradigm is proposed towards approaches capable of pro-
viding a rapid diagnostic snapshot of whole samples through quantification of a ro-
bust marker. As outlined in Chapter 1, this would allow for samples to be rapidly
triaged according to p16 expression, so that the volume of samples requiring the di-
agnostic expertise of a cytopathologist would be reduced to borderline results and
routine quality control.
Paper-based biomarker assays or immunochromatographs (ICs) are a well-established,
inexpensive and scalable method of clinical whole-sample assessment, the most recog-
nisable example of which is the home pregnancy test [217]. They are primarily based
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on two technological principles: the use of paper as a diagnostic platform and the phe-
nomenon of antibody-antigen reactions in a quantitative ‘assay’ format. The first was
explored by Martin and Synge [218] and the second observed by Yalow and Burson
[219], for which Nobel Prizes were awarded in 1952 and 1977 respectively. The expiry
of the associated patents and their additions in recent years was predicted to generate
increased interest in paper assay development for global healthcare endpoints [220].
This is indeed reflected in current academic literature (Figure 6.1) as more research
addresses global healthcare issues requiring point-of-care (PoC) solutions [221].
FIGURE 6.1: The number of papers published 1997 to 2018 with key words "lateral flow"
and "immunochromatograph*" as generated by Scopus. The lateral flow patent was pub-
lished in 1997; this publication and its add-ons expired 2006-2013 [220].
ICs have been produced to address diagnostic challenges in situations as diverse
as viral, bacterial and fungal infections [222, 223, 224]; food contamination [225, 226];
drug abuse [227, 228], genetic profiling [229, 230] and allergen response [231, 232]. The
majority of assays developed in the cervical cancer context are for detection of HPV
[233, 234] or proteins thereof [235, 236, 237], possibly reflecting the emphasis on this
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high-specificity triage mechanism being implemented in clinical settings. However,
detection of p16 has been considered from a paper-based assay perspective. A HRP-
conjugated in-house antibody to p16 was passively conjugated to AuNPs, used to
classify clinical samples with 85.2% accuracy [187]. An electrochemical sensor for p16
has also been produced, using a complementary pair of unspecified antibodies cloned
in-house [186].
Despite this diversity of application the basic layout varies minimally, consisting of
a paper substrate including wicking pad, capture lines and a conjugate reservoir (Fig-
ure 6.2) alongside storage considerations. Each of these aspects is considered briefly
from a technical perspective below. ‘Dipstick’ and ‘lateral flow’ assays (LFAs) differ
in approaches to conjugate and sample mixing: in the former (Figure 6.2A), the assay
is dipped into a well containing a mixture of conjugate and analyte. In the latter (Fig-
ure 6.2B), the conjugate is embedded in a dried format in the assay pores, rehydrating
as the liquid analyte is added. In printed assays, the assay components are stacked
vertically, allowing for multiple tests across the whole ‘plate’.
A major additional benefit of paper-based devices, and particularly the LFA, is that
these assays possess the characteristics required for PoC diagnostics in low-resource
settings. As described in the Introduction, most cervical cancer cases occur in areas as-
sociated with limited income and medical infrastructure. Typically, technologies intro-
duced in this setting must be ASSURED: affordable, sensitive, specific, user-friendly,
rapid and robust, equipment-free, and delivered to those who need it [238]. Paper-
based devices typically adhere to these criteria, providing that they are easily disposed
and do not require constant refrigeration.
Two significant challenges in paper-based assay development are flow control and
detection sensitivity [239]. The former is a particular issue for an emerging field of
more complex designs which fall under ‘paper-based microfluidics’. As with pow-
ered devices, paper-based microfluidic assays address the need for multiple stages of
reagent addition and mixing not required for the proposed use with cervical smears.
These are reviewed extensively elsewhere [240, 241, 242, 243, 244].
In the past, detection sensitivity using the intrinsic colorimetric response of nanopar-
ticle based systems has been a limitation when compared to radio immuno (RIA) or
enzyme linked immunosorbent (ELISA) assays [245]. It is proposed that the SERS
activity of the developed conjugate would allow for a p16 expression assay to be de-
veloped that could be used for rapid colorimetric assessment and subsequent triage
of samples, as well as a sensitive SERS-based quantification of p16 expression. In the
past two decades, SERS PoC assays have not flourished to the same extent as other
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FIGURE 6.2: Schematic of a typical paper-based assay layout. In both cases, the sample
and conjugate travel up the strip via capillary flow where they interact with the test and
control lines. A) A dipstick assay, where the conjugate and sample are mixed separately
before being introduced to the substrate. B) A lateral flow assay, where the sample is
introduced to a sample pad before flowing into the dried conjugate pad. This reconstitutes
the conjugates and allows the two reagents to react before reaching the test and control
lines, as before.
more complex diagnostic assays using this optical phenomenon [246]. However re-
cently, paper-based assays with SERS functionality have been developed for bacterial
infection [247], stroke [248] and heart disease [249]. A portable SERS LFA reader has
also been developed [250]. Thus far, no successful attempts have been made in the
cervical cancer context. A brief summary of the technical considerations of such an
assay follows below.
Substrate
The substrate consists of a porous, analyte-binding polymer membrane with a polyester
backing for improved handling. Nitrocellulose and nylon membranes employ electro-
static binding. The binding capacity of the membrane is determined by its available
surface area, including that of the internal pores, and by the loading capacity of the
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protein or other analyte. For nitrocellulose membrane, the peptide bonds of the pro-
tein bind to the nitrate esters through strong dipole interactions. The pore size of the
membrane determines both the strength of capillary action and the porosity or ‘bed
volume’ of the membrane, which signifies the amount of liquid required to completely
wet the device. Overly large pore sizes can cause capture-line spreading and therefore
decreased assay sensitivity. Insufficient volumes can result in disruption of capillary
flow, resulting in a failed test. Excess sample volumes cannot be incorporated into the
device structure and so will reduce the overall signal.
Capture lines
For both colorimetric and SERS-based quantification, the capture lines should be printed
at the membrane surface to prevent loss of signal to membrane depth. Proteins bind
almost instantaneously on contact with nitrocellulose, and so the wetting properties
of the streptavidin binding layer and capture peptides should be controlled such that
narrow lines are produced. A narrower capture region results in a more concentrated
and therefore optically sensitive signal.
The use of streptavidin anchoring on nitrocellulose membrane has been reported
as insufficiently robust for lateral flow assays, and so use of nitrocellulose-binding
mutant streptavidin may be required [251].
Sample flow and detection
Owing to the often homogeneous nature of the membrane’s pore structure and the
exponential decay of capillary flow rate with distance travelled, substrates are charac-
terised by their capillary flow time - the time taken for the liquid sample of interest to
completely fill a strip of defined length. Longer flow times typically result in higher
sensitivities, as the ligands have more time to interact with their target.
The addition of a sample pad to membranes can fulfil several functions, from sim-
ply allowing a more controlled distribution of sample to adding other reagents. In
the case of a lateral flow assay, the sample liquid must then hydrate and interact with
nanoparticle conjugates, stored in the conjugate pad. The conjugate pad itself must
not bind to the nanoparticle complex. Slow release of conjugates is preferential, as
a colorimetric signal will only be produced by analyte flowing with or ahead of the
conjugates.
If a paper-based device for p16 quantification were to incorporate SERS-active con-
jugate, it could easily be combined with a handheld Raman spectrometer with ‘point
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and shoot’ attachment. This would allow for rapid, quantifiable triage of smear sam-
ples in low-resource settings without the requirement for a trained cytopathologist.
Raman interrogation requires optimisation of laser power and acquisition times and
cycles to ensure a rapid test which does not burn the membrane.
Storage
Storage is a key consideration for paper-based devices - the completed device must
be suitably robust to withstand transportation and handling within ASSURED criteria
whilst maintaining biological functionality of the peptide and antibody components.
This is the case for both temperature and drying considerations. Antibody-conjugated
nanoparticles and capture layers must maintain their structural integrity when dried,
and be capable of binding immediately upon rehydration with the sample complex.
Drying is often carried out in the presence of sucrose or trehalose, which forms a
protective layer around the protein molecules [252].
6.2 Concept: paper-based diagnostic devices
As described above, a typical dipstick or lateral flow strip has four key physical fea-
tures; the paper substrate, wicking pad, conjugate reservoir and capture regions, which
consist of a test and control line.
The test line must be populated by a ligand capable of binding to the target molecule
of interest - in this case, p16 protein - when it is in complex with the nanoparticle-
tagged antibody conjugate described in Chapter 4. Binding kinetics must be suffi-
ciently rapid for the target to be captured within the time taken for the sample volume
to run across the test line. In addition, the binding ligand must be specific for the tar-
get in question; competition would reduce the colorimetric and SERS signal at the test
line as the conjugate label is specific for the target. A complementary antibody could
fulfil this role; currently none are known to be available.
The control line must simply consist of a ligand capable of binding to the nanoparticle-
tagged antibody conjugate when it is not bound to p16, to ensure that negative test
results are not merely the result of a failed assay. In commercial conjugate assays this
often takes the form of a Protein A/G mix, which binds to the heavy chains of a vari-
ety of IgG types from mammalian hosts and is therefore largely universal. However,
the epitope of p16 itself also represents an ideal candidate. Provided that the capture
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line is printed upstream of the test line to prevent disassociation of control line mimo-
topes and subsequent false positive results, the use of the p16 epitope would confirm
in each test that the antibody conjugate is still biologically functional.
In summary, a successful paper-based device would require ligands capable of
binding to p16 antigen and p16 antibody in a rapid and specific manner. The ligand to
p16 itself should be specific for a different epitope than that already used. Conversely,
the ligand to p16 antibody should mimic the epitope already used for conjugate bind-
ing (Figure 6.3).
FIGURE 6.3: A schematic of p16 epitopes and ligands in the context of a paper-based assay
design. A) The ‘antibody’ and ‘antigen’ epitopes of p16. B) Interaction of analyte-bound
and unbound nanoparticle (NP) conjugates with the paper-printed test line (yellow) and
control line (purple) peptides.
One method capable of elucidating the protein motifs described above is phage-
displayed peptide biopanning, referred to as ‘phage display’ or ‘biopanning’ for con-
venience. Developed by George Smith and Sir Gregory Winter in the 1980-90s, it was
awarded the 2018 Nobel Prize in Chemistry [253]. Its ability to link peptide affinity to
DNA sequence inexpensively in a broad range of biomedical contexts [254] has led to
significant advances in biopharmaceuticals in particular, including the first six com-
mercialised antibody medicines [255].
In this method, a large population of viruses or ‘phages’ capable of infecting bac-
teria are genetically engineered to include a randomised insert in their genome which
produces a short protein sequence or ‘peptide’ that is displayed on the outside of the
bacteriophage at the end of the pIII coat protein. Libraries typically contain 109 unique
sequences, with many copies of each sequence within a working volume. The random
library of displayed peptides can then be panned against targets of interest (Figure 6.4)
over multiple rounds to enrich the library for peptides specific to the target.
In the panning process, the target is coated onto a polyester substrate and the
phage library introduced for peptide binding to take place. The system is washed
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FIGURE 6.4: A schematic of the full biopanning process, including the panning proto-
col (grey panel) and library enrichment for consensus, high-affinity peptide motifs over
Rounds 1, 2, 3 and 4.
to remove unbound phage before the remaining phages are eluted and introduced to
the appropriate bacterial culture. The bacteria replicate, amplifying the eluted phage
pool. The pool, once purified, can be reused as an enriched library to narrow the pop-
ulation for target ‘hits’. By sequencing the altered phage genome, the corresponding
DNA and protein sequence can be found. Thus, biopanning represents a convenient
method for discovering novel binding ligands.
In the context of this paper-based device, the peptides need to mimic the binding
conditions described above. Once the DNA sequence is known, the peptides can be
synthesised with a spacer and biotin tag at the C-terminus. The addition of a biotin
tag allows the peptides to be oriented consistently during affinity testing by binding
to a layer of streptavidin immobilised on the assay plate. Critically, it also allows them
to be fixed to a printed line of streptavidin during paper-based assay preparation, re-
ducing the likelihood of disassociation from the membrane during flow and binding.
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6.3 Materials and methods
Sterilised tips were used for all procedures and all washes pooled and treated with
Virkon to eliminate contamination. Ultrapure water (‘dH2O’, MilliQ) was used for all
experiments. All plate shaking steps were carried out at room temperature (RT) on a
benchtop plate shaker (IKA MS 3) set to 500rpm and plates sealed with Parafilm M for
all incubation steps. Centrifugation steps were executed at 4◦C. Phosphate buffered
saline (‘PBS’, pH7.3) consists of 137mM sodium chloride (NaCl), 3mM potassium
chloride (KCl), 8mM disodium hydrogen phosphate (Na2HPO4) and 1.5mM potas-
sium dihydrogen phosphate (KH2PO4). For ease of reference, all other reagent com-




Lysogeny broth In-house 1.0% tryptone, 0.5% yeast ex-























0.1M NaHCO3 (pH8.6) RT
Tris-buffered saline
(TBS)





Albumin Bovine Fraction V
(BSA) in sodium bicarbonate
buffer*
4◦C






20% PEG 8000 [v/v], 2.5M NaCl RT,
sterile
TABLE 6.1: Constituents of buffers and other reagents used during the peptide discov-
ery process. Tris-HCl is abbreviated nomenclature for tris(hydroxymethyl)aminomethane
((HOCH2)3CNH2) hydrochloric acid (HCl). *BSA concentration in blocking buffer varied
depending on experiment iteration (see main text for details).
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6.3.1 Phage-displayed peptide biopanning
Phage-displayed peptide panning was carried out with a Ph.D.TM-12 Phage Display
Peptide Library Kit (New England Biolabs, Cat. # E8110S) and recommended Tetracycline-
resistant E. coli strain K12 ER2738, with genotype
F′proA+B+laclqδ(lacZ)M15zz f :: Tn10(TetR)/
f huA2glnVδ(lac− proAB)thi− 1δ(hsdS−mcrB)5
The supplied randomised library of 12-mer peptides are expressed at the N-termini
of the pIII minor coat proteins of individual M13KE filamentous bacteriophages, am-
plified to give approximately 10 copies of each insert per 1µl of phage library. The pIII
protein binds to the F-pilus of E. coli. The M13KE phage vector (Figure 6.5) is derived
from M13mp19, which carries the lacZα gene. In the presence of IPTG, a functional β-
galactosidase enzyme hydrolises Xgal to form 5,5’-dibromo-4,4’-dichloro-indigo, pro-
ducing blue plaques in a blue-white screen upon successful infection of ER2738.
PBS and NaCl/PEG mix were autoclaved before use. In all cases, lysogeny broth
(LB) was used with a 1:1000 dilution of Tetracycline solution (abbreviated to ‘LB/Tet’)
to prevent bacterial contamination of the ER2738 competent E.coli cells with other
wild-type (‘w/t’) lines.
Biopanning
This protocol has been slightly adapted from that provided in the kit manual due to a
combination of the experiment requirements and issues with low phage titre following
the wash protocol.
A 96-well plate was washed with Tris-buffered saline with 0.1% Tween 20 (0.1%
TBS-T), 1µl p16 monoclonal antibody (‘mAb’, BD Pharmingen, 0.5mg/ml) added in
199µl sodium bicarbonate buffer for each experiment and the plate incubated overnight
at 4◦C. For the first round of biopanning, mAb solution was removed from one well
(antigen panning, ‘AN’ samples), washed three times with 0.1% TBS-T and 1µl puri-
fied p16 added (100ng/µl in PBS) in 199µl sodium carbonate buffer for 2h at room
temperature (RT). Antibody was retained in the remaining well for antibody pan-
ning, referred to as ‘AB’ samples. Both wells were washed as above and filled with
250µl blocking buffer with either 30 or 5mg/ml bovine serum albumin (BSA) [w/v]
for 30min with shaking before washing three times with blocking buffer (see Sections
6.4.1 and 6.4.2 for details).
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FIGURE 6.5: Sequence map of M13KE bacteriophage, used for the biopanning process.
The library insert sequence appears in between Acc65 I/Kpn I and Eag I (purple box),
at the end of the pIII minor coat protein, preceded by an additional serine residue and
followed by a GGG spacer (top right).
For the first round of panning, the randomised Ph.D.-12 peptide library was intro-
duced to the AB well for 1hr with shaking in order to ‘pre-clear’ any peptide sequences
with high affinity for the BD Pharmingen antibody before adding to the AN well, so
as to reduce the likelihood of false hits for p16. This was then transferred to the AN
well under the same conditions, with the AB well filled with TBS-T to prevent drying.
Both wells were washed five times with blocking buffer before the remaining, bound
phage were eluted with shaking for 20min using 200µl 0.1M glycine (pH2.5)+1mg/ml
BSA [w/v]. The elutants were transferred to sterile microfuge tubes, neutralised with
20µl 1M Tris (pH8.8) and stored temporarily at 4◦C for amplification.
The second round of panning was conducted as described above but using the
amplified phage eluate (see below) instead of the randomised library and without the
pre-clearing step. Third and fourth rounds followed the same protocol as the second,
but with TBS-T washing buffer containing 0.5% rather than 0.1% Tween-20 to remove
weakly bound phage.
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Phage amplification
Prior to amplification, 10ml LB/Tet medium was inoculated with ER2738 stock (stored
at -80◦C) in a closed 50ml Falcon tube and incubated overnight at 37◦C in a Heraeus
Function Line incubator. The resulting stock culture was maintained throughout the
panning experiment by diluting every 24hr 1:100 in LB/Tet.
For amplification, the stock culture was diluted 1:100 in 20ml LB/Tet in 125ml Er-
lenmeyer flasks to ensure adequate aeration. The two unamplified eluates, AB and
AN, were added to two separate flasks and incubated at 37◦C for 4.5hr at 200rpm.
Flasks were loosely coated with foil to reduce likelihood of contamination with wild-
type phage. The phage-infected cultures were then transferred to 50ml Falcon tubes
and centrifuged at 3184g for 15min to pellet the ER2738 cells. The phage supernatants
were transferred to fresh tubes and the process repeated for 2min. The upper 80% of
supernatant was transferred again and PEG/NaCl added at 1/6 volume of the super-
natant. The solution was allowed to precipitate overnight at 4◦C.
The PEG/NaCl precipitations were centrifuged at 3184g for 15min. The super-
natant was carefully removed and discarded, and the white phage pellet suspended
in 1ml TBS and transferred to a microfuge tube. The samples were centrifuged again
at 16100g for 5min to pellet residual cells and the resulting supernatant precipitated in
a fresh tube with 1/6 volume PEG/NaCl for 1hr on ice. The precipitations were cen-
trifuged at 16100g for 10 minutes, the supernatant carefully removed and discarded
and the phage pellet suspended in 200µl TBS. The amplified eluate from the previous
round was used in place of the randomised library for the second, third and fourth
rounds of panning.
Eluate titration
IPTG/Xgal plates were produced for blue-white plaque selection and stored at 4◦C
until use (plates were discarded if contaminated or discoloured). For this, 15g Ultra-
pure Agarose (Invitrogen 16500500) was dissolved by heating in 1l LB/Tet. Once the
LB/Tet/Agar was cooled below 60◦C, IPTG/Xgal stock was added at 1:1000 dilution
and the mixed solution poured rapidly into bacterial culture plates (Thermo Scientific
Sterilin Single Use Plastics) at approximately 20ml per plate. Once cooled and set, the
prepared plates were warmed at 37◦C in an incubator for at least one hour before use.
To titrate phage samples, 10ml LB/Tet was inoculated with 1:100 dilution of ER2738
stock and the bacterial cells incubated for 4-8 hours with shaking at 200rpm until no
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more than mid-log phase was reached (OD600 ≤ 0.5), confirmed by spectrophotome-
try (NanoDrop 2000c, Thermo Scientific) using 1ml of sample in a cuvette. An over-
confluent culture was found to produce ‘lawns’ of bacteria upon plating, rather than
discrete plaques. Overconfluent cultures were diluted with LB until a suitable optical
density was reached.
Shortly before plating, ‘top agar’ was produced as a growth matrix for ER2738 by
dissolving 7g UltraPure Agarose, with heating, per 1l LB required. Immediately before
use to prevent premature solidification, 3ml top agar was dispensed into 15ml Falcon
tubes per plate to be titred. The bacteriophages were serially diluted in 1ml volumes
of LB, typically ranging 1010 to 1020 or 102 to 106 for amplified or unamplified phage
pools respectively. 10µl of each serial phage dilution was added to 200µl mid-log
phase ER2738, vortexed briefly and left to incubate for 5min at RT before adding to
the dispensed volumes of top agar. This preparation was inverted very briefly to mix
before being poured onto labelled IPTG/Xgal plates and swirled to distribute. Once
set, the plates were inverted and incubated overnight for no more than 18hr to allow
for plaques to form.
To calculate the number of plaque-forming units per microlitre (pfu/µl) or more
typically per 10µl volume, the plaques on plates with no more than 100 blue plaques
were counted and the number multiplied by the inverse of the dilution for that plate.
For example, a plate with 34 plaques produced with serial phage dilution of 1:109, or
10−9, would contain 34×109 plaque-forming units per 10µl sample used, equivalent
to 34×108 pfu/µl. Typical examples of titred plaques can be seen in Figure 6.6.
Selection and characterisation
Titred phage plaques were selected for individual amplification following the fourth
round of biopanning. Here, 3ml dispensed volumes of 1:100 ER2738 stock in LB/Tet
were inoculated with individual well-separated plaques, picked from the plates us-
ing sterile pipette tips. The resulting infected ER2738 were left to multiply for 4.5hr
at 37◦C. The tubes were centrifuged at 3184g for 2min to pellet ER2738 cells. The
resulting supernatant for each phage sample was transferred to sterilised Eppendorf
tubes: a 1ml sample for DNA extraction, a 1.5ml sample for short-term use including
ELISA (stored at 4◦C) and a 0.5ml sample for long-term storage, diluted 1:1 with sterile
glycerol and stored at -20◦C. Affinity ELISA protocols are discussed in Section 6.3.2.
Phage DNA was extracted for sequencing using a variant of the ‘Rapid Purification
of Sequencing Templates’ protocol supplied with the phage display kit. 1ml amplified
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FIGURE 6.6: Typical example of successful blue/white plaque titration. No white plaques
are seen, indicating a wildtype contaminant-free pool. Lower dilutions (1:106) result in a
faint blue ‘lawn’ of plaques, whereas higher dilutions yield well-separated and quantifi-
able plaques.
phage supernatant per sample was mixed with 400µl PEG/NaCl solution and pre-
cipitated on ice for 45min. The precipitate was centrifuged for 10min at 16100g and
the supernatant carefully removed. The pellet, often difficult to visualise, was resus-
pended thoroughly in 100µl iodide buffer and added to 250µl EtOH. The phage DNA
was preferentially precipitated by leaving for no more than 20min at RT, before cen-
trifuging at 16100g for 10min. The resulting phage DNA pellet was washed once in
ice-cold 70% EtOH [v/v] before re-spinning, discarding the supernatant and drying
the pellet at RT. The DNA pellet was suspended in 25µl TE buffer and sequenced in-
house on a 3730 DNA Analyzer (Applied Biosystems, Thermo Scientific) using -96gIII
reverse primer (5’- CCC TCA TAG TTA GCG TAA CG -3’).
The library insert sequence and conserved surrounding sequence of M13KE Gene
III can be seen in Figure 6.7. This information was used to identify the library insert
sequence and interpret the corresponding amino acids, shown in Figure 6.8.
6.3.2 ELISAs
Enzyme-linked immunosorbent assays (ELISAs) were used to determine the binding
affinity of native phage and synthetic biotinylated peptides without the additional
complexity of paper-based assay formats, which require significant optimisation in
their own right. ELISAs were conducted in Costar 96 Well White Polystyrene High
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FIGURE 6.7: The phage library insert sequence and surrounding M13KE phage vector.
The enzyme cutters Kpn I/Acc56 I and Eag I were used to rapidly identify the position of
the insert from sequencing data. The third base in each codon of the insert is always G or
T (3’ to 5’).
Binding Assay Plates (#3922). All washing steps were carried out with 150µl 1% Tween
20 in PBS (PBS-T) or TBS (TBS-T) per well, repeated five times unless otherwise stated.
The solution was removed through rapidly inverting plates onto paper towels. ECL
solution was produced in-house as described in Chapter 2.
Native phage peptide affinity ELISA
Following an initial amplification of individual phage clones as described in Selection
and Characterisation, Section 6.3.1, the phage titres were further enriched to test for
target specificity as recommended in the kit protocol. A native phage ELISA, where
the peptides are displayed on the pIII minor coat protein of the virus rather than being
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FIGURE 6.8: 21 amino acids, grouped by side chain characteristics. Residues in dashed
boxes represent special cases that do not conform to the typical structure of the group.
Letters circled in red indicate the amino acid shorthand labelling used throughout the
analysis. (Modified from image by Dan Cojocari, CC License BY-SA 3.0.)
synthesised as an independent moiety, allows for affinity tests to be conducted prior
to the expensive synthesisation process.
An overnight culture of ER2738 was diluted 1:100 in LB/Tet, sufficient for 20ml
per clone to be amplified. The diluted culture was aliquoted 20ml per clone into la-
belled 125ml Erlenmeyer flasks, adding 10µl phage per flask before leaving to shake at
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200rpm for 4.5 hours at 37◦C. The amplification protocol described in ‘Phage Ampli-
fication’, Section 6.3.1, was then followed to produce amplified samples in 100µl TBS.
Concentration was assessed using IPTG/Xgal plate titration as described in ‘Eluate
Titration’, Section 6.3.1.
For the ELISA, primary target was added to sodium bicarbonate buffer to a total
volume of 200µl, one well in a 96-well plate for each clone to be characterised. The
target was left to bind overnight at 4◦C. In the case of additional targets (such as pu-
rified p16 to antibody), the appropriate wells were aspirated and washed three times
with TBS-T, the target added as described above and the plate incubated for 1.5 hours
at room temperature. The plate was washed again in the same manner. All target
wells and an additional row for block-control were filled with 200µl 5mg/ml BSA in
NaHCO3 solution. In addition, a separate 96-well plate was filled with BSA solution
for phage dilution, with both plates incubated at 4◦C for 1.5 hours. The sample and
dilution plates were washed with TBS-T.
In the blocked dilution plate, 1:200 serial phage dilutions were carried out in 200µl
TBS-T across four rows. 60µl of the final dilution (equivalent to ≈1010 virions) was
added to the primary target row, secondary target row and BSA-only row for each
phage to be tested, and the plate incubated with shaking for 1.5hr at room tempera-
ture. After washing, 100µl HRP-conjugated anti-M13 monoclonal antibody (GE Health-
care #27-9421-01, diluted 1:5000 in blocking buffer) was added immediately to each
well to prevent drying and incubated with shaking at RT for 1hr.
After washing, sufficient ECL solution was prepared for 100µl per well. The so-
lution was added quickly to the wells using a multichannel pipette and the plate im-
mediately analysed at 425nm for 400ms on an Ascent Fluoroskan FL plate scanner
(Thermo Scientific). The uncoated well luminescence values were averaged as an ‘ab-
solute blank’ to indicate intrinsic measurement error.
Synthetic peptide sandwich ELISA
Peptides were synthesised from the picked DNA sequences in the format Biotin-SGSG-
PEPTIDE-NH2, where the peptides were 12 and 6 amino acids long for sequences
against p16 protein (AN) and antibody (AB) respectively.
Streptavidin-coated 96 well plates were prepared by diluting a 2mg/ml Strepta-
vidin (Sigma Aldrich SA101) stock 1:400 in dH2O, adding 50µl per well and incu-
bating at 37 overnight until dried. The plates were blocked with 100µl 3% BSA in
PBS-T for 1hr at RT prior to addition of peptides. This ensured that binding was
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streptavidin-biotin specific and therefore correctly oriented, rather than passive. Bi-
otinylated peptides, synthesised by Mimotopes UK using Fmoc solid phase synthesis
and supplied as a dry powder, were dissolved for 45min with shaking in 200µl 4:1
mix of DMSO/dH2O to form a 25mg/ml stock solution, stored at -20◦C when not in
use. Stock solutions of both sample and control peptides (dissolved in 1ml dH2O)
were diluted in PBS-T before use. Following washes, 50µl peptide solution per well
was incubated on the plates with shaking for 1hr at RT. The plate was washed again
before addition of target to sample wells, again diluted with PBS-T. The sample wells
were washed to remove unbound target before addition of 50µl relevant primary an-
tibody to sample and control wells, diluted 1:1000 in PBS-T and incubated at RT for
1hr with shaking. Plates were washed before addition of HRP-conjugated rabbit anti-
mouse secondary antibody (Polyclonal Rabbit Anti-Mouse HRP, DAKO) to all wells
under the same conditions. Plates were washed before addition of 50µl ECL solution
to each well. The plate was visualised immediately at 425nm for 400ms and the lu-
minescence values analysed in triplicate against secondary-only control with blocked
streptavidin-coated wells and true blank (empty wells) unless otherwise specified.
6.3.3 Phage samples for next-generation sequencing (NGS)
Phage plaques were picked in sets of 96 using sterile pipette tips and amplified in 1ml
ER2738 culture each within a polypropylene 96-Well Deep Square Plates (2ml well
volume, Thomas Scientific) at 200rpm for 4.5hr at 37◦C. The plates were centrifuged
at 3184g for 5min using microplate adapters in an Eppendorf 5810R centrifuge. The
phage supernatant was transferred to new plates, sealed and stored at 4◦C until fur-
ther use. Each plate was pooled by taking 1µl from each well and amplifying the re-
sulting volume using 1:100 ER2738 in 192ml LB/Tet in an Erlenmeyer flask at 200rpm
for 4.5hr at 37◦C. The resulting culture was aliquoted into 50ml Falcon tubes and
precipitated as described in ‘Phage amplification’, Section 6.3.1. The amplified phage
aliquots were then recombined for PCR, so that the sequences of individual phages
could be analysed using next-generation sequencing.
A polymerase chain reaction (PCR) was carried out directly with the amplified
pooled phage from each set alongside a phage-free control using UltraPure DNase-
RNase-Free Distilled Water (‘DNA-free dH2O’) in a 50µl reaction volume. The PCR
reagents are detailed in Table 6.2; the reaction volume was prepared on ice to pre-
vent premature denaturing of DNA. The primers, shown in Figure 6.9, were designed
6.3. Materials and methods 185
to hybridise to the M13KE phage vector on either side of the randomised library in-
sert, with additional adapters to be recognised by the Illumina MiSeq System as dis-
cussed below. The reverse primer was based on the 28gIII primer sequence, known
to produce a readable sequence within a relatively short read from the insert of inter-
est (Figure 6.7) as necessary for paired-end reads. The forward primer was designed
on the basis of two limiting factors: the need for a suitable ‘buffer zone’ between the
primer hybridisation site and the sequence of interest to ensure clean PCR amplifi-
cation, and the presence of a forward terminator in the M13KE vector upstream of
the insert. The forward and reverse primers were ordered from Sigma Aldrich, poly-
acrylamide gel electrophoresis (PAGE)- and high performance liquid chromatography
(HPLC)-purified respectively. Primers were aliquoted once reconstituted and stored
at -20◦C.
FIGURE 6.9: The forward and reverse primers used to prefer the phage vector library for
Illumina sequencing. The red sections of each sequence indicate the Illumina adaptors,
which hybridise to the sequencing flow cell. The black regions indicate the phage-specific
sequence. In each case the hybridisation region of the primer is shown in the context of
the conserved phage sequence, underlined.
PCR was carried out using the thermal cycling conditions described below on a
SureCycler 8800 (Agilent).
1. 95◦C for 1min
2. 95◦C for 15s
3. 55◦C for 20s
4. 70◦C for 1min
5. Steps 2-4 repeated 30 times
6. 70◦C for 3.5min
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Reagent Supplier [Stock] Volume
(Concentration)
Hercule II Reaction Buffer Agilent (600675-52) 5x 10.00µl (1x)
Betain Solution for PCR Sigma (B0300-1VL) 5M 5.00µl (0.5M)
D-(+)-Trehalose dihydrate Sigma (T9531-5G) 100mM 6.6µl (13.2mM)
dNTP Stratagene (200415-51) 100mM 0.25µl (500µM)






Eluted pooled phage In-house - 1.00µl
DNA-free dH2O Invitrogen - 25.65µl
TABLE 6.2: Constituents of buffers and other reagents used during PCR with pooled
phage.
7. 4◦C forever
The resulting amplified pool of phage vectors, prepared for next-generation se-
quencing with barcoded adaptors, were run on a gel to assess size and purity. Gels
were produced by melting 1.5g Ultrapure Agarose in 100ml Tris-acetate-EDTA (TAE)
buffer and adding 10µl SYBR Safe DNA Gel Stain (Invitrogen, S33102) before setting
in a gel cast with sample comb. 50x TAE buffer stock was produced by dissolving
242g tris(hydroxymethyl) -aminomethane (Tris, VWR), 54.6ml acetic acid (Fluka) and
100ml 0.5M ethylenediamine tetraacetic acid (EDTA, pH8.0, VWR)) in 1l dH2O. A 5µl
aliquot of each sample was mixed with 1µl 6x Orange Gel Loading Dye (ThermoFisher
R0631), loaded alongside 6µl DNA reference ladder and the gel run in TAE buffer at
100V for 45-60min depending on gel cast size. The gel was visualised using UV trans-
illumination on a ChemiDoc MP Imaging System (BioRad) with Image Lab 6.0.1 soft-
ware. DNA was extracted from the remaining sample volume using a QIAquick PCR
Purification Kit (Qiagen 28104), following the kit protocol.
The final sample was sent for next-generation sequencing (Figure 6.10) on a MiSeq
System at Edinburgh Genomics, with 11M, 250 base paired-end reads. A single-lane
flow cell is loaded with the pooled samples, prepared with Illumina adaptors. The
flow cell is populated with a lawn of two adaptor-complimentary oligonucleotides,
one of which anchor the sequence library to the cell. A polymerase then creates a
complement of the hydridised sequence. Bridge amplification is carried out, where
sequences are tethered between the complementary flow cell adaptors before being
separated. In this way, any sequences of the same length prepared with the correct
adaptors can be amplified simultaneously. The reverse sequences are then removed.
6.3. Materials and methods 187
Sequencing is carried out through the use of fluorescent nucleotides: as each labelled
nucleotide is added to the growing sequences, the cell is illuminated with a light
source and the nucleotide label recorded for each tethered chain. This process is then
performed in reverse, generating two complementary sets of data.
FIGURE 6.10: A schematic of the next generation sequencing process. A) The ready-to-
sequence library following PCR amplification with Illumina-adapted primers, feating the
Illumina forward (pink) and reverse (yellow) adaptors, the forward and reverse primers
(dark grey), buffer sequence (light grey) and variable library insert (blues and greens). B)
Bridge amplification of the sequences, which hybridise to the flow cell via the Illumina
adaptors. Once released, the sequence ‘read’ takes place though addition of colour-coded
bases. C) Image of the flow cell during one sequence cycle. The fluorescence emission is
used to interpret the sequence of each tethered library.
6.3.4 NGS data analysis workflow
Owing to the small sample pool size relative to other NGS datasets, the samples were
made up with 50% PhiX Control v3 Library by Edinburgh Genomics. The library
consists of a well-characterised bacteriophage PhiX genome which provides more bal-
anced fluorescent signals in the case of low sample sequence diversity. This sequenc-
ing data was removed by Edinburgh Genomics to leave 3.89M paired-end reads in
compressed FASTQ Sanger format. FASTQ files contain additional quality informa-
tion to standard FASTA files. Owing to the excessive number of reads for 192 samples,
only the forward sequencing was analysed. Initial quality control analysis performed
using FastQC, developed at the Babraham Institute [256]. This showed that the se-
quencing was high-quality and of the correct length (Figure 6.11).
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FIGURE 6.11: Quality control data for the forward (A) and reverse (B) reads from Edin-
burgh Genomics. An average Phred score per base of 33 is equivalent to 0.05% probability
of an incorrect read. The modal read length was 250bp as expected, dropping off rapidly
after 249 and 251bp (data not shown).
All pre-processing was performed using Galaxy, an online processing tool for large-
scale sequencing projects. The forward-read file was decompressed and converted
to FASTA format using Mothur v.1.39.5, developed by Patrick D. Schloss at the Uni-
versity of Michigan [257]. The forward adapter sequence was used as a Galaxy Clip
guide, simultaneously trimming the M13KE phage sequences and removing sequences
not containing the adapter. These are likely to be misreads.
The remaining 1,084,815 sequences were filtered to remove exact duplicates, re-
ducing the file to approximately 1M reads. The first sequence was found to be modal
and filtered out using the Galaxy Select tool to leave 210k sequences. These remaining
sequences were subjected to ‘Select’ on the basis that they contain the characteristic
glycine spacer associated with the phage insert, GGTGGAGGT. This left 9255 reads
which were analysed as described in the results section.
6.4 Peptide discovery for p16 protein and antibody capture
6.4.1 Optimisation of the biopanning process
As described in Section 6.2, the lateral flow device requires peptide capture layers
capable of binding to p16 (test line) and the conjugation antibody (control line). More-
over, the p16 capture layer should have affinity for the protein when already bound
to the conjugation antibody. As such, two phage-displayed peptide panning experi-
ments were carried out in parallel - one against p16 protein when bound to the con-
jugate antibody (labelled as ‘AN’) and one against the conjugate antibody in isolation
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(‘AB’).
Preliminary work with a three-round panning process as detailed in Section 6.3.1
yielded pooled phage populations demonstrating affinity for AN and AB targets with
some phage library inserts in both pools showing affinity for BSA block, used at
30mg/ml (Figure 6.12). The amplified pools were titred on blue/white plates to yield
separate phage plaques. AN and AB samples were found to contain 85×1011 and
129×1011 pfu/ml respectively. After some issues with efficient DNA precipitation
from individual phage plaque-infected ER2738 cultures using the rapid sequencing
protocol, 1ml rather than 0.5ml amplified phage samples were used.
FIGURE 6.12: Characterisation of amplified Round 3 from the preliminary phage display
optimisation. A) ELISA-based affinity testing of the phage pool, indicating the presence
of binders for both targets as well as non-specific populations. B) MEMESuite analysis of
the antigen sequences, indicating some consensus motifs. C) ELISA-based affinity testing
of individual native phage.
18 AB samples and 20 AN samples were picked, amplified and prepared for se-
quencing. The sequencing results for AN and AB samples can be seen in Tables 6.3 and
6.4 respectively. AN2 is a shorter sequence, which can occur in the case of frameshift
mutations in the phage vector. Sequences were analysed using SnapGene Viewer, with
the randomised library insert identified using the characteristic bracketing sequences
as described in ‘Selection and characterisation’, Section 6.3.1. Initially six sequences
(AN4, 8, 12, 14, 17 and 19) were assessed for binding affinity on the basis of either con-
sensus or similarity of amino acid sequence, analysed using MEMEsuite (Figure 6.12).
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AN# Amino acid sequence AN# Amino acid sequence
AN1 YVPWATLSQNSH AN11 QDSTTLVPDEYI
AN2 DLLQKHSGWSA* AN12 AETVESCLAKSH
AN3 ATTSIPPYWQAL AN13 ALNWSPKLPVPP
AN4 NMDIEHSASFRW AN14 HCCAITQNTDLA
AN5 NPKMSSNMAGPL AN15 ATDWLSRYTYAA
AN6 TKNMLSLPVGPG AN16 MPAVMSSAQVPR
AN7 LGNSPDFLVPTS AN17 SHPWNAQRELSV
AN8 FSPLHTSTYRPS AN18 QVIALARLPAPI
AN9 HYGMVMVRHIVA AN19 SHPWNAQRELSV
AN10 HSSSASDRSRPL AN20 HNARFPTSHPGG
TABLE 6.3: Sequences for the Round 3 antigen (AN) peptides individually sequenced as
part of phage display optimisation. *AN2 is a shorter sequence by one residue. Amino
acid shorthand labels are given in Figure 6.8.
Five of the six samples appear to have higher binding affinity for BSA than target.
Following this, the panning procedure was repeated with three key alterations to
the initial method tested. First, the original randomised library was re-panned but
with reduced BSA concentration (5 instead of 30mg/ml) at the blocking and wash-
ing stages to reduce the likelihood of selecting BSA-binding sequences. Second, four
rounds of amplified panning were completed to further enrich the pool for high-
affinity peptides. Finally, sequencing was performed in parallel to ELISA-based affin-
ity testing. This is due to the fact that the preferential amplification of certain se-
quences over others, leading to consensus sequences within a cultured pool, is due to
the ability of individual phage sequences to replicate and is not related to their binding
affinity for a given target.
6.4.2 Discovery of peptide sequences
Prior to repeating the panning process, the library was reassessed for activity. IPTG/XGal
plating of the unpanned library provided successful ER2738 infection and yielded a
titration of approximately 1×1011 pfu per 10µl when averaged across ten-fold serial
dilutions from 109 to 1012. Following the first round of panning, the titrations for the
unamplified AN and AB pools were 11×104 and 21×104 pfu per 10µl.
The panning process was then carried out as described and modified previously.
Following amplification of the fourth round, the phage pools were titred on IPTG/Xgal
plates and 24 plaques picked from each pool for an initial amplification, carried out in
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AB# Amino acid sequence AB# Amino acid sequence
AB1 SAHQLLLNKMPN AB10 GSTQAWMSPPLA
AB2 TMGFTAPRFPHY AB11 ATWSHHLSSAGL
AB3 TMGFTAPRFPHY AB12 NTYVPNLLSSFR
AB4 DSTLHKNRLQTR AB13 DQMPPLNRSPSL
AB5 GSDLYASKIWTA AB14 AEQGTYRVWLLP
AB6 RPSYTDHDHRSN AB15 SWWPFPPQPDPA
AB7 YASSTKADGFLS AB16 YQLRPNAESLRF
AB8 TQCCSSGATYPR AB17 THSKSTSLWDSN
AB9 FVSTTMKLSADS AB18 QSFASLTNPRVL
TABLE 6.4: Sequences for the Round 3 antibody (AB) peptides individually sequenced as
part of phage display optimisation. Amino acid shorthand labels are given in Figure 6.8.
3ml LB as described in ‘Selection and Panning’, Section 6.3.1. A further amplification
was performed in 20ml cultures before ELISAs were carried out.
Owing to the large number of samples, titration of the amplified phage stocks was
carried out for a representative selection of samples and the individual clones diluted
on this basis. AN1, 7, 13 and 19 yielded titrations of 1.0×1020, 4.6×1019, 5.7×1019
and 1.8×1019 pfu per 10µl respectively. As such, only intra-sample comparison can
be made from native phage ELISAs, as luminometric intensity is partly dependent on
these small variations in sample concentration. As described in ‘Native phage peptide
affinity ELISA’, Section 6.3.2, phage samples were diluted 1:200 in TBS-T using the
blocked dilution plate, to yield sample titres for incubation on the order of 1.25×1010
virions per well.
Antigen samples were affinity tested in two formats. Both used p16 bound to BD
Pharmingen antibody as in the original panning procedure, and BSA only as a blank
control. Final concentrations per well of 0.5ng/µl p16 mAb and 100ng/µl purified
p16. The first assay used p16 only as a positive control, and the second assay antibody
(mAb) only, as a negative control. This allowed for consideration of specificity and
affinity, particularly to account for the selection of phages specific to antibody rather
than target. Samples had to be assessed in singlicate owing to the limited availability
of purified target and the large number of samples.
For the first assay (Figure 6.13A), it was posited that samples which bound to
p16+mAb and BSA at the same or higher affinity than p16 only were unlikely to be
specific for the target. The second assay (Figure 6.13B) was carried out to confirm
binding affinity for p16 without the issue of randomly oriented target and potential
denaturation upon passive binding to the plate. Here, samples producing a higher
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luminescence intensity for mAb or BSA than mAb+p16 were judged as non-specific.
However, it is worth noting that there are caveats to using a native phage-based ELISA
approach.In addition to non-specific binding arising from the peptides themselves, the
phages can also adhere to the antibody, protein or complex thereof, as well as the BSA
blocking layer.
The results for the AN sample ELISAs can be seen in Figure 6.13. Figure 6.13A
suggests, as expected, that the random orientation and potential denaturation of p16
upon plate binding reduces, in some cases heavily, the ability of the phage peptides to
bind to their target in a different conformation to the one in which they were selected.
Some samples show a higher BSA than target affinity, indicating non-specificity. The
potential candidates from this assay - those demonstrating higher p16 than BSA lumi-
nometric signal - are samples AN1, 3, 9, 10, 15, 17, 19, 21 and 22.
For the negative control test in Figure 6.13B, the samples producing a higher signal
for mAb+p16 than mAb only are AN14, 16, 20, 21, 22, 23 and 24. Sample AN20 appears
to be binding to BSA. AN1, 3, 9, 10 and 17 appear to be specific for mAb, leaving only
AN22 as a cross-referenced potential candidate in this context.
The affinity ELISA for AB samples can be seen in Figure 6.14. Here, mAb+p16
was added as a negative control to compete out peptides with specific affinity for the
binding site of the antibody.Firstly, it is clear that there are general issues with binding
strength of Samples 13-24 which may be the result of the original panning process
but is more likely to result from issues with solution volume error arising from the
multi-channel pipette used for the assay, probably during the sample dilution phase.
Samples AN1, 2, 7 and 12 indicate high levels of p16+mAb binding, rendering them
unsuitable for discovery of the p16 epitope or for use as a paper-based assay control
peptide.
The samples were sequenced according to the rubric described in Section 6.4.1 -
the results for AN and AB samples are detailed in Figure 6.15. Samples 8, 14 and 17
had no insert. Sample AB4 did not yield a readable sequence after multiple sequenc-
ing rounds, and AN2 lacked a glycine spacer and contained non-library codons, in-
dicating wild-type phage. Many of the AN samples are consensus or near-consensus
sequences, as expected after four rounds of panning. However this data also demon-
strates that some of the conserved sequences produce different affinity results with
native phage ELISA, not simply by intensity but also by ratio. This may well be due to
the caveats described earlier. It is also possible that a combination of lack of replicates
and low target density, both arising from lack of viable target availability, mean that
binding affinities are being assessed very close to the limit of detection and are there-
fore subject to low signal-to-noise ratio. In the future, the native phage ELISA could
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FIGURE 6.13: ELISA affinity results for amplified Round 4 AN phages. A) Phages tested
against original panning target (mAb+p16), target only (p16) and BSA control. B) Phages
tested against original panning target (mAb+p16), negative (mAb only) and BSA controls.
C) Repeat of graph B without BSA results for ease of viewing.
be completely replaced with an assessment of peptides synthesised on the basis of se-
quencing data, or in the instance of large datasets, used to make a smaller selection of
phage when conducted in triplicate.
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FIGURE 6.14: ELISA affinity results for amplified Round 4 AB phages, tested against
original panning target (mAb), competition control (mAb+16) and BSA control. Only one
sequence (AB2) was found to have similarity to p16 protein sequence.
6.4.3 Affinity of synthetic peptides by ELISA
Peptides were synthesised as described in Section 6.3.2. For AN samples, each unique
sequence (Figure 6.15) was produced. For AB samples, the amino acid sequences were
compared to p16 protein sequence in order to find a potential motif. Only one se-
quence, AB2 (W—FYPGRIPG), was found to be a potential match for the p16 sequence
(WGRLPV). To test for potential affinity for the antibody being used, an alanine scan
was carried out as seen in Table 6.6. The synthesised peptides were tested for affin-
ity in a sandwich ELISA as described in Section 6.3.2. The antigen samples required
both target and antibody to be introduced; for antibody samples, only the latter was
required. For the ELISA results shown in Figure 6.16, the ‘primary target’ (p16 protein
or antibody) was incubated at 4◦C overnight to ensure binding.
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FIGURE 6.15: Peptide sequence summary for Round 4, with antigen samples organised
according to recurring or non-recurring sequences. Similar sequences are provisionally
aligned. Antibody samples were sequenced using a different supplier, and returned poor-
quality sequence information.
The control peptides were provided by Mimotopes as a guide for assay develop-
ment rather than direct lumimetric comparison and so are shown separately. The con-
trols used both different working dilutions (1:10 as opposed to 1:1000) and a different
antibody. The ‘positive’ and ‘negative’ control sequences and expected signal inten-
sity from a control antibody titration can be found in Figure 6.17. The small difference
in amino acid variation accounts for the relatively high absorbance signal produced
by the nominally negative control peptide, but also demonstrates the small sequence
size necessary to create a strong binding affinity.
Table 6.5 lists the antigen peptide samples and their corresponding phage sample
number in order of luminometric intensity, with samples significantly higher (p < 0.01)
than secondary-only control displayed above the dividing line. The results show some
consistency with the second native phage ELISA (Figure 6.13C). Intra-sample analy-
sis shows that all of the phage samples demonstrating a higher signal for p16+mAb
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FIGURE 6.16: Sandwich ELISA affinity of synthetic peptides, both tested in triplicate at
1:1000 stock dilution. A) Antigen (AN) peptides, tested against purified p16. B) Antibody
(AB) peptides, tested against monoclonal antibody. Secondary only control contained
target but no primary antibody.
over mAb only (An14, 16, 20, 22, 23 and 24) feature in the statistically significant syn-
thesised list in Table 6.5. The second highest affinity synthesised sequence (Sample
9, equivalent to phage sample An6) does not feature at all in the phage ELISA ‘hits’,
however. Upon sequencing, An7, 15 and 19 were found to be identical to An16 and
yet produce different binding characteristics in native phage ELISA, again indicating
the error-prone nature of the first affinity assay tested.
Analysis of the amino acid groupings and potential motifs are considered in Sec-
tion 6.4.4.
The antibody peptide samples are shown in Table 6.6. These are not listed in order
of intensity, as none of them produced a signal statistically different to that of the
secondary-only control at the same level as the antigen samples (p < 0.01). This would
indicate that the six-residue sequence is not sufficient for binding on its own, as the
remaining panned sequences did not share any common regions with the p16 protein
sequence.
The four highest affinity samples were then tested against p16 titrated in a serial
dilution (Figure 6.18), with Sample 12 demonstrating increased binding sensitivity
across all concentrations. The peptide sequence is ASHYHINYRKWT. Controls for
the samples included p16 only and mAb only samples to test for specificity. Both the
sample and control peptides were used at 1:100 dilution. The results are consistent
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An# Mimotope Sequence Molecular weight
Sample (kDa)
An20 12 ASHYHINYRKWT 2.089
An6 9 SINIHALGGIPY 1.768
An23 14 IPLENQHKIYST 1.956
An7, 15, 16, 19 2 FLQDAWEAVDIR 1.976
An21 13 SMQDDCMVMADW 1.945
An12, 22 3 FKQDAWEAVDIR 1.991
An5, 9 1 SANYNVQAGWTH 1.860
An24 4 HHEANSLGLVQS 1.804
An13 6 SHVSWDTKQSGQ 1.873
An1 5 NHLSWDTKQSGQ 1.914
An3 8 SNSHPNWVELRP 1.949
An18 11 EPTTWFNSDSIT 1.911
An4 10 KNQDATETGKII 1.831
An10 7 SYDGTMLKQVRL 1.924
TABLE 6.5: The synthetic peptides against p16, produced from phage sequences discov-
ered through the biopanning process. Sequences displayed above the dividing line pro-
duced significantly stronger luminometric signal than secondary-only control.








TABLE 6.6: The synthetic peptides against p16 antibody, produced from phage sequences
discovered through the biopanning process. Each sample represents an alanine scan of
the proposed p16 binding site (Sample 15).
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FIGURE 6.17: Characterisation of control peptides supplied by Mimotopes. A) Sandwich
ELISA affinity, tested in triplicate at 1:10 stock dilution alongside samples in Figure 6.16.
B) Repeat sandwich ELISA at 1:100 stock dilution with antibody titration. C) Reference
ELISA data supplied by Mimotopes, using 1:10 stock dilution. D) Sequence of control
peptides.
with those shown in Figure 6.16 in terms of binding affinity. The increase in signal
with p16 concentration increase, while the antibody content is kept constant, indicates
specificity for target.
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FIGURE 6.18: Serial dilution curve of purified p16 against a 1:100 stock dilution of the
four highest affinity peptides from Table 6.5, tested in triplicate.
6.4.4 Amino acid analysis of peptide sequences
Due to the randomised nature of the phage insert library, it is important to analyse the
amino acid residues for consensus sequences and potential epitopes for the target of
interest. Initially, the unique sequences shown in Table 6.5 were uploaded to GLAM2:
Gapped Local Alignment of Motifs, a sub-programme of MEMESuite capable of align-
ing sequences with potential gaps in the motif. In hindsight the gap functionality was
not required but this initial step still allowed for rapid alignment and the identification
of modal sequences at each position.
The full sequences were then considered as summarised in Figure 6.19 and po-
tential alternatives added manually (shown in italics). This was justified on the basis
that repeated or shared motifs within the same sequence may well produce a positive
binding assay signal from two different binding configurations. On an unweighted
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basis (without considering peptide affinity), the modal residues in the ‘core’ region
(positions 9-13) are N(7,0), Q(5,5), D(5,1), A(4,0) and W(8,0). The values in brack-
ets correspond to the frequency of the given amino acid in the GLAM2 and manual
considerations respectively. In addition, the most frequently occurring residues (N at
position 07 and W at position 11) feature alongside similar amino acids from other
sequences, namely S and L/I respectively.
FIGURE 6.19: AN peptide sequence alignment and residue analysis, summarised as an
idealised motif. Sequences are ordered by affinity and residues highlighted according to
their grouping.
The motifs were then ordered by binding affinity to purified p16 as previously
listed in Table 6.5. This was to increase likelihood of highlighting the true motif, rather
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than an ineffective but consensus sequence from the inital randomised library. This
highlighted the potential importance of different amino acids in creating a specific
binding sequence. As before, the N, Q and W residues appear to be important, but
only in the context of neighbouring basic and non-polar regions. Based on frequency
and order, there also seem to be contributions from hydrophobic residues at positions
08 and 16, and to a lesser extent polar residues at position 14.
Analysis of positions 11 and 12 becomes more complex when the sequences are
ordered by affinity. Basic residues - those positively charged in a pH neutral environ-
ment - are not especially common overall and yet appear in the top three hits in this
region. Owing to the heterogeneous population at position 12, alanine (A) was chosen
as being the least disruptive residue due to its shared structure with the majority of
other amino acids.
The tentatively assigned ’Ideal’ sequence, also shown in Figure 6.19, offers oppor-
tunities for further optimisation of sequence affinity which was beyond the scope of
this thesis.
6.5 Peptide activity with cell models
6.5.1 Quantification of p16 in cell lines
Following the emergence of a high-affinity sequence for p16 when bound to antibody
(ASHYHINYRKWT), consideration of the peptide’s efficacy in a cell model context
was considered. First, the ability of the purified target to be detected in the context
of cellular lysate was tested by Western Blot. This was to explore the extent to which
the epitope may be cleaved or denatured in the presence of lysis buffer or other active
cellular components. A purified protein ladder was also produced as a quantifiable
reference for the level of p16 present in the cell models used. The results can be seen
in Figure 6.20.
Figure 6.20A and B demonstrate a serially diluted reference ladder of purified p16,
introduced to the wells alone and spiked into HaCaT lysate respectively. The remain-
ing 20µl sample volume was made up with dH2O before being mixed with sample
buffer and denatured by heating, as described in Section 2.3.1 (‘Bradford Assay’) of
Chapter 2. The reference ladders themselves demonstrate that purified p16 is pre-
served in the presence of HaCaT lysate (p16 undetectable) and through the Western
Blotting process, although the protein is dimerising to a greater extent in this context.
As little as 0.79ng absolute p16 protein content could be detected using a 20s exposure,
equivalent to approximately 0.0001% of total protein content or 40ng/ml.
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FIGURE 6.20: Western Blots demonstrating p16 expression. A) Purified p16 reference
ladder in dH2O. B) Purified p16 reference ladder spiked into HaCaT lysate. C) Cell lines
used for p16 binding affinity of peptides, including HaCaT w/t (p16 undetectable due
to hypermethylation of promoter [258, 43, 259]), SiHa w/t (high endogenous p16) and
SiHa+p16 (high endogenous and transfected his-tagged p16). SiHa samples were tested
in both pelleted snap-frozen (P) and fixed (F) formats.
Sample Format Absolute content Percentage Concentration
HaCaT w/t Pellet 0ng 0% 0ng/ml
SiHa w/t Pellet 3-6ng 0.05-0.1% 150-300ng/ml
SiHa w/t Fixed 3-6ng 0.05-0.1% 150-300ng/ml
SiHa+p16 Pellet 6-25ng 0.1-0.4% 300-1250ng/ml
SiHa+p16 Fixed 6-12ng 0.1-0.2% 300-600ng/ml
TABLE 6.7: Expression of p16 in cell line models as interpreted from the p16 in lysate
reference ladder shown in Figure 6.20B. Expression shown in terms of absolute content,
percentage of Western Blot sample volume, and sample concentration.
The cell lines used were compared to the reference ladder in HaCaT lysate to as-
sess approximate levels of p16 expression. The results are summarised in Table 6.7.
When compared with Figure 6.18, it can be seen that the protein concentrations are
well within the operating range of the four highest affinity peptides and particularly
Sample 12.
6.5.2 Peptide binding efficacy with cell lysate
The best performing peptide (Sample 12, ASHYHINYRKWT) was tested in the pres-
ence of lysate, reserved from the samples demonstrated in Figure 6.20. This was both
to investigate the ability to differentiate between levels of p16 expression in cell mod-
els rather than through an idealised pure protein ladder, but also to confirm that the
peptide’s biological functionality is not disrupted in the presence of crude cell lysate.
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The ELISA was carried out according to the protocol described in ‘Synthetic pep-
tide sandiwch ELISA’, Section 6.3.2, with three instead of five washes following lysate
addition to mitigate for lower levels of target protein which might otherwise be re-
moved altogether. Prior to addition, the samples were heated to 70◦C for 4min as in
Western Blot sample preparation so that the results were comparible. The samples
were tested with the same absolute protein content as their Western Blot counterparts
in Figure 6.20, made up to 50µl with PBS-T to ensure well coverage. The samples were
tested with two technical replicates, with the luminometric response shown in Figure
6.21.
FIGURE 6.21: ELISA-based capture of endogenous and transfected p16 by synthetic pep-
tide in a sandwich format. Luminometric results were visualised using BD Pharmingen
primary monoclonal antibody to p16 and polyclonal HRP-conjugated secondary. SiHa
models were analysed in both pelleted snap-frozen (P) and PreservCyt-fixed (F) formats.
In terms of the cell lines used, the results are consistent with the Western Blot
in Section 6.5.1 - the assay demonstrates the lowest response for HaCaT wildtype, a
middling response for SiHa wildtype and highest response for SiHa+p16. However,
the response to ‘native’ snap-frozen, pelleted versus PreservCyt-fixed cells differs with
this format. A higher signal is seen in cells which were stored in fixative before lysing.
It is possible that methanol fixation better preserves the p16 binding epitope for the
peptide, which is a positive outcome for application to clinical smear samples.
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There is a significant difference (p ≤ 0.05) between each of the sample types but
not between the same sample types processed in pelleted or fixed form. This indi-
cates that the chosen peptide and antibody could be used in conjunction to assess
p16 expression in PreservCyt-fixed cervical cells. The control well, consisting of pri-
mary and secondary antibody incubated with streptavidin-coated, BSA-blocked plate,
demonstrates that the assay is prone to variability from the visualisation method alone
regardless of peptide affinity or lysate content. This may be due to non-specific inter-
actions with BSA as seen in Chapter 4, or because of the less stringent washing con-
ditions used. To improve background variation, the initial washing conditions (5x)
should be adopted for all steps.
6.6 Next generation sequencing of phage populations
6.6.1 Large-scale sequencing of phage populations
Following the residue analysis carried out in Section 6.4.4, a larger population of
phage plaques were selected by blue/white plate titration from the amplified fourth
round pool. To increase the likelihood of identifying high-affinity but low-frequency
motifs, 192 separated phage populations were prepared for sequencing in two pools
of 96 (A and B), as described in Section 6.3.3.
The use of next generation sequencing allowed for the phage populations to be
amplified and sequenced as a pool, thereby negating the requirement for batch pro-
cessing of small culture volumes. The purified, pooled phage vectors were amplified
directly with Illumina adaptors alongside dH2O control as described in Section 6.3.3.
5µl of each sample was run in a DNA gel alongside 10bp O’Range Ruler and 1kb DNA
ladder (NEB) to assess purity and size (Figure 6.22) - the gel was visualised using UV
trans-illumination with 1.227s acquisition, optimised for faint bands. The ready-to-
sequence pools were approximately 250bp in length as expected. The full product, as
illustrated previously in Figure 6.10, is 251bp including Illumina adaptors. Any wild
type phage contamination in the PCR would have resulted in an insert-free population
at 203bp and therefore an additional band, which was not seen.
The remaining 45µl of each pool was purified and sent for analysis on an Illumina
MiSeq platform (Edinburgh Genomics), using 50% PhiX volume due to the similar-
ity of the sequences. The individual amplified pools A and B yielded concentrations
of 94.1 and 122.5ng/µl respectively. The pools were combined to yield a ready-to-
sequence pool of 108.3ng/µl, equivalent to 637.7nM.
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FIGURE 6.22: Band visualisation of the two phage pools following PCR amplification with
Illumina adaptors, with a dH2O-only negative PCR control to confirm primer orthogonal-
ity.
6.6.2 Analysis of large-scale peptide sequencing
Following removal of the PhiX sample data by Edinburgh Genomics, the NGS dataset
was analysed primarily using Galaxy as described in Section 6.3.4. Following ini-
tial processing, the remaining 9255 reads, consisting of distinct sequences and their
replicates along with nonsense reads, were analysed in Excel. The ’Find & Replace’
function was used to highlight banks of identical sequences, thus reducing the need
to analyse individual reads. The most common 192 sequences are summarised by or-
der of frequency in Table 6.8 - only the peptide insert is shown. It was assumed that
the remaining unique sequences (200+), all with a frequency of 1, were misreads of
other sequences as only 192 unique samples were submitted as a pool.
TABLE 6.8: Phage peptide insert sequences and their associated frequency.
Sequence Freq. Sequence Freq. Sequence Freq.
QAHDVMRGRMPG 860k QAHDVMRGRMPG 55 QAHDVMRAYAG 4
QAHDVMRGRMPG 745 QALDVMRGRMPG 55 PAHDVMRGRMPG 4
QAHDVMRGRMSG 423 QAHDVMRGLMPG 53 QAHEVMRGRMPG 4
QAHDVMRGRMPG 398 QAHDAMRGRMPG 52 QAHAVMRGRLPG 4
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QAHDVMWGRMPG 240 QAHDVMRGRMPV 52 QAPAVLRGRLPG 4
QAHDVMRGRMPG 231 QAHDVMRGRMPG 48 QAHDVMRGRRPG 4
QAHDGMRGRMPG 194 QAHYVMRGRMPG 48 QAHDVMRGGCR 3
PAHDVMRGRMPG 192 QAHDVMRGGMPG 46 QAQDVMRGRMPG 3
QAHDVMRGVCR 191 QAHDVMRGRMPD 44 QAHDVMRGRMPA 3
PAHDVMRGRMPG 186 QAHDVMRGRMPS 44 QAHDVMRGRMR 3
QAHDVMRGHMPG 130 QAHDVTRGRMPG 39 QGMMLCGGVCR 3
QAHDVMRGRMLG 128 QAHVVMRGRMPG 39 HAHYFIRGRIPG 3
QARDVMRGRMPG 119 QAHDVMRGRIPG 38 QAPDVMRGRMPG 3
QAHEVMRGRMPG 118 QAHDVCGGVCR 37 QAHDVRRGRRPG 3
QAPDVMRGRMPG 112 LAHDVMRGRMPG 36 QAHDVMRGGMRG 3
QAHDVMLGRMPG 110 EAHDVMRGRMPG 35 QSHDVMRGRMPG 3
QVHDVMRGRMPG 108 QAHDVMRGRKPG 31 PAHAVMRGRMPG 3
QAHDVMRGRMPG 104 QADDVMRGRMPG 31 QEHDVMRGRMTG 3
QAHDVMRGRIPG 103 QAHDFMRGRMPG 31 QAHYVIRGRMPG 2
RAHDVMRGRMPG 99 QAHDVMRGRMRG 26 QAHDGMRGRRPG 2
QAHDVMRGRMPG 99 QGHDVMRGRMPG 26 QAHDVMLGRMPG 2
QAHDVMQGRMPG 98 QAQDVMRGRMPG 25 HAHYVIRGRIPG 2
QAHDVMRGRMQG 98 QAHDVMRGRMPG 24 QAHEVMGGRMPG 2
QAHDVMRWRMPG 96 QAHDVMGGRMPG 23 QAHDVMRGGFP 2
QAHGVMRGRMPG 96 QAHDDMRGRMPG 22 QAHDVKRGSMRG 2
QAHDVMRGRMPG 95 QAHDIMRGRMPG 20 QAQEVMRGRMPG 2
QAHDVMRGRMPG 92 QAHDVLRGRMPG 20 QARDVMRGRMPG 2
KAHDVMRGRMPG 90 QAHDVMRGRMPG 19 QARDVMRGRMPG 2
QAHDVRRGRMPG 86 QAHDVMRGRMAG 19 QAHDFMRWRMPG 2
QAHAVMRGRMPG 86 QAHDVMRGRLPG 18 QAHDVMRGRMPG 2
*AHDVMRGRMPG 83 QANDVMRGRMPG 16 QAHDVMRGRMKG 2
QAHDVMRGRMPC 83 QAHDVMRGRMPR 15 QAHYVLRGRMPG 2
QAHDVMRGRMTG 82 QAHDGMRGRMPG 13 PAQDVMRGRMPG 2
QAHDVMRGSMPG 80 QAHDVMGGVCR 12 QAHDGMRGRMRG 2
QAHDVLRGRMPG 79 QAHDVMRGAYAG 12 QAHDGMRGRMPG 2
QAHDVIRGRMPG 79 QAHDVMRGRIPG 12 QAQDVMGGRMPG 2
QAHDVMRGRLPG 77 QAHDVMRGRMPG 12 QAHDVMRGLMPC 2
QAHDVMRGRRPG 76 QAHDVMRARMPG 12 PAHDVLRGRMPG 2
QAHDVMRGRMPG 75 QAHNVMRGRMPG 11 HSHYFIRGRIPG 2
QAHDVMRGCMPG 74 QPHDVMRGRMPG 11 QAHDVMRGRFPG 2
QEHDVMRGRMPG 74 QAHDVIRGRMPG 11 QAPDVMLGRMPG 2
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QAHDVMRVRMPG 73 QAHEVMRGRMPG 11 QAHDVMRGRMPG 2
QAHDVVRGRMPG 73 QAHDVMRGRMPG 10 QAHDVMRGGMPG 2
QAHDVMRGRMPG 72 QAHDVMRRRMPG 10 QAHDVRRGRMQG 2
QAHDVMRGRMPG 72 QAHDVRRGRMPG 9 KAHDVMRGSMPG 2
QAHDVMRGRTPG 72 QAHDVMRGVCR 8 QAHDVCGGVCR 2
QTHDVMRGRMPG 71 QAHDVMRGPMPG 8 QAHYVMRGRMPG 2
QAHDVMRGRMPG 70 QAHDLMRGRMPG 8 QAHEGMRGRMPG 2
QAHDVKRGRMPG 67 QAHHVMRGRMPG 8 QAHAVMRGRMPG 2
QAHDVMRGRMPG 67 HAHDVMRGRMPG 6 QGHDVMGGRMPG 2
QAHDVMRERMPG 66 QAHDVMRGRMPG 6 QEHDVMRGRMPG 2
QAHDVMRRRMPG 65 QAHDVMPGRMPG 6 QAPAVMRGRMPG 2
QAHDVMRGRMPG 63 QAHDGMRGRMPG 6 *ADDVMRGRMPG 1
QAHDVIRGRMPG 63 QEHDVMRGRMPG 6 QAHDVMRGRMRG 1
HAHDVMRGRMPG 62 QAHDVMRGRMPG 5 HAHYVIRGRMPG 1
QAYDVMRGRMPG 62 QAHDVMRGRMPG 5 QADDVMRGRMAG 1
QSHDVMRGRMPG 62 PAPDVMRGRMPG 5 QAEDVMRGRMPG 1
QAHDVMRGRMPG 61 QAHDGMRGRMQG 5 RAQDVMRGRMPG 1
QAHDVMRGRMPG 60 QAHDVMRGRMPG 5 QAHYVMRGRMPG 1
QAHDVMRGRMP 60 QAHDVCGGVCR 4 QAHDVMPGRMPG 1
QAHDVMRGRMPG 59 HAHYVIRGRMPG 4 QTPDVIRGRMPG 1
QAHDVMRGRMPG 58 KAHDVMRGRMPG 4 QAHGVERGRGRG 1
QAQDVMRGRMPG 58 PAHDVMRGRLPG 4 QAHDVMRGANAG 1
QAHDVMRGRVPG 56 QAHYVMRGRIPG 4 QAHGVRRGRMPG 1
Of these 192 most frequent samples, 92.71% were 36bp as expected, 5.73% were
35bp, 1.04% were 37bp and 0.52% were 34bp, reflecting a combination of natural phage
variation and possible sequencing errors. The 36bp samples were uploaded to MEME
Suite for motif analysis [260]. There is a strongly conserved 12-residue motif observed
(Figure 6.23). This shares the glutamine (Q) residue followed by basic and non-polar
domains seen in the original small-sample analysis (Figure 6.19, Positions 10-13), but
also offers a much more consistent motif than seen previously. The differences in
sequence demonstrate both the importance of large-scale motif analysis and the po-
tential for a higher-affinity binding peptide to be produced in the future for assay
purposes.
It must be noted that latter half of the sequence shown in Figure 6.23 bears con-
siderable similarity to the p16 motif posited as the binding site for the antibody used
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FIGURE 6.23: The 12-residue peptide motif produced as a result of analysing the 1,000,000
reads of 192 pooled samples, as analysed in MEME Suite.
(WGRLPV). It is possible that the peptides have preferentially bound to the antibody,
although the similarity of sequence with p16-only binders would suggest otherwise.
In either case the results are useful to the production of a paper-based assay, owing to
the need for a control peptide. Further tests to confirm binding specificity are required.
6.7 SERS activity of paper-based devices
6.7.1 Choosing a substrate architecture
Initial investigations into the most appropriate vehicle for a paper-based assay were
made through the exploration of constructed or commercially available dipstick as-
says and wax-printed ‘dot blots’, as described in Sections 2.6 and 2.7 of Chapter 2 re-
spectively. Basic preliminary tests showed that paper assays were capable of produc-
ing an easily discernible Raman signal in the absence of a collimating pinhole (Figure
6.24).
A wax-printed nitrocellulose 96-well assay was prepared with a two-fold serial
dilution ladder of purified p16 in PBS with 5µl added to each ‘well’ and left to dry at
ambient temperature. Different absorption times and wetting effects were observed
for the different concentrations of protein. The dry assay was then affixed to blotting
paper using a spray adhesive (3M Photo Mount) before 5µl SERS-active conjugate
(5µM BPE) was added to each well and left to flow through. The completed assay
was interrogated using a Renishaw inVia upright microscope at 5x magnification with
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FIGURE 6.24: Raman spectra of initial dipstick tests, taken at 785nm with 1.0s single acqui-
sition of the colorimetric spot. A) Spectral signature with pinhole. B) Spectral signature
without pinhole, showing characteristic BPE peaks.
633nm laser. The brightfield microscopy and Raman peak intensity data can be seen
in Figure 6.25.
The blotchy effect in Figure 6.25A is clearly the result of interaction with the droplets
of spray adhesive, but there are also artefacts from the wax printing process. Colori-
metric values were sampled in triplicate from non-artefact areas and can be seen in
Figure 6.25B. Higher values correspond to colours closer to white in these 8-bit im-
ages, with each colour channel capable of displaying from 0 to 255 . Thus there is an
inverse correlation with p16 concentration. The trend is extremely weak and could
not form the basis of a quantitative test.
For the Raman interrogation, a map was generated using the process described in
Section 2.8, Chapter 2. Principal Component Analysis (PCA) was carried out to isolate
the chief source of variance - the SERS conjugate signal - from weak background inten-
sities from the dyed wax or nitrocellulose membrane. Representative spectra from the
maps were matched to the SERS signal principal component for each concentration.
The intensities of the 1202cm−1 BPE peak are shown in Figure 6.25C. Again, there is a
weak positive correlation.
It is likely that, due to the extremely shallow flow column of each well (101.6µm),
small variations in adhesion to blotting paper generate significant contributions to
the wicking properties and therefore Raman signal intensity of each well. Even on
the basis of significant improvement to the adhesion method, variation in flow rate
through the composite layers of the device also raises questions as to the quantitative
robustness of such an assay.
Efforts were then focused on the use of dipstick assays, which overcome the Raman
sampling issue by virtue of the lateral rather than depth-wise nature of the binding
interaction.
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FIGURE 6.25: Conjugate response to purified p16 in a wax-printed assay format. A)
Brightfield images of the spots, starting at 100ng/µl at position 1 in twofold serial dilution
through to position 12. Glue aggregation (dark spot) and wax resist (light spot) artefacts
are clearly visible. B) Direct colorimetric values from the brightfield red (R) and green (G)
channels, averaged from analysis in triplicate. C) Single acquisition SERS response of p16
concentrations.
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6.7.2 Raman response of assembled dipsticks
Dipsticks were assembled in house as described in Section 2.6.1, Chapter 2 and 1µl
serially diluted purified p16 spotted onto the membrane as before, but starting at
100ng/µl. The assays were left to dry completely before applying 20µl conjugates
mixed 1:1 with 1x conjugate buffer + 1% BSA (Expedeon). Owing to slow flowthrough
another 20µl conjugate buffer was added to reduce the likelihood of high background.
This was still a clear issue for the assembled assays. Nevertheless, the protein-bound
areas were spot-sampled with a Raman spectrometer as described in Section 2.8 and
scanned for colorimetric analysis as in Section 2.6.2.
For the colorimetric assessment, the scanned dipstick images were converted to
greyscale to reduce dimensionality and then colour-sampled using a 5x5 pixel aver-
age in the spot centre and base of the strip, taken as a background value. Both were
subtracted from 255 (8-bit absolute white) to give a scale which varies proportionally
with colour saturation. For Raman analysis, single acquisitions were taken in the same
manner using 10% laser power and a 1.0s acquisition. The results are summarised in
Figure 6.26.
FIGURE 6.26: Conjugate response in assembled dipsticks. A) Inverted colorimetric values
of the p16 binding region (spot value) and blank region (blank value). B) Single acquisi-
tion SERS response of p16 concentrations and corresponding blank region.
The colorimetric response in Figure 6.26A demonstrates no discernible trend, and
in some cases is lower than the background signal for the strip. The Raman intensity
results in Figure 6.26B also suffer from high background, but with a possible trend
emerging for 25-100ng/µl p16 concentration. The primary issue for the assembled
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dipsticks, demonstrated by high background and signal noise with both analysis tech-
niques, is the variation in flow characteristics caused by the assembly itself. It was ob-
served that the cellulose wicking pad in particular varied in terms of the thickness and
quality of adhesion. If a paper-based assay were to be produced for clinical testing this
would be overcome through automated manufacturing, and so the commercial dip-
sticks used previously for conjugation testing were adopted to remove this source of
error.
6.7.3 Detection limits of commercial dipsticks
The conditions used in Section 6.7.2 were repeated with commercial dipstick assays
optimised for use with gold antibody conjugates (‘Conjugate Check and Go!’, Expe-
deon) but with a lower starting concentration of 50ng/µl. Each concentration (50.00,
25.00, 12.50 and 6.25ng/µl) was run in duplicate. The completed assays were scanned
for colorimetric analysis as before. Raman point acquisitions were also conducted
with the same settings. Prior to spot sampling the SERS intensity, rapid Raman maps
were acquired to ensure spectral consistency across the protein-bound area. This was
carried out using StreamlineHR on Wire 4.4, with 5x magnification, 1.00s acquisition,
10% laser power, no pinhole, high gain and fast raster. All maps were 56x55 sam-
pling pixels, with 20 and 12.5µm steps in X and Y respectively. The results, shown in
Figure 6.27, were interpreted using differential classical least squares analysis (DCLS)
with the bulk conjugate SERS signal as a reference component. The map colours were
scaled to include the central 5-95% of spectral intensities.
A direct comparison of SERS response from the spots and associated background
can be seen in Figure 6.28, which validates what was seen colorimetrically; the back-
ground signal is much lower for the commercial strips. The Raman and colorimet-
ric results are seen in Figure 6.29. As seen in Section 6.7.2, the colorimetric results
were ‘inverted’ such that higher values correspond to a more intense signal. For sin-
gle point acquisitions an average of three measurements was taken for each sample,
which was averaged again between the samples in duplicate. The spectral bands in
Figure 6.29A indicate a single standard deviation on either side of the mean spectrum.
The 1203cm−1 peak of the BPE spectrum was used for analysis and compared against
the average blank SERS signal as seen in Figure 6.29B. The reference values do not
intersect with the background signal, indicating that even vanishingly small concen-
trations of p16 could legitimately be compared to the reference curve.
For a more conservative estimate, the limit of detection (LoD) was calculated,
given by
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FIGURE 6.27: Raman maps of commercial dipsticks in the protein binding region. A) False
colour Raman maps of colorimetric spot, created using a Classical Least Squares (CLS) fit
of the spectral data using the conjugate bulk SERS signal as the reference component. B)
Representative spectra from each level of p16 content and bulk conjugate reference.
LoD = LoB + xσsamples (6.1)
where x is dependent on the confidence interval chosen and the limit of blank
(LoB) is given by LoB = µblank + xσblank. In terms of Raman intensity for the 1203cm−1
peak, the values are µblank = 71.39 and σblank = 32.89. If calculated as the average
of sample standard deviations, σsamples = 100.33. This gives LoB and LoD values as
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FIGURE 6.28: SERS spectra of commercial dipsticks at increasing concentrations of p16
(1µl volume used), compared directly to blank region response from each completed assay
as an assessment of signal-to-noise ratio. A) 6.25ng. B) 12.50ng. C) 25.00ng. D) 50.00ng.
summarised in Table 6.9. In terms of absolute protein content, which represents the
most suitable unit of measurement on the basis of the assay’s capture mechanism, this
is of a sufficient level of protein detection for wildtype SiHa cells (3-6ng) to a 99%
confidence level. Further tests would be required to indicate whether this would be
sufficient for detection in heterogeneous cell populations such as clinical samples.
The colorimetric data can be seen in Figure 6.29D. Here, the blank values are all
zero giving non-existent background, but the reference curve also reduces to zero at
4.55ng p16 content. As such, this value forms the limit of detection for colorimetric
analysis, showing that SERS enhancement of the paper-based assay offers higher sen-
sitivity than colorimetric analysis . Furthermore, at this level of detection the wildtype
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FIGURE 6.29: SERS and colorimetric responses of the commercial assays, tested as sample
duplicates. A) The average spectral response as recorded from three single acquisitions
of each assay, averaged again over sample duplicate. B) Peak intensity at 1203cm−1 char-
acteristic peak of BPE with average assay blank SERS value (dotted line). C) Scanned
images of assays used for colorimetric analysis. D) Colorimetric analysis, taken from a
5x5 average in the spot centre.
expression levels of p16 in SiHa would not be detected, showing that SERS enhance-
ment is necessary for a quantifiable paper-based test.
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Confidence (%) x LoB (Raman) LoD (Raman) Protein (ng)
90% 1.645 125.49 290.54 0.876
95% 1.960 135.85 332.51 1.530
98% 2.326 147.89 381.26 2.289
99% 2.576 156.11 414.57 2.807
TABLE 6.9: The limits of blank and detection for SERS paper assays in terms of Raman
intensity, along with the equivalent protein content determined by linear extrapolation.
6.8 Conclusions
In this Chapter, a paper-based diagnostic device for p16 expression in fixed cell sam-
ples has been proposed and characterised in conjunction with the SERS-active anti-
body conjugate developed in Chapter 4.
Capture layers consisting of biopanned phage-displayed peptides were discov-
ered, analysed and synthesised ready for addition to a streptavidin-printed mem-
brane, with opportunity for high affinity motifs to be produced following residue
analysis. Eight of the 24 panned antigen sequences were found to be significant in
terms of binding affinity compared to secondary-only control. Of the top four, one
sequence (ASHYHINYRKWT) provided easily discernible detection of purified p16 to
62.5ng/ml in a sandwich format, as well as significant differentiation between cell line
models using native and transfected expression of target.
Next-generation sequencing of a larger phage population served both to validate
initial results and search for other high-afffinity motifs. The NGS analysis yielded 192
unique motifs of frequency of 1 to 860,000 which produced, overall, a highly conserved
12-residue motif which can form the basis of further binding sensitivity experiments.
Having laid foundations for capture layer development, the detection mechanism
and assay substrate were considered in Section 6.7. Commercial dipstick assays, pro-
duced by Expedeon, were identified as the basis for further assay development owing
to their low background and consistent flow characteristics. Comparisons of colori-
metric and SERS analysis of conjugate binding to p16 on the chosen substrate indi-
cated detection limits of 4.55ng and 0.88ng to 90% confidence respectively, showing
SERS to be the more sensitive imaging mechanism. In addition, SERS was able to
detect p16 content at biologically relevant levels not found with colorimetric analysis.
Significant progress towards a feasible clinical assay has been made, but the assay
clearly requires further development. Orbital raster scanning could be used to sample
the whole spot, rather than mapping or spot sampling. Suggestions for further work in
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the long term are considered in Chapter 7. In the immediate future, the peptide motifs
for the test and control lines should be optimised for target affinity by testing a variety
of motif candidates according to the analysis performed in Section 6.4. Following
this, the biotin-tagged motifs should be bound to streptavidin-printed nitrocellulose
dipsticks so that whole system testing can be carried out in earnest using cell models
and eventually, clinical samples.
Through combination with a handheld Raman spectrometer and following the
steps outlined above, this assay has the potential to be developed in keeping with




Conclusion and suggestions for
further work
In this thesis, a broad range of enhanced Raman spectroscopic techniques have been
explored and considered in a clinical context before a paper-based device for p16
quantification was judged to be the most feasible method and selected for further de-
velopment.
In the global imaging approach, a previously developed wavelength modulated
spectrometer was used to automatically classify fluorescence-free spectra of PreservCyt-
fixed cultured cells in an analogue for cervical smears. PCA-based modulated spec-
tral classification provides clear benefits over standard spontaneous classification. For
comparison of HPV status in cervical cancer lines C33A (HPV negative) and SiHa
(HPV16 positive), sensitivity and specificity were 88.0% and 90.5% respectively for
standard classification, rising to 100.0% and 95.8% for modulated classification. For
comparison of transformation status in normal (NHEK), spontaneously immortalised
(HaCaT), cervical carcinoma in situ (SiHa) and metastasised (CaSki) cells, the standard
sensitivity and specificity were 84.8% and 85.1% respectively, again rising to 95.1% and
96.2% for modulated classification.
Intracellular sampling location studies indicated that fixed harvested cells were
less sensitive to sampling location than live, adhered cultures, which may have prac-
tical benefits in terms of sampling tolerances. Nonetheless, the sensitivity of the tech-
nique and the discriminatory nature of PCA means that statistically significant num-
bers of clinical samples would require interrogation to guarantee disease-specific spec-
tral classification.
As discussed in Chapter 3, the sampling speed and acquisition method of this
technique are the major barriers to sufficient throughput and therefore clinical util-
ity. Although the introduction of primary HPV testing will significantly reduce the
number of samples requiring cytologic analysis and the automated system would not
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require office-hours supervision as in current practice, a single smear would still have
to be processed in approximately 162min or 1s per cell in order to ‘break even’, based
on HPV incidence [261].
The possibility of an optical coherence tomography or digital holographic mi-
croscopy map co-registered with the current point-sampling system has been posited
as a way of removing the need for raster scanning empty areas of the slide. Cou-
pling with existing digital image guidance systems would achieve the same purpose.
There is also the possibility of a flow cell-style setup, with cells held in place with
optical tweezers during interrogation. Again, significant improvements to acquisi-
tion speed would be required. Finally, light-sheet Raman spectroscopy would allow
for multiple spectra to be acquired simultaneously and deconvoluted post-capture.
Potential models for such a system include selective plane illumination microscopy
(SPIM) with Fourier transform analysis [262] or digital scanned lightsheet microscopy
(DHLM) with an interferometric tunable filter [263]. Certainly, a global method in this
form would offer enormous benefit not just for cervical smears, but for any pathology
where cell sampling is useful and feasible.
A functional SERS-active nanoparticle conjugate to p16 was then developed for
consideration of targeted approaches. The three most common methods of conjuga-
tion have been assessed and optimised, including EDC/NHS covalent, passive and
Protein G’ bioconjugation. The final Protein G’ conjugate described can be produced
in 2.5 hours at room temperature at a material cost of £2.32 per 1ml (unconcentrated),
demonstrating baselined Raman intensity of 11530 ± 2650 counts without concentra-
tion and a clear colorimetric and Raman response to 50ng purified p16 in a paper-
based assay. A workflow was also developed for strategic approaches to general
antibody-nanoparticle conjugation in the case where maintaining binding function-
ality proves difficult.
Two targeted approaches to Raman spectroscopic classification of cervical smears
were broadly explored using the developed conjugate, with a third considering a hy-
brid global-targeted approach using alkyne-labelled antibodies with stimulated Ra-
man spectroscopy.
In the more established SERS mapping framework, a dummy conjugate was de-
veloped for ratiometric analysis of whole cell p16 expression which demonstrated a
calibrated system capable of translating ratiometric conjugate intensity into the per-
centage volume of target. This allows for binding specificity of the initial 1:1 mix to be
considered, but this requires further validation in terms of expected expression levels
in clinical samples. In the cell analogues tested, there was a 2.2-fold Raman inten-
sity increase for transfected versus endogenously expressing SiHa cells. Preliminary
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method optimisation indicated that PreservCyt fixing leads to lower non-specific ac-
cumulation of conjugates within cells.
As with global point sampling, this approach still suffers from relatively cumber-
some acquisition, although it does offer improvements on sampling speed in compar-
ison with the wavelength modulated approach. SERS mapping could be combined
with topographical or image guidance methods as described above for increased ac-
quisition rate per sample, or by considering overall signal from a pooled cell pellet.
However, this offers no real advantage over fluorescent labelling unless marker mul-
tiplexing levels were high. In the multiplexing scenario the practicalities of cost in a
clinical setting would become an issue and is irrelevant for screening which incorpo-
rates a robust and well-established marker.
The SERS-SRS method, in which a SERS-active nanoparticle conjugate is used as a
labelling moiety in the global SRS method, was insufficiently developed as a technique
to justify further work at this time, especially in a fixed cell context which does not
require the use of nanoparticle stealth properties or multiplexing.
Alkyne labelling was then taken up for further study, owing to the availability of
strongly Raman active molecules for SRS labelling without the need for considera-
tions of nanoparticle stability. A method was optimised for succinimide-conjugated
antibody amines using a fluorescent analogue, meaning that alkyne labelling can be
continued in earnest in the future. This global-targeted hybrid method, which al-
lows for simultaneous consideration of specific markers with global morphological
information from key vibrational modes, offers the prospect of a genuine advance on
established fluorescent imaging which could be expanded to histological studies and
biomarker discovery within the molecular pathology framework. It is suggested that
upon successful production of an alkyne-labelled antibody, a comparison of global
only, target only, and global-target hybrid approaches are compared directly with each
other and traditional cytology to quantify the extent of classification power. The global
method could use significant vibrational modes discovered in Chapter 3.
The targeted approaches explored clearly offer benefits in a diagnostic context, but
these benefits are not suited to cervical screening. After consideration of the strengths
and weaknesses of the trialled targeted approaches, a different paradigm was adopted
which used the SERS-active conjugates in a paper-based assay setup similar to that
used for optimisation work. This capitalised on the advantages of the targeted SERS
approach in the cervical cancer context, allowing for sensitive, point of care quantifi-
cation of a relevant marker which has the potential to transform screening practices in
a variety of settings, conforming with ASSURED criteria.
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Phage-displayed peptide biopanning was used to discover potential binding mo-
tifs for p16 protein and antibody. This was first carried out on a small scale, with one
sequence providing easily discernible detection of purified p16 to 62.5ng/ml in a sand-
wich format, as well as significant differentiation between cell line models using native
and transfected expression of target. Validation through larger scale next-generation
sequencing produced a high-consensus alternative motif ready for binding validation
tests. A commercial dipstick assay was used to test SERS activity of conjugates in
a paper-based format. Comparisons of colorimetric and SERS analysis of conjugate
binding to p16 on the chosen substrate indicated detection limits of 4.55ng and 0.88ng
to 90% confidence respectively, showing SERS to be the more sensitive imaging mech-
anism in this instance. In addition, SERS was able to detect p16 content at biologically
relevant levels not found with colorimetric analysis. As such, the assay components
offer genuine functionality in a clinical context, but require further development.
Beyond immediate optimisation and characterisation of the discovered peptide
motifs through alanine scanning, binding assays and the discovery of the antibody
binding site through the same method, the identified components should be combined
into a functional assay. First, biotinylated peptides should be printed onto nitrocellu-
lose strips using streptavidin adhesion zones. It is possible that successful printing
and binding could be tested using an adapted Western Blot method for the targets
in question. Once the assay architecture itself has been validated, the substrate and
conjugates should be tested with analytes in a variety of formats, including a spiked
purified p16 concentration ladder, lysed cell models, and finally clinical samples. It
is recommended that an industrial partnership with Expedeon should be formed in
order to develop a scalable manufacturing process for the assays.
Further optimisation of the detection sensitivity is also recommended. Basic col-
lection performance improvements such as improved lighting and analysis of colori-
metric data, plus longer acquisition times for SERS measurements subject to substrate
degradation, would give a more realistic understanding of the technical limits of each
technique. Smaller nanoparticles (30nm) would yield both a higher colorimetric con-
trast and SERS amplification, but may also be subject to lower stability. In this case,
optimisation of the excitation wavelength could be considered an alternative whilst
retaining the current conjugate. The 40nm gold conjugates produced were designed
for optimal SERS enhancement at 532nm excitation, but were found to give highly
variable signals. This is posited to be due to excessive heat conversion at the LSPR
peak, which may have degraded the surface molecules.
One of the key criteria for a robust assay in this context is the ability to threshold
p16 values across a whole sample so that they can be classified with reasonable levels
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of confidence. Although outcome of borderline samples could still be confirmed by
a cytopathologist, the number of samples requiring this pathway would have to be
relatively small for the test to significantly reduce cost and workload. To date studies
of p16 stain or p16/Ki67 dual stain have been conducted with conventional cytology
samples consisting of discrete cells, and so a whole-sample study of clinical samples
or modelled analysis of existing stained cytology slides would be required, preferably
in comparison to colorimetric methods to ascertain the relative benefit of SERS-based
paper assays in relation to their additional complexity. In the case that p16 alone has
insufficient resolving power, the assay could easily be adapted to include a test for
Ki67 as discussed in Chapter 1 - indeed, this is recommended for any possible clinical
introduction in a non-morphological format.
The diagnostic landscape and future avenues explored in this thesis are summarised
in Figure 7.1. It is hoped that this research will provide a useful reference for all those
working in diagnostic and Raman research contexts, as well as resources required to
create a point-of-care, inexpensive test for p16 which could streamline and broaden
access to cervical screening across the globe.
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FIGURE 7.1: A summary of strengths and suggested directions for Raman spectroscopic
studies in different contexts. Standard SERS mapping strengths are not listed as they were
not considered to be relevant to cervical screening.
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Appendix A: Published research
This appendix contains a reproduction of the paper "Towards automated screening ",
published in the Journal of Biophotonics online in Janurary 2018 and in print in April
2018.
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The ability to provide quantitative,
objective and automated pathological
analysis would provide enormous ben-
efits for national cancer screening pro-
grammes, in terms of both resource
reduction and improved patient well-
being. The move towards molecular
pathology through spectroscopic
methods shows great promise, but has
been restricted by spectral quality,
acquisition times and lack of direct
clinical application. In this paper, we
present the application of wavelength modulated Raman spectroscopy for the auto-
mated label- and fluorescence-free classification of fixed squamous epithelial cells
in suspension, such as those produced during a cervical smear test. Direct compar-
ison with standard Raman spectroscopy shows marked improvement of sensitivity
and specificity when considering both human papillomavirus (sensitivity +12.0%,
specificity +5.3%) and transformation status (sensitivity +10.3%, specificity
+11.1%). Studies on the impact of intracellular sampling location and storage
effects suggest that wavelength modulated Raman spectroscopy is sufficiently
robust to be used in fixed cell classification, but requires further investigations of
potential sources of molecular variation in order to improve current clinical tools.
KEYWORDS
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1 | INTRODUCTION
The introduction of national screening programmes such as
the Papanicoloau (‘Pap’) test and mammogram have
achieved considerable success, and are estimated to prevent,
for example, 4500 [1] and 1300 [2] deaths in the United
Kingdom every year from cervical and breast cancer,
respectively. However, these programmes require large,
sustained financial input and human resources and are not
completely accurate. The primary purpose of cervical
screening is to detect abnormal epithelial cells that indicate
the presence of cervical pre-cancer or cancer. In a cervical
screen, cells are brushed from the cervix and stored in fix-
ing solution as a liquid-based cytology sample. This ‘smear’
is transferred to a microscope slide, stained and viewed by a
cytopathologist, who classifies it as normal, borderline, low
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or high grade dyskaryosis, glandular neoplasia or unsatisfac-
tory [3]. However, interpretation of cell morphology is
hugely complex and therefore, open to subjectivity and false
diagnosis, as small numbers of abnormal epithelial cells
must be identified in a background of numerous normal epi-
thelial and inflammatory cells. In 2008, clinical trial com-
paring reviewed with initial pre-treatment histologic
diagnosis, the probability of unnecessary treatment was
found to be 8% to 27% (dependent on initial cytologic find-
ings) [4], indicating that many women may be being
referred to colposcopy unnecessarily. The use of biomarker
screening has been posited as a potential method for
improving diagnostic accuracy, but identifying targets rele-
vant to genetically heterogeneous populations exposed to a
variety of environmental factors while maintaining high-
positive predictive value is often unfeasible [5]. Thus, a
technique which provides the benefits of quantitative molec-
ular pathology but with a broader scope and automated clas-
sification could vastly improve screening outcomes.
One technique with the potential to deliver these charac-
teristics is Raman spectroscopy. Raman spectroscopy is a
label-free technique based on the inelastic scattering of
light. It can be used to identify the molecular vibrational
bonds present in a sample. Changes in disease state are
accompanied by alterations in molecular pathology, which
are reflected in spectral data. Raman spectroscopy in its var-
ious forms is emerging as a key contender for analysis of
cancer status [6], including colorectal [7], lung [8] and cer-
vical cancer [9–11]. However, the likelihood of clinical
uptake is highly dependent upon the ability to contend with
the practicality as well as accuracy of diagnostic gold stan-
dards such as histopathology. As such, a new classification
method would need to be incorporated into current systems
for trials to be conducted in the first instance.
In this paper, we demonstrate the use of wavelength
modulated Raman spectroscopy (WMRS) [12] as a tool for
the automated classification of unlabeled fixed cells in sus-
pension, reflecting its potential utility in diagnosing clinical
liquid-based cytology samples. One of the major technical
barriers to the introduction of Raman spectroscopy as a clin-
ical tool is the long acquisition time associated with the rare
event of Raman scattering of photons. The acquisition of
high-quality spectra is further compounded by the presence
of autofluorescence in samples, which is a particular prob-
lem for biological interrogation and can often lead to the
loss of smaller Raman peaks obscured by a fluorescent
background. Several approaches for reducing the back-
ground have been explored, including post-acquisition
baseline correction, nonlinear optical methods and time-,
frequency- and wavelength-domain methods [13].
WMRS is a wavelength-domain approach. During mea-
surement, the laser wavelength is modulated throughout the
acquisition process using a tunable laser [14]. This causes
the Raman spectral peaks to shift fractionally when measured
in terms of scattered wavelength. When this shift is measured
across several wavelengths, a ‘differential spectrum’ can be
generated which demonstrates the true Raman peaks in
wavenumber shift from the incident wavelength. Wavelength
modulation does not affect the position of autofluorescence
from the sample and substrate, allowing the background to
be automatically removed [12]. Methods for post-processing
wavelength modulated spectra in order to account for wave-
length shift and remove this static fluorescence background
have been tested, including standard excitation Raman dif-
ference spectroscopy, SD, Fourier filtering, least-squares fit
and principal component analysis (PCA), with PCA provid-
ing the best signal-to-noise ratio [15]. The differential
Raman spectrum is formed from the first principal compo-
nent (PC) of the modulated data set, corresponding to the
component which captures the greatest variance in the data.
This method has been used to investigate single living
Chinese Hamster Ovary cells (CHO-K1) [12] as well as T
lymphocytes (CD4+, CD8+), killer T cells (CD56+) and
dendritic cells (CD303+, CD1c+) [16]. It has also been
shown to provide high specificity and sensitivity for the
characterisation of human urothelial (SV-HUC-1) and blad-
der cancer (MGH) cell lines cultured normally [14] or
exposed to urine [17], which represents another step
towards an automated optical platform for cancer screening.
The aim of this study is to assess the practical potential of
WMRS as a method for the automated classification of
fixed squamous epithelial cells, modelling cervical cancer
diagnosis.
2 | MATERIALS AND METHODS
2.1 | Cell sample preparation
A total of 4 established cell lines, and primary cells, from
squamous epithelial tissue were used for this project, reflect-
ing the intention to investigate WMRS as a method of clas-
sifying cervical smear samples. CaSki, SiHa, C33A (all
squamous cell carcinoma, adult human cervix), HaCaT
(immortalised squamous epithelium, adult human skin) and
primary normal human epidermal keratinocytes (‘NHEKs’,
normal squamous epithelium, neonatal human skin) were
cultured to 80% to 90% confluency. These were harvested
by trypsinisation, washed in triplicate by centrifugation and
resuspension in sterilised phosphate buffered saline (PBS),
and fixed in the clinical methanol-based fixative PreservCyt.
Samples were stored in PreservCyt at −20∘C until use. All
centrifugation steps were executed at 400. for 5 minutes at
4∘C. Prior to interrogation, fixed cell samples were washed
in triplicate by centrifugation and resuspension in sterilised
PBS in order to remove traces of fixing solution, as metha-
nol produces strong Raman signatures. Twenty microliter of
PBS cell suspension was then transferred to a quartz cavity
slide (Figure 1), carefully sealed with a 150 μm quartz
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coverslip and inverted. The quartz assemblies were rested
for at least 20 minutes prior to interrogation in order to pro-
mote cell adherence to the quartz coverslip, which was
placed face down on the inverted microscope assembly for
measurement. Details of the origin and cell culture reagents
used for each cell type are provided in Appendix S1,
Table 1.
2.2 | Spectral acquisition
A confocal Raman microscope built and modified for acqui-
sition of both standard and modulated spectra (Figure 2)
was used to evaluate the fixed cell samples. Raman spectra
were generated from individual cells inside the quartz cavity
assembly using a tunable continuous wave Ti-Sapphire laser
(‘SolsTis’, M Squared Laser Ltd, maximum power 1 W at
785 nm), delivering 150 mW power in a 1 μm spot in the
sample plane through a 40× oil immersion objective
(Nikon, NA1.3). A translational stage allowed the laser to
be focused on the nuclear region of each cell, with Raman
scattered photons collected from a confocal collection vol-
ume 2.86 μm in depth and 2.63 μm in diameter about the
laser spot. The signal was resolved with a Shamrock SR-
303i spectrometer (400 lines/mm grating, Andor Technol-
ogy) and collected with a CCD camera (Newton, Andor
Technology) thermoelectrically cooled to −70∘C. ‘Standard’
spontaneous and wavelength modulated Raman spectra
were acquired using Solis (s) Software (Andor Technology)
along with a brightfield microscope image (Imaging Source
USB Camera) of each cell (see Supplementary Information
S3). Standard acquisitions were conducted at 785 nm, using
5 accumulations of 2 seconds laser exposure for both the
cell and adjacent background. The adjacent background,
including any spectral contribution from the quartz slide,
was removed from the raw cell spectrum for data analysis.
In the modulated acquisitions, 5 accumulations of 2 seconds
exposures were performed with 5 different cycles of excita-
tion wavelengths over a total range of Δλ = 1 nm centred at
785 nm. No background acquisition was necessary here due
to the inherent autofluorescence removal. It has been shown
previously that no significant phototoxicity was experienced
by the cells as a result of laser exposure at similar set-
tings [16].
Reference spectra for laser calibration were acquired
from 1 μm polystyrene beads in distilled water. These
spectra were used to account for fluctuations in laser power,
wavelength and spot location due to heating, fibre-optic
coupling or mirror alignment, as well as post-acquisition
spectral processing.
2.3 | Spectral processing and data analysis
All spectra were considered in the fingerprint region of
interest, 800 to 1800 cm−1. Spectra were normalised
according to the total area under each modulation set, which
is linearly proportional to the laser power. Laser wavelength
was also monitored by linearly interpolating the intensity
and Raman shift of the characteristic 1001.4 cm−1 polysty-
rene peak according to the sample measurement time stamp
and adjusting spectral position accordingly. Overall, this
accounts for any laser power and wavelength fluctuations
over time, thereby preventing the PCA script from grouping
cells according to these parameters. Immediately prior to
analysis, individual spectra were assessed and removed
from the analysis if a high spectral background was appar-
ent. Such artefacts arise from suboptimal focusing or cell
movement during acquisition. All spectra were analysed
using PCA, a commonly used multivariate spectral analysis
technique [18]. PCA breaks spectra down into orthogonal
spectral components PCs which describe the variation in the
dataset. The first principal component describes the greatest
variation, with higher components eventually describing
noise [19]. The first 7 PCs were used in all data analysis
conducted. The weighting of these PCs (the extent to which
each PC represents a particular spectrum in the dataset) was
used to generate PCA cluster plots, which may be used for
diagnostic classification. Sensitivity and specificity values
were generated through ‘leave-one-out cross-validation
(LOOCV)’, also known as a ‘jacknife’ [18]. When per-
formed for 2 datasets, the classifications can be quantita-
tively estimated as sensitivity and specificity values by
assigning the each cell line as ‘positive’ or ‘negative’. Sta-
tistically significant variations between spectra were also
estimated for each cell line pair using student's . test at a
significance level of . < 10−12. This was conducted using
the established ‘ttest2’ function in MATLAB, where the
average spectral intensity at each wavenumber is compared,
with consideration to spectral variation across the dataset
(indicated in figures by coloured bands around the average).
The PCA script used was written in MATLAB by the Bio-
photonics Group at the University of St Andrews.
3 | RESULTS
3.1 | Comparison of human papillomavirus status
A preliminary comparison of standard and wavelength mod-
ulated Raman spectroscopy as a classification tool was
made using fixed C33A human papillomavirus (HPV
FIGURE 1 The cavity slide assembly used for all acquisitions. Slides
were sterilised with ethanol, air-dried and polished in between
measurements
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negative) and SiHa (HPV16 positive) cells, kindly donated
by the Scottish HPV Archive [20]. The samples were resus-
pended in PBS and prepared for analysis as described in
Section 2.1. Initial analysis of the C33A cell line found that
an acquisition time of 2 seconds over 5 accumulations
yielded superior standard Raman spectra to a single acquisi-
tion of 10seconds. This is due to a comparative reduction in
CCD camera noise for the shorter acquisitions. The bright-
field cell images were morphologically similar, consisting
of 10 μm cells which were highly rounded due to the trypsi-
nisation process. The PCA plots for the standard and modu-
lated Raman can be seen in Figure 3. LOOCV was applied
to the datasets to yield sensitivity values of 88.0% and
100.0% for standard and modulated Raman, respectively,
representing a considerable improvement of 12%. Specific-
ities of 90.5% and 95.8% were found for standard and mod-
ulated Raman respectively, or a 5.3% improvement. It is
clear from both PCA and LOOCV that modulated Raman
spectroscopy provides a superior separation and classifica-
tion of 2 cervical carcinoma cell lines with differing HPV
status. The main spectral disparities occur at approximately
730, 760, 890, 920, 1130, 1250, 1380 and 1480 cm−1.
3.2 | Comparison of different status in squamous
epithelial cell lines
The investigation of standard and modulated Raman spec-
troscopy was then extended to 4 cell lines (1 normal,
1 immortalised and 2 transformed), which were chosen to
represent the spectrum of abnormality typically found in the
progression to cervical cancer. NHEKs are normal squa-
mous epithelial cells which stop dividing when they reach a
certain age. HaCaT cells [21] are a spontaneously
immortalised epithelial line which can proliferate beyond
this normal limit. These were used as a model for cervical
precancer. SiHa [22] and CaSki [23] are cervical cancer cell
lines from primary and metastatic tumours, respectively.
These are both transformed phenotypes, consisting of cells
capable of forming tumours. A total of 163 cells were inter-
rogated using both standard and wavelength modulated
Raman spectroscopy, consisting of 42 NHEK, 41 SiHa,
40 CaSki and 40 HaCaT cells. As before, the established
cell lines in particular could not be discerned on a purely
morphological basis, which furthers the case for biochemi-
cal classification as a complementary technique. It must be
noted that the morphology of the primary NHEK cells var-
ied significantly in terms of both shape and size compared
to the established cell lines. Following removal of subopti-
mal spectra, Raman spectra and PCA plots were generated
as seen in Figures 4 and 5, respectively. The ability of PCA
to act as a classification algorithm was explored using
cross-validation of the data. LOOCV was performed on all
4 cell lines for both datasets; the confusion matrices for
standard and modulated PCA can be seen in Table 1 and 2,
respectively, along with misclassification statistics. For all
3 established cell lines, the modulated spectra provide better
discrimination. However, classification is slightly superior
using standard Raman spectra for NHEKs.
In order to gain further understanding of both the effi-
cacy of the test and the major vibrational signals contribut-
ing to the analysis, each possible pair combination of cell
lines was analysed using the PCA script. The average sensi-
tivity was 84.8%  9.0. and 95.1%  5.6., and specificity
was 85.1%  10.7. and 96.2%  4.6., for standard and
modulated PCA respectively. This demonstrates that, for
both metrics, wavelength modulated Raman spectroscopy
FIGURE 2 The optical diagram of the
spectrometer designed for WMRS and
standard Raman spectral acquisition.
Brightfield microscope images are acquired
separately on CCD1 and blocked from the
spectrometer by secondary EF
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provides superior discrimination (+10.3% sensitivity,
+11.1% specificity) as well as lower variation between cell
types. The generated spectra were also marked with signifi-
cance bands as decribed in Section 2.3. Spectra with marked
bands are shown for NHEK-Siha, NHEK-CaSki and
NHEK-HaCaT are shown in Figures 6 and 7. The . test sta-
tistics used did not identify any bands for the combination
HaCaT-SiHa, for either standard or modulated Raman. The
lack of statistically significant spectral differences here
explain the reduced classification accuracy for the 4 cell line
validation, where the largest populations of misidentified
cells were from the HaCaT-SiHa pairing. A lack of signifi-
cant spectral differences may suggest that mechanisms
behind the biological similarities between these 2 cell lines
(eg, their ability to proliferate indefinitely) make a greater
contribution to the Raman spectra than those characteristics
which constitute a difference (such as DNA content). Signifi-
cance bands for HaCaT-CaSki and SiHa-CaSki were only
seen for the modulated Raman dataset, again suggesting that
the application of PCA to differential spectra provides more
FIGURE 3 Standard (A) and modulated
(B) spectral datapoints represented as PC1/2
weightings for C33A (HPV negative
carcinoma) and SiHa (HPV-16 carcinoma)
cells. The number of cells used for each
comparison are indicated in the legend
FIGURE 4 (A) Standard and (B) modulated
Raman spectral averages for the 4 cell lines
used, 800 to 1800 cm−1
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useful information than traditional approaches. Prior to con-
sideration of significance bands, it can be seen in the stan-
dard Raman spectra that for each comparison of NHEKs to
the 3 established cell lines, the same peaks are demonstrating
significant change. The peak at approximately 1590 cm−1
(adenine/guanine) only appears for the established cell lines,
although significant difference is seen only for NHEK-
HaCaT here. It is interesting that the largest peak at approxi-
mately 1450 cm−1 (CH2/CH3 deformation of lipids/colla-
gen/other hydrocarbon modes) is significant for NHEK-
HaCaT (normal vs immortalised) but not for the standard
normal vs. transformed cell types (NHEK against SiHa or
CaSki). The modulated NHEK-CaSki comparison shows
several significant spectral differences not seen in the
remaining comparisons. The statistically significant bands
and tentative peak assignments based on previous literature
[9, 24] are shown in Appendix S2, Table 2.
Overall, it is clear that the use of a differential spectrum
in modulated Raman spectroscopy highlights different sta-
tistically significant regions of the spectrum in comparison
to standard Raman spectra. Due to the format of the differ-
ential spectrum, real Raman peaks correspond to differential
zero-crossing points. Therefore differential spectral variation
represents subtle alterations in the shape, slope and position
of peak ‘shoulders’ as opposed to absolute peak height and
position. Small variations in these parameters result from
FIGURE 5 (A) Standard and (B) modulated
PCA weightings for the 4 cell lines used.
Variation in the number of datapoints used
arises from the rejection of different spectra in
each set
TABLE 1 The confusion matrix resulting from cross-validation of
standard Raman PCA, with accompanying percentage classification
accuracy
Predicted
Actual NHEK SiHa CaSki HaCaT Class acc. (%)
NHEK 31 2 1 1 88.6
SiHa 2 25 6 7 62.5
CaSki 1 9 19 10 48.7
HaCaT 3 9 6 22 55.0
TABLE 2 The confusion matrix resulting from cross-validation of
modulated Raman PCA, with accompanying percentage classification
accuracy
Predicted
Actual NHEK SiHa CaSki HaCaT Class acc. (%)
NHEK 29 4 0 1 85.3
SiHa 1 32 0 8 78.0
CaSki 0 1 38 0 97.4
HaCaT 0 2 0 38 95.0
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changes to the population of a molecular group (in the case
where multiple Raman peaks occupy the same region) or
changes to the environment of a bond. This may lead to a
significant increase in utility for the differential spectrum
approach in biological contexts, as Raman peaks frequently
overlap and biological changes are often the result of alter-
ations in molecular conformation in addition to type (as is
the case for protein conformation or DNA packaging). The
only regions which were statistically significant for all stan-
dard Raman spectral comparisons were those corresponding
to Amide I:β-sheet/C-O stretch/ν(C-C) and Amide III:α-
helix/collagen/CH in phospholipids/C-C in fatty acids. It is
suggested that the increased density of protein conforma-
tional changes may arise from histones [9]. Many of the
remaining significant peak differences also result from
DNA-associated structures, including DNA O-P-O back-
bone stretching and polynucleotide chains. The only differ-
ential region which demonstrated statistically significant
variations in each case was that of the symmetric ring
breathing mode of phenylalanine and tryptophan.
3.3 | Impact of intracellular variation
It was previously found that the Raman spectra for intracel-
lular locations in CHO-K1 cells were very distinct, with the
nucleus providing the optimum signal-to-noise ratio [12].
However, that data was generated from adherent cells
grown directly onto glass slides, giving the characteristic
flattened morphology associated with cells in culture. This
distinctive morphology did not translate to the spectral
acquisitions from fixed cells considered in this article: the
cell rounding effects associated with trypsinisation and fix-
ing made the consistent identification of intracellular organ-
elles challenging. Typical brightfield images are shown in
Appendix S3, Figure 1. To investigate the importance of
intracellular location on characterisation, further samples of
the Section 3.2 cell lines were fixed and each cell interro-
gated multiple times at locations designated as cell wall,
cytoplasm, nucleus and nucleolus. Typical images are
shown in Appendix S3, Figure 2. Cells were rejected if the
specified components could not be discerned clearly. The
nucleolus was identified as a high-density sphere within the
nuclear volume. All 4 datasets were recorded in the modu-
lated setup only and analysed as discussed previously.
Figure 8 shows the overall PCA plot from the cells, disre-
garding laser spot location. The resulting confusion matrix
and classifications are detailed in Appendix S3, Table 3.
Despite some misclassifications (particularly for NHEKs),
the average predictive accuracy is high at 91.2%. The
FIGURE 6 Direct comparison of the standard
spectra for NHEK against the remaining
established cell lines SiHa, CaSki and HaCaT.
Shaded bands refer to regions of statisitically
significant difference (student's . test) between
the spectral intensities
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analysis can then be expanded to consider location for each
cell line in turn. This can be seen for the SiHa line in
Figure 9—the remaining expanded PCA plots can be seen
in Appendix S3, Figures 3–5. The classification accuracies
for the location-specific subset of each expanded matrix are
summarised in Table 3. These are much lower and more
variable than both classifications by cell line and location-
based results from de Luca et al. experiment [12], suggest-
ing that there is insufficient spectral disparity to separate
clusters by location when rounded cells are interrogated in
solution.
As such, the matrices were then considered by grouping
points according to their location inside (nucleus, nucleolus)
or outside (cytoplasm, cell wall) the nucleus. The
FIGURE 8 The PCA plot for the overall
classification of cell lines without
consideration of location
FIGURE 7 Direct comparison of the
modulated spectra for NHEK against the
remaining established cell lines SiHa, CaSki
and HaCaT. Shaded bands refer to regions of
statisitically significant difference (student's
t test) between the spectral intensities
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summarised classification accuracies shown in Table 4. The
resulting accuracies from this test indicate that there is suffi-
cient spectral difference to separate these location clusters
from inside and outside the nucleus with an accuracy
approaching that of cell line classification. However, the
fixed cells do not provide sufficient spectral difference to
account for specific cellular regions with the accuracy seen
for adherent cells interrogated directly on their culture sub-
strates. Thus, cell shape and sampling method should be a
key consideration for sampling location accuracy.
3.4 | Impact of other variation sources
Finally, the potential effects of storage time on spectral clas-
sification were investigated. Recent work by Hobro
et al. considered spectral differences between live mouse
embryonic fibroblast cells and those fixed with different
agents, including methanol [25]. Methanol acts as both a
fixing and permeabilisatio n agent which dehydrates cells
and precipitates proteins. In that case, a significant loss of
overall Raman signal was observed in cells fixed with meth-
anol, which were mostly associated with lipid bands. The
effects of storage in fixative were not considered by Hobro
et al. Based on the routine morphological and genomic anal-
ysis of stored smear samples without alterations to data, we
hypothesised that changes over time after initial fixation
would not be significant. If such changes do occur, it would
have considerable impact on the use of Raman spectroscopy
as a tool for clinical sample classification where samples
may be archived in fixing solution for long periods of time
either before analysis, for revisiting borderline samples or
for comparing with new samples for disease progression. A
total of 150 cells were interrogated from SiHa cell samples
which had been stored at −20C for 3 days, 1 month or
6 months in PreservCyt before following the same protocols
described previously. The average Raman spectra are in
Figure 10. Pairwise comparisons of each sample type as
FIGURE 9 The PCA plot for classification
where SiHa cells have been considered in
terms of sampling by nucleus, nucleolus,
cytoplasm or cell wall. The remaining
location-expanded plots can be found in
Appendix S3
TABLE 3 The percentage classification accuracies for the cell lines by
intracellular location. The average classification error is a single SD from
the mean
Classification accuracy (%)
Loc. NHEK SiHa CaSki HaCaT Average
Nucleus 50 60 50 60 55  5
Nucleolus 50 20 50 80 50  21
Cytoplasm 44 88 44 80 64  20
Cell wall 60 50 60 80 63  11
TABLE 4 The percentage classification accuracies for the cell lines based
on location in reference to the nucleus. The average classification error is a
single SD from the mean
Classification accuracy (%)
Loc. NHEK SiHa CaSki HaCaT Average
Inside 93.3 90.0 90.0 94.1 91.9  1.9
Outside 88.9 86.7 77.8 100.0 88.4  7.9
FIGURE 10 Average spectra of 50 cells from
each sample, stored in PreservCyt for 3 days,
1 month or 6 months
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conducted before revealed significant differences between
3 days and 1 month cells, and between 1 and 6 months
cells, but not between the 1 day and 6 months cells. These
differences occur in both the former cases at 992 to
997 cm−1 (ring breathing of tryptophan/phenylalanine),
1595 cm−1 (adenine/guanine) and 1715 cm−1 (C=O, lipids).
None of these bands were indicated in the live-fixed cell
comparison for methanol [25]. Figure 11 shows the corre-
sponding PCA plot, where grouping can be seen clearly for
the 3 days and 6 months clusters in the PC1/PC2 and
PC2/PC3 projections. The confusion matrix (Table 5) for
the 3 days and 6 months samples are consistent with the
hypothesis that no changes should occur during storage, as
classification accuracy is low. However, the 1 month sam-
ple shows high-classification accuracy, which indicates that
there are sufficient spectral differences to classify these
nominally identical cells in relation to the remaining sam-
ples. The lack of trend according to storage time suggests
that while storage should not be an issue for classification,
other sources of variation are present and can be detected
by the WMRS.
4 | DISCUSSION
In Sections 3.1 and 3.2, the comparisons of standard and
modulated methods for spectral acquisition clearly demon-
strate that WMRS is able to provide superior cell classifica-
tion accuracy. The ability to discriminate between HPV
positive and negative cervical carcinoma cell lines is an
encouraging step towards the potential integration of HPV
and smear testing using optical discrimination. However, it
must be noted that these carcinoma lines represent different
mechanisms of origin, and by extension molecular patholo-
gies. The ability to also identify HPV status in normal cervi-
cal cells would be a requirement of an integrated platform
and so this will require consideration. The presence of sig-
nificant spectral differences only in the modulated Raman
acquisition between SiHa and CaSki cells, which represent
primary and metastatic cervical carcinoma respectively, also
points towards greater clinical utility for the sampling
method and resulting spectral analysis. The investigation of
location impact for spectral sampling provides important
data regarding the expected differences between sampling
particular cell morphologies or methods of collection. It is
suggested that the lower specificity of sampling location for
fixed cells in suspension compared to previous experiments
with adherent, plated cells is due to the superposition of
spectral data from different components of the cell, as the
surface area occupied by the cell is lower. This lower mar-
gin of error could provide benefits for coupling the spec-
trometer with automated cell sampling capabilities, and will
have to be taken into consideration for clinical samples
acquired with a cytology brush. Finally, although overall
cell classification was unaffected by storage time in fixative,
the relationship between spectral characteristics and fixation
was complex, consistent with recent evidence that methanol
fixatives affect spectral data, particularly in relation to lipid
peaks [25]. The sensitivity of the technique to these changes
suggests that similar issues with sample heterogeneity will
have to be addressed with large clinical datasets.
5 | CONCLUSION
In this study, fluorescence-free wavelength modulated
Raman spectroscopy has been used to consider the benefits
and practicalities of such a system in the context of label-
free classification of fixed cell samples, such as those from
cervical screening. The use of wavelength modulation in
FIGURE 11 The PCA plot of the 3
‘archived’ fixed samples, stored for different
periods of time
TABLE 5 The confusion matrix resulting from cross-validation of the
fixed cell storage time dataset, with accompanying percentage classification
accuracy
Predicted
Actual 3 d 1 mo 6 mo Class acc. (%)
3 d 29 0 21 58.0
1 mo 1 47 2 94.0
6 mo 17 1 32 64.0
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Raman spectroscopy and the resulting removal of autofluor-
escence provides clear benefits to its ability to automatically
classify cells over conventional Raman scattering, without
the requirement for manual baseline fitting, additional lasers
or optical gates. It is entirely feasible that the technique
could be combined with other imaging methods such as
optical coherence tomography [26] or digital holographic
microscopy [27] in order to provide a cell ‘topography’ map
for automated point sampling. It is hoped that such a system
could be introduced to clinical settings in order to reduce
the burden on manual cytological diagnosis, as well as
increasing the likelihood of a correct outcome for patients.
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Chapter 9
Appendix B: SERS-SRS imaging
To date, published examples of SRS imaging with additional nanoparticle-based la-
belling are limited. Earlier work indicated that the short laser pulses - and therefore
high peak powers - typically employed with SRS in order to excite third-order pro-
cesses were insufficient for sustaining LSPRs on colloidal metal due to the intensity
fluctuations associated with the phenomenon [264] and also cause significant pho-
todegradation [265]. Continuous-wave SRS has shown greater promise [266, 267] and
some studies have been performed on supporting LSPRs with short pulses [268] but
the field is still in its infancy.
9.1 Materials and methods
9.1.1 Stimulated SERS mapping
Stimulated Raman spectroscopy (SRS) images were acquired using a custom-built
multi-modal microscope setup, designed by Dr Alan Serrels as part of a collaboration
with the Frame, Brunton and Elfick groups at the University of Edinburgh (Figure 9.1).
A picoEmerald (APE) laser system provided both a tunable pump laser (720-990nm,
7ps pulse) and a spatially overlapped Stokes laser (1064nm, 5–6ps), set to 80MHz rep-
etition rate. The laser was inserted into a multi-photon laser-scanning microscope
(FV1000MPE) coupled to an objective lens (NA 1.05, XLPL25XWMP) using a short-
pass 690nm dichroic mirror. For SRS measurements, the Stokes beam was modulated
with a 20MHz electro-optic modulator (EoM). Forward scattered light was collected
by a 25×water-immersion objective lens (NA 1.00, XLUMPLFLN) and the Stokes scat-
tering removed using an ET890/220m filter (Chroma). A telescope focused the light
onto an APE silicon photodiode connected to an APE lock-in amplifier which was fed
into the analogue unit of the microscope.
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FIGURE 9.1: The optical setup for the multi-photon laser scanning microscope (left) cou-
pled to picoEmerald laser system (blue and green box, right).
The pump laser was tuned to 810.5nm for the 2939.6cm−1 protein-rich CH3 stretch
to delineate cell membranes, before being tuned between 905.0 and 911.1nm, equiva-
lent to 1577.2-1651.2cm−1 with the Stokes laser used. The equation for pump wave-
length to wavenumber conversion is given below, where the wavenumber ν = 1λ ×
107. The laser powers after the objective were measured to 40-70mW for the pump
laser and up to 70mW for the Stokes laser before imaging. All images were recorded
at 800×800 pixels, equivalent to a 127.041µm square, with a pixel dwell time of 20µs.
Olympus FV10-ASW software was used for image acquisition and image analysis and
processing was performed in ImageJ.
Pumpν − Stokesν = Interrogatedν (9.1)
9.2 Consideration of stimulated SERS imaging
In order to address the continuing issue of cumulative acquisition time for the prac-
tical imaging of cervical smear samples, another imaging modality was considered:
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stimulated Raman spectroscopy (SRS). As discussed in the introduction to this Chap-
ter, SRS is able to produce maps of intrinsic Raman vibrational modes, creating digital
analogues of tissue and cell stains. It was hypothesised that by combining SERS-active
nanoparticle labelling with global mapping, a ‘hybrid’ imaging system could be cre-
ated which would provide the targeted analysis of a p16-specific conjugate alongside
global structural information about the cells themselves. This could be used for a
data-rich exploration of structural biology in the cervical cancer context. More prag-
matically, spatial information about the cell boundaries would provide a straightfor-
ward method of determining the quantity of nanoparticles inside and outside the cells
which could not be achieved easily using the relatively low-contrast brightfield im-
ages seen in Section 5.5.2. Furthermore, SRS imaging simply provides faster image
acquisition, with pixel dwell times of 20µs as opposed to 1s.
The fixed cell samples prepared for SERS imaging in Section 5.5.2 were imaged
using the SRS system as described in Section 9.1.1 and published previously by Serrels
et al. [269]. The results can be seen in Figure 9.2. Although the images show signal
in the region of the 1606 and 1636cm−1 BPE peaks, this signal does not vary with
peak intensity as the pump laser sweeps through the wavenumber region. Thus, the
signal can only be attributed to background or cellular vibrational scattering. Given
the stability requirements outlined in Lee et al’s paper [267], it is unsurprising that
the in-house colloids were unable to support LSPRs with such a short laser pulse. A
continuous-wave optical setup was not available to test in the SERS-SRS context and
so it was suggested that alkyne labelling of antibodies should be explored instead, as
described in Section 5.6.
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FIGURE 9.2: Representative images of Raman shift sweep of targeted conjugates in fixed
SiHa w/t cells as prepared for standard SERS experiments. The image intensity does
change with shift but not in proportion to the Raman signal of BPE as shown, meaning
that the SRS setup is not capable of supporting hyrbid SERS imaging.
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